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Abstract 
 
 
This thesis focuses on studies investigating the structure of intermediates involved in 
fluorometabolite biosynthesis, and the potential applications of the fluorinase enzyme in 
positron emission tomography (PET). 
 
Chapter 1  introduces the rare natural occurrence of fluorinated compounds.  The bacterium 
Streptomyces cattleya is known to biosynthesise two fluorinated secondary metabolites: the 
toxin fluoroacetate (FAc) and the antibiotic 4-fluorothreonine (4-FT).  The enzymes and 
intermediates identified on this fluorometabolite biosynthetic pathway in S. cattleya, prior to 
this research, are discussed in detail. 
 
Chapter 2  presents studies towards the unambiguous structural identification of (3R,4S)-5-
deoxy-5-fluoro-D-ribulose-1-phosphate (5-FRulP) as the third fluorinated intermediate on the 
biosynthetic pathway to fluoroacetate and 4-fluorothreonine in S. cattleya.  
 
Chapter 3 describes the synthetic routes to key molecules, necessary as reference compounds 
and substrates, to underpin the subsequent studies in this thesis.  In particular, synthetic routes 
to 5-deoxy-5-fluoroadenosine (5-FDA), 5-deoxy-5-fluoroinosine (5-FDI), 5-deoxy-5-
fluoro-D-ribose (5-FDR) and 5-deoxy-5-fluoro-D-xylose (5-FDX) are described.  
 
Chapter 4  describes the use of the fluorinase enzyme from S. cattleya as a tool for the 
synthesis of new [18F]-labelled sugars with potential application in positron emission 
tomography (PET).  A new route to 5-deoxy-5-[18F]fluoro-D-ribose ([18F]FDR) is developed 
in a two-step enzymatic synthesis.  A total of three potential radiotracers ([18F]FDA, 
[18F]FDR and [18F]FDI) are synthesised using fluorinase-coupled enzyme reactions. 
In addition, in vitro studies are reported with these [18F]-labelled sugars to investigate their 
uptake and potential as PET radiotracers in cancer cells. A preliminary rat imaging study with 
[18F]FDA is reported. 
 
Chapter 5  details the experimental procedures for the compounds synthesised in this 
research and the biological procedures for chemo-enzymatic syntheses and protein 
purification. 
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Introduction 
 
 
 
 
Throughout history human cultures have always been searching for substances for the 
treatment of pain and suffering, for life-enhancement, for rituals to get closer to God and also, 
if necessary, for a quick and easy death. Thus, there are ancient records describing the use of 
natural extracts, for a wide variety of purposes, long before they were isolated and named.1,2 
This is the case of opium, which use and cultivation was documented by Homer in 
The Odyssey (ca. ninth century B.C.):  “Presently   she  cast   a  drug   into   the  wine  whereof   they  
drank, a drug to lull all pain and anger, and bring forgetfulness of every sorrow […] Where 
earth the grain-giver yields herbs in greatest plenty, many that are healing in the cup, and 
many baneful.” 3 
Likewise, native people in South America were well aware of natural toxins and learned to 
extract potent and deadly poisons, as reported by the Spaniard Gaspar de Carvajal, chronicler 
of the discovery of the Amazon4:  “In  this  village  the  Indians  were  familiar  with  some  kind  of  
poisonous plant, for this became evident from the wound of the aforesaid man, because at the 
end of twenty-four hours he surrendered […]  The  centre  must  have  been  Curaray, name from 
which   ‘curare’ is perhaps derived, as the poison with which these Indians poisoned their 
arrows  was  called.”  About 400 years later, curare became part of the practice of anaesthesia.5 
Nature has provided the active ingredients for the traditional medicine and the unsurpassable 
biological activity of these substances has given leads for the design of valuable and 
important  medicines  in  today’s  health  care.  However,  the  idea  of  ‘pure’ compounds as drugs 
evolved from the isolation of the active principles of commonly used plants and herbs, such as 
morphine 1 and caffeine 2 in the early 1800s (see Figure 1.1). These isolations were then 
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followed by what can be considered the first commercial pure natural product, morphine 1, by 
E. Merck in 1826 and the first semi-synthetic pure drug, aspirin, based on a natural product 
(salicin 3) by Bayer in 1899.6 These bioactive molecules, extracted not only from plants and 
trees but also from microorganisms (e.g., 5 and 8, Figure 1.1), have been used as medicines, 
narcotics and hallucinogens, stimulants and poisons. Some common selected natural products 
are shown below in Figure 1.1. 
 
 
Figure 1.1 Morphine 1, caffeine 2, salicin 3, tetrahydrocannabinol 4, penicillin G 5, quinine 6, 
atropine 7, streptomycin 8. 
 
On the other hand, it is of note the significant role that natural products have played in the 
development of organic chemistry. The study of these bioactive compounds resulted in the 
advancement of the major chemical and physical methods for structure elucidation, as well as 
the discovery of many reactions of great synthetic importance.7 
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Natural products may be divided in two main categories: 
 Primary metabolites, which are the common compounds to all cells that play a central 
role in the metabolism and reproduction of those cells (e.g., nucleic acids, the common 
amino acids and sugars) 
 Secondary metabolites, the characteristic compounds of a limited range of species that 
have a biological effect on other organisms. They are subdivided into: polyketides and 
fatty acids; terpenoids and steroids; phenylpropanoids; alkaloids; specialised amino 
acids and peptides; and specialised sugars. 
The principal building blocks for the biosynthesis of secondary metabolites are acetate, 
shikimate and the amino acids.7 The relationship between the primary and secondary 
pathways of metabolism is illustrated in Scheme 1.1. 
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Scheme 1.1 Primary and secondary metabolism pathways. 
 
 
CHAPTER 1 
 
 6 
1.1 Halogens in natural products 
Some organisms are capable of incorporating halogens into their biosynthetic metabolic 
pathways. Thus, nature has synthesised an impressive collection of halogenated natural 
products, referred to as halometabolites, showing very different chemical structures and 
properties. Chloro-metabolites and bromo-metabolites predominate; iodinated and fluorinated 
natural products are much less common. The great diversity of these organohalogens, both in 
their chemistry and their origin, suggests considerable biochemical importance to living 
organisms. Thus, the functions of these halometabolites are varied and they can have distinct 
physiological or biochemical roles. For example,  the  ‘lone star tick’ uses 2,6-dichlorophenol 9 
(vide infra, Figure 1.2) as a sex pheromone,8,9 while 4-chloroindolyl-3-acetic acid 10 
(Figure 1.2) is a universal growth hormone biosynthesised by numerous Leguminosae 
plants;10,11 and the Ecuadorian poison tree frog Epipedobates tricolor secretes epibatidine 11 
(Figure 1.2), a unique chlorinated compound with a novel 7-azanorbornane structure, that is 
500 times more potent than morphine as an analgesic.12 
 
 
Figure 1.2 2,6-Dichlorophenol 9; 4-chloroindolyl-3-acetic acid 10; (+)-epibatidine 11. 
 
The first reported naturally-occurring halogenated organic compound was an iodinated amino 
acid isolated from the coral Gorgonia cavolinii in 1896, and subsequently identified as 
3,5-diiodotyrosine.13 Later, in the 1960s, the few known natural organohalogens 
(e.g., griseofulvin, chloramphenicol, aureomycin, vancomycin) were considered bizarre 
compounds of nature or even artefacts of the isolation process, and were not recognised as the 
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unique organic compounds with great biological activity part of an enormous class of natural 
products yet to be discovered. For example: “Present information suggests that organic 
compounds containing covalently bound halogen are found only infrequently in living 
organisms.”14 As of February 2005, the number of known natural organohalogens was over 
4100.15 This is a consequence of the general interest in natural products as a potential source 
of new medicinal drugs. The breakdown of these naturally occurring organohalogens was 
approximately: 2300 organochlorines, 2100 organobromines, 110 organoiodines and 
30 organofluorines. A few of these compounds contain both chlorine and bromine. Although 
most of the organohalogens discovered in the past thirty-five years are marine-derived, many 
other halogenated compounds are produced by bacteria, fungi, lichen, terrestrial plants, 
insects, some higher animals (including humans) and geothermal processes, making natural 
organohalogens ubiquitous in both marine and terrestrial environments. A selection of 
examples from the wide spectrum of halogenated compounds from many natural sources is 
shown in Figure 1.3 (vide infra). 
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Figure 1.3 Selection of halogenated natural products: biotoxin 12 (Mytilus galloprovincialis), 
barbamide 13 (Lyngbya majuscula), chloramphenicol 14 (Streptomyces venezuelae), 
7-chlorotetracycline 15 (Streptomyces aureofaciens), vancomycin 16 (Amycolatopsis 
orientalis), fluoroacetate 17 (Streptomyces cattleya), 5-neoirietetraol 18 (Laurencia 
species), and thyroxine 19 (human thyroid gland). 
 
The marine environment is the richest source of halometabolites and halogenating enzymes, 
thus generating most of the halogenated secondary metabolites known to date. The majority 
of these marine organohalogens contain bromine, whereas chlorine-containing compounds are 
usually synthesised by terrestrial organisms. Bacteria are amazing chemical factories and they 
produce some of the most commercially important chlorinated antibiotics, such as the 
antibiotics chloramphenicol 1416,17,18 and the polyketide-derived chlorotetracycline 1519,20 
(Figure 1.3). More than 50 Streptomyces bacteria have yielded biologically active 
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organochlorine compounds, many of which possess complex structures and show unique and 
powerful biological activity. Among them, there is the life-saving antibiotic 
vancomycin 16 (Figure 1.3, vide supra), produced by Amycolatopsis orientalis.21 It has been 
used for nearly 50 years to treat penicillin-resistant life-threatening infections, and the two 
chlorine atoms in this glycopeptide are essential for optimal biological activity.22,23 
Barbamide 13 (Figure 1.3), produced by the biosynthetically prolific cyanobacterium 
Lyngbya majuscula,24 is an example of marine organohalogen. It contains an unusual 
trichloromethyl group, the metabolic origin of which has been investigated in order to 
elucidate the chlorination mechanism.25,26,27 Also from the marine environment a large 
number of halogenated terpenes are produced by the red alga genus Laurencia, as for example 
neoirietetraol 18 28,29 (Figure 1.3). One of the most toxic organohalogens is fluoroacetate 17 
(Figure 1.3). It is synthesised, along with the similarly toxic long chain -fluorocarboxylic 
acids, by several plants indigenous to West Africa, Australia and other countries.30,31,32 
Examples of organohalogen natural products from animals are compounds 12 and 19, 
illustrated in Figure 1.3. The novel cytotoxic polychlorinated sulfolipid 12 has been isolated 
from toxic mussels (Mytilus galloprovincialis) located along the Emilia Romagna coasts of 
Italy.33 Thyroxine 19 is another example of halometabolite with animal origin; isolated from 
the human thyroid gland, where it plays an important role in its control.34,35  
 
 
1.2 Fluorinated natural products 
Only a few fluorinated metabolites have been identified in nature. So far, there are no 
examples of organofluorine natural products from higher animals or insect sources. However, 
some reported findings suggest that the occurrence of organofluorine compounds in nature 
may not be only restricted to plants and microorganisms.36  
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1.2.1 The element fluorine in nature 
Fluorine, in the form of fluoride ion, is the most abundant halogen   in   the   earth’s   crust  
(Table 1.1) with concentrations in the range of 270740 ppm.32,37 
 
Table 1.1 Halides and abundance.38  
 
 
 
This low frequency of organofluorine compounds lies to a great extent in the chemical 
properties of fluoride ion. Only 13 fluorinated natural products have been characterised.32 One 
of the principle reasons for this is the low solubility of fluoride-containing minerals 
(e.g., fluorospar: CaF2), which reduces the bioavailability of fluoride to living organisms. This 
is highlighted by the fact that sea water contains only 1.3 ppm of fluoride39 in comparison to 
19,000 ppm of chloride (Table 1.1). 
Another factor that limits the participation of fluoride in biochemical processes is the high 
heat of hydration of fluoride ion.40,41 Thus, in aqueous solution fluoride ion is heavily 
hydrated making it a substantially weaker nucleophile in water than all of the other halogen 
ions, as shown in Table 1.2 (vide infra). This reduces its ability to act as a nucleophile in 
displacement reactions. 
 
Halide 
Abundance (ppm) 
Order of abundance 
Crustal rocks Ocean water 
F- 544 1.3 13 
Cl- 126 19,000 20 
Br- 2.5 65 46 
I- 0.46 0.05 60 
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Table 1.2 Heat of hydration and standard redox potential for the halogen group.40,41 
 
 
 
 
 
 
Furthermore, the haloperoxidase reaction,42 which plays a significant role in the formation of 
natural organohalogen compounds by generating X+ at the expense of hydrogen peroxide 
reduction, does not extend to fluorination37 due to the high redox potential necessary to 
generate F+ from F (Table 1.2).  
 
 
1.2.2 Fluorinated natural products from plants 
1.2.2.1 Fluoroacetate 
Fluoroacetate 17 was the first organofluorine natural product to be reported and is by far the 
most widespread of this class. It was initially identified and isolated by Marais in 1943 from 
the South African shrub Dichapetalum cymosum.43,44 The plant was known to be extremely 
toxic and had long been recognised as a hazard to livestock.  
 
 
 
Fluoroacetate 17 has subsequently been found in a variety of plants throughout the world.45,46 
Many other species of the genus Dichapetalum, such as D. heudelotti,47 D. stuhlmannii,45,46 
Halogen 
X- 
Heat of hydration 
KJ mol1 
Standard redox potential 
E0 
F- 490 3.06 
Cl- 351 1.36 
Br- 326 1.07 
I- 285 0.54 
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and D. toxicarium47,48 are known to produce fluoroacetate. The highest concentrations 
reported to date are those found in D. braunii, with 8 mg/g dry weight in young leaves and 
seeds.49  
A great number of the species that produce fluoroacetate 17 can be found in Australia,50 
where over 40 plant species have been identified, most of them belonging to the genus 
Gastrolobium and Oxylobium.51,52 Although fluoroacetate-producing plants are in general 
confined to Africa and Australia, fluoroacetate 17 has also been reported in Brazilian and 
Indian species.53,54 In addition, it has been detected in very low concentrations in other plant 
materials which are not normally regarded as toxic.55,56 57,58,59,60  
 
1.2.2.2 Fluorocitrate 
The toxicity of fluoroacetate 17 was investigated by Sir Rudolph Peters in the early 1950s. He 
proposed that the high toxicity of this fluorometabolite arises from its in vivo conversion to 
(2R, 3R)-fluorocitrate 20 by the action of citrate synthase, the enzyme that normally feeds 
acetyl-CoA into the citric acid cycle.61,62 This is consistent with trace amounts of 
fluorocitrate 20 which are found in many plants that accumulate fluoroacetate 17.55,58,60,63 
 
 
 
The stereospecific condensation of fluoroacetyl-CoA with oxaloacetate to form 
fluorocitrate 20 gives the only toxic stereoisomer of fluorocitrate64 as shown in Scheme 1.2 
(vide infra). This metabolic conversion of fluoroacetate 17 to (2R, 3R)-fluorocitrate 20 has 
been  termed  the  ‘lethal  synthesis’.65,66 
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Scheme 1.2 Stereospecific condensation of fluoroacetyl-CoA 21 with oxaloacetate 22 to form 
fluorocitrate 20 and its subsequent conversion to 4-hydroxy-trans-aconitate 24. 
 
Fluorocitrate 20 is a potent inhibitor of aconitase,67 the enzyme responsible for the conversion 
of citrate to isocitrate. It has been revealed that (2R, 3R)-fluorocitrate 20 acts as a mechanism 
based inhibitor of aconitase by first being converted to fluoro-cis-aconitate 23, followed by 
addition of hydroxide and loss of fluoride to form 4-hydroxy-trans-aconitate 24 as illustrated 
in Scheme 1.2. This product has a high binding affinity for aconitase and is a potent 
competitive inhibitor.68 Additionally, it has been proposed that (2R, 3R)-fluorocitrate 20 
interferes with membrane transport processes by covalently binding to proteins.69 
 
1.2.2.3 Fluoroacetone 
Fluoride metabolism in some fluoroacetate-producing plants was explored by Peters and 
Shorthouse in the late 1960s. They reported some evidence for the presence of 
fluoroacetone 25 as a metabolite of the Australian plant Acacia georginae.70,71  
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Nonetheless, the method used for detecting fluoroacetone 25, which involved derivatisation of 
the fluorinated molecules with a 2,4-dinitrophenylhydrazine solution, could not distinguish 
between fluoroacetone 25 and fluoroacetaldehyde 26. As a result, the authors admit some 
uncertainty over the existence of this fluorometabolite. Considering the identification of 
fluoroacetaldehyde 26 as an intermediate in fluorometabolite biosynthesis in 
Streptomyces cattleya,72 it is possible that the fluorinated hydrazone derivative isolated in 
those experiments was actually that of fluoroacetaldehyde 26. Hence, the identification of 
fluoroacetone 25 as a natural product is still unclear. 
 
1.2.2.4 Fluorinated fatty acids 
In 1959, Peters and co-workers succeeded in isolating the principal fluorinated compound in 
the seed oil of the shrub Dichapetalum toxicarium.73,74 This fluorinated natural product was 
identified conclusively as -fluorooleic acid (C18:1F) 27 by synthesis, and accounted for 
around 80% of the organic fluorine present in the seeds.75 Small amounts of -fluoropalmitic 
acid (C16:0F) were also purified from the oil.76  
 
 
 
Further analysis of the seeds resulted in the identification of an additional five -substituted 
fluorinated acids.77,78,79 All of these metabolites clearly derive from -fluorooleic acid 27. 
These are -fluoropalmitoleic acid (C16:1F), -fluorostearic acid (C18:0F), -fluorolinoleic acid 
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(C18:2F), -fluoroarachidic acid (C20:0F), and -fluoroeicosenoic acid (C20:1F). The position of 
the double bonds was located after GC-MS analysis.78 
The chain lengths and degree of unsaturation of these -fluorofatty acids seems to accompany 
those of their non-fluorinated analogues, but the former are 510-fold less abundant.77,79 The 
postulated biosynthetic route for the formation of -fluorofatty acids from fluoroacetate in 
D. toxicarium80 is illustrated below in Scheme 1.3.  
 
 
Scheme 1.3 Putative biosynthetic pathway to -fluorofatty acids in D. toxicarium showing 
fluoroacetate 17 as a starter unit. 
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Fluorine is always confined to the terminal position in these fluorofatty acids. This suggests 
some kind of enzymatic restriction on the use of fluorinated analogues at later stages of the 
biosynthetic process. Thus, it is plausible that either acetyl-CoA carboxylase cannot 
synthesise fluoromalonyl-CoA or chain elongation involving the incorporation of 
fluoromalonyl-ACP instead of malonyl-ACP does not occur.14,81  
 
1.2.3 Fluorinated natural products from marine sources 
The first fluorinated natural products 3236 from a marine source were isolated recently from 
the sponge Phakellia fusca collected in the South China Sea.82 Sponges of the genus 
Phakellia are well known to yield alkaloids, sterols, peptides and polyether acids. 
 
 
Figure 1.4 Fluorouracil alkaloids 3236 isolated from Phakellia fusca. 
 
Two of these 5-fluorouracil derivatives, metabolites 35 83 and 36 84 were previously known as 
synthetic anti-tumour agents,85 and metabolites 32, 33 and 34 were reported as novel 
fluorinated natural products.82 However, there is no evidence of how these compounds are 
accumulated in the sponge, and the possibility that they are products of industrial 
contamination cannot be discarded, particularly because 5-fluorouracil 36 is a major 
pharmaceutical product.86  
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1.2.4 Fluorinated natural products from bacteria 
1.2.4.1 Nucleocidin from Streptomyces calvus 
The bacterium Streptomyces calvus, isolated from an Indian soil sample, was shown in 1957 
to produce the antibiotic nucleocidin 37.87,88 
 
 
 
This adenosine derivative89 proved to exhibit a rather broad antibacterial spectrum, being 
particularly active against trypanosomes.88,90 However, it was not until 1969 that it was 
realised that nucleocidin 37 actually contained fluorine,91 and subsequent synthetic work by 
Shuman et al.92 suggested the -D-configuration for the pentose moiety. The assignment of 
the D-ribose configuration and the proposed structure of nucleocidin 37 were confirmed by 
total synthesis in 1976.93  
This fluorometabolite is significantly different from the other known fluorinated metabolites 
in that the position of the fluorine atom on the ribose ring shows no obvious biosynthetic 
origin from fluoroacetate 17 and suggests the presence of a novel enzymatic fluorination step. 
So far there are no experimental data on the biosynthesis of this unique fluorocarbohydrate. 
Even the source of fluoride for the synthesis of nucleocidin 37 is not clear, since the 
fermentation medium was not specifically supplemented with fluoride.88 Therefore, trace 
contamination of fluoride ion in the medium salts of the water appears to be its source. 
Several attempts to re-isolate nucleocidin 37 from cultures of S. calvus have been 
unsuccessful and biosynthetic studies have therefore been frustrated.94,95 
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1.2.4.2 Fluoroacetate and 4-fluorothreonine     
 from  Streptomyces cattleya 
The actinomycete Streptomyces cattleya was known to produce, along with Streptomyces 
penemifaciens, the antibiotic thienamycin 38.96,97,98 This naturally occurring -lactam 
antibiotic was the first to be isolated that contained the carbapenem ring system.99,100  
 
 
 
In 1986, experiments carried out by Merck to optimise thienamycin 38 production led to the 
observation of a novel antibiotic activity in S. cattleya, generated when a particular soya 
protein was used in the culture medium.101 This soya protein contained significant levels of 
fluoride ion, which explained the accumulation of fluorometabolites. These secondary 
fluorometabolites were identified as the well-known toxic natural product fluoroacetate 17 
and the amino acid 4-fluorothreonine 39, responsible for the novel antibiotic activity. 
 
 
 
Streptomyces cattleya and Streptomyces calvus are the only identified microorganisms 
capable of biosynthesising fluorometabolites. Since all attempts to re-isolate nucleocidin 37 
from S. calvus have been unsuccessful, work carried out to investigate the enzymology of 
fluorometabolite production has been focused on S. cattleya.95,102 
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1.3 Techniques used for studying  
 the biosynthesis of natural products 
Once the structure of a secondary metabolite is elucidated, it is usually possible to propose a 
biosynthetic hypothesis for its formation from one of the basic building blocks: acetate, 
mevalonate, shikimate, or the amino acids. A biosynthetic pathway can only be considered 
delineated once each individual intermediate and enzyme has been identified. 
A biosynthetic pathway involves the enzyme-catalysed conversion of a series of intermediates 
(A  B  C  D) to a natural product. Biosynthetic investigations involve both labelling 
and enzymatic experiments. The complementary role of these approaches provides 
information on building blocks and the structures of the intermediates, together with the 
order, stereochemistry, and mechanisms of biosynthetic events.7,103 
  
1.3.1 Isotopic labelling 
In order to investigate biosynthetic pathways, the fate of a labelled precursor can be 
determined after incubation with the living system. In early studies, isotopic labelling studies 
for the elucidation of biosynthetic pathways commenced with the availability of the 
radioisotopes carbon-14 (14C) and tritium (3H). The disadvantages associated with the 
handling and storage of radioactive isotopes have subsequently been overcome with the 
deployment of stable isotopes. The use of the non-radioactive isotopes carbon-13 (13C) and 
deuterium (2H), and to a lesser extent the isotopes 15N and 18O, have revolutionised the study 
of biosynthetic pathways, since these isotopes have non-zero nuclear spin and are thus 
detectable using nuclear magnetic resonance (NMR) techniques. Carbon-13 and deuterium are 
widely used to probe pathways, and can be assayed by mass spectrometry or NMR 
spectroscopy, either directly using 2H NMR spectroscopy or indirectly via 13C NMR 
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spectroscopy. Moreover, the extent of incorporation of label and the distribution can be 
determined by mass spectrometry and GC-MS analysis.7,103 
The incorporation of stable isotopes into natural products represents an effective and 
attractive method for studying biochemical pathways and has proven to be a very powerful 
technique for exploring such pathways. In the mid 1930s, Schoenheimer and co-workers 
proposed the use of deuterium for the study of intermediary metabolic processes, such as fatty 
acid biosynthesis.104 
The biosynthetic origin of the secondary metabolites fluoroacetate (FAc) 17 and 
4-fluorothreonine (4-FT) 39 was investigated in cell suspensions of S. cattleya using labelled 
precursors,102,105 and this will be discussed later in the chapter. 
 
1.3.2 Enzyme experiments 
Questioning of the enzymes that mediate biosynthetic events provides further information on 
particular steps. If an enzyme that catalyses a specific step is absent, either in a genetically 
deficient mutant or because the enzyme system has been inhibited or poisoned, the 
biosynthetic substrate which is normally transformed may accumulate.  Biosynthesis takes 
place in highly structured living cells. If the cell membrane is disrupted, it is often possible to 
develop cell-free enzyme preparations which catalyse individual steps. It can then be possible 
to purify the enzyme itself for assay and even to obtain it in a crystalline form. The enzyme 
may then be examined by X-ray crystallography, with or without a bound substrate.  
Now that it is possible to identify the genetic sequences that code for specific enzymes and to 
clone these systems, this has become a very powerful tool in biosynthesis. The transfer and 
over-expression of genetic information into an easily grown bacterium permits the preparation 
of quantities of the relevant enzyme systems, and enables individual steps in a biosynthesis to 
be studied in detail.7,103 
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1.3.3 19F NMR spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy has significantly advanced the investigation 
of 13C and 2H incorporation of metabolic precursors into natural products after isotopic 
labelling studies.106 However, the 12-year gap between the discovery of nucleocidin and the 
detection of fluorine in the molecule90,91 illustrates the complexity in identifying 
organofluorine compounds in the past. Without the present-day tools of analytical chemistry 
(e.g., 19F NMR, mass spectrometry, ion chromatography, F-selective electrodes), it would be 
difficult to distinguish between a C-H bond and a C-F bond. Therefore, an extension to 
19F NMR spectroscopy offers an extremely powerful method by which fluorometabolite 
biosynthetic pathways can be monitored in real time and in a non-invasive manner. 
Fluorine-19 has a natural abundance of 100% and has a sensitivity to NMR detection that is 
approximately 83% that of the sensitivity of 1H, as shown below in Table 1.3.107  
 
Table 1.3 Nuclear properties of 1H, 13C and 19F. 
 
Nuclide 
Nuclear spin 
I 
Relative sensitivity 
% 
Natural abundance 
% 
1H 1/2 100 99.98 
13C 1/2 1.59 1.11 
19F 1/2 83.3 100.00 
 
Whilst the definitive identification of natural fluorine-containing products requires 
purification and full structural elucidation, 19F NMR spectroscopy can provide rapid insights 
into the biosynthesis and biodegradation of such compounds and their regulation in vivo, 
without purification or derivatisation. In addition, once the products have been identified, 
NMR experiments allow assessment of the changes related to genetic and physiological 
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manipulation.108,109 This originates from the favorable features of the fluorine isotope,107,110 
such as: 
 Fluorine-19 is a spin I = ½ nuclide, and is present in 100% abundance. It has 
receptivity to NMR detection almost comparable to 1H. 
 The sensitivity is further increased because of the absence of naturally occurring 
background signals, since biological systems do not contain endogenous 
NMR-visible fluorinated compounds. This implies that all resonances observed can 
be assigned to the metabolite or compound under study. 
 The fluorine nucleus in a molecule is on average surrounded by 9 electrons rather 
than a single electron (as is the case with hydrogen). Thus, it is highly sensitive to its 
molecular surroundings and to changes in the local environment. The 19F nucleus is 
characterised by a broad chemical shift range of about 500 ppm (this is large 
compared to the chemical shift range of, for example, 1H and 13C NMR spectra; 
15 ppm and 250 ppm, respectively), which results in virtually no resonance overlap. 
As a result, 19F NMR spectroscopy has emerged as an efficient tool for elucidating pathways 
for the conversion of fluorine-containing molecules by microorganisms, with a special 
emphasis on possibilities for investigating biohalogenation and the type of fluorometabolites 
involved.  
The utility of 19F NMR spectroscopy for studying the fate of organofluorine compounds in 
biological systems has been recognised for more than 40 years.111 In the late 1980s, 
Baron et al. used 19F NMR spectroscopy for the detection and measurement of 
fluoroacetate 17 in plant extracts,112 while Cass and co-workers studied the fate of 
fluoro-aromatic compounds in a mutated strain of Pseudomonas putida using the same 
technique.113 From the recent literature, many examples demonstrate the ability of 19F NMR 
experiments to provide data about ligand binding, unfolding, mobility, and other aspects 
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related with the study of biological systems, such as quantification of fluorinated 
contaminants and pharmacokinetics of fluorinated drugs.114,115,116 
Since 19F NMR spectroscopy has proved to be an effective and sensitive method for 
investigating fluorine-containing metabolic pathways, this has been the main technique, 
before protein isolation, for the study of fluorometabolite biosynthesis in S. cattleya. The 
chemical environment in which the fluorine is located can be established with some degree of 
accuracy by 19F-1H coupling constants. This is exemplified in the 19F NMR spectra for the 
known fluorinated secondary metabolites fluoroacetate (FAc) 17 and 
4-fluorothreonine (4-FT) 39, as illustrated below in Figure 1.5. 
 
 
Figure 1.5 19F NMR spectra (in D2O at 25 ºC) showing the fluorine signals of FAc 17 
(Spectrum A) and 4-FT 39 (Spectrum B). 
 
For fluoroacetate 17 (Figure 1.5, spectrum A) the 19F NMR signal is a triplet (t) (19F NMR, t, 
–216.9 ppm, 2J 48.3 Hz). For  4-fluorothreonine 39 (Figure 1.5, spectrum B) the signal is a 
doublet of triplets (dt) (19F NMR, dt, –231.6 ppm, 2J 46.9 Hz and 3J 25.0 Hz) due to the 
additional vicinal coupling with the vicinal hydrogen.101 
 
 
-218.0-217.8-217.6-217.4-217.2-217.0-216.8-216.6-216.4-216.2-216.0-215.8-215.6-215.4-215.2-215.0-214.8-214.6-214.4-214.2-214.0
-232.6-232.4-232.2-232.0-231.8-231.6-231.4-231.2-231.0-230.8-230.6-230.4-230.2-230.0-229.8-229.6-229.4-229.2
Spectrum A 
Spectrum B 
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1.4 Biosynthesis of fluorinated secondary metabolites 
by Streptomyces cattleya 
1.4.1 Fluoroacetaldehyde as a biosynthetic intermediate 
Fluoroacetate 17 and 4-fluorothreonine 39 are the end products of the fluorometabolite 
pathway in S. cattleya. Initial investigations to determine the metabolic relationship between 
FAc 17 and 4-FT 39, and to identify the carbon substrate for the fluorinating enzyme, 
consisted of the use of isotope labelled precursors in resting cells of S. cattleya and 
subsequent analysis by 19F NMR spectroscopy and GC-MS analysis.102,105,117 From these 
studies it was concluded that fluoroacetate 17 was not a precursor of 4-fluorothreonine 39 and 
vice versa, suggesting that each metabolite must therefore arise by further metabolism of a 
common fluorinated intermediate. Further investigations into the origin of these 
fluorometabolites indicated that their metabolic precursor was fluoroacetaldehyde (FAd) 26.72  
 
 
Scheme 1.4 Fluoroacetaldehyde 26 is a common intermediate in the biosynthesis of FAc 17 and 
4-FT 39. 
 
This was confirmed by incubating a synthetically-prepared sample of FAd 26 in resting cell 
suspensions of S. cattleya, which resulted in the efficient conversion of 26 to 
fluoroacetate 17.72 
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1.4.2 Identification of fluoacetaldehyde dehydrogenase 
 from S. cattleya 
The identification of fluoroacetaldehyde 26 as a precursor of fluoroacetate 17 and 
4-fluorothreonine 39 opened up prospects for the identification and isolation of the last 
enzyme on the pathway. Cell-free extracts of S. cattleya were analysed for their capacity to 
oxidise FAd 26 to FAc 17 in the presence of NAD+. Hence, the enzyme responsible for the 
oxidation of 26 (Scheme 1.5) was isolated and characterised.118  
 
 
Scheme 1.5 Biotransformation of fluoroacetaldehyde 26 to fluoroacetate 17 catalysed by 
fluoroacetaldehyde dehydrogenase in S. cattleya. 
 
The native NAD+-dependent aldehyde dehydrogenase showed a molecular weight of 
200 kDa, suggesting a tetramer. The optimum pH was found to be pH 9. The activity of the 
enzyme was significantly reduced in the presence of iodoacetamide, indicating an important 
thiol residue. In terms of substrate specificity, the enzyme showed high affinity for 
fluoroacetaldehyde 26 (Km = 0.08 mM) and, surprisingly, acetaldehyde is a poor substrate.118 
 
1.4.3 Identification of PLP-dependent threonine 
 transaldolase from S. cattleya 
Labelling studies and feeding experiments revealed [1-2H1]fluoroacetaldehyde 26 as the 
metabolic precursor of 4-fluorothreonine 39.72 In order to explore the production of this 
secondary metabolite in S. cattleya, cell-free extracts of the bacterium were then incubated 
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with FAd 26 and various amino acids and co-factors. The co-factor pyridoxal 
5-phosphate (PLP) is well known to be utilised by bacterial threonine aldolases in 
condensations of acetaldehyde with glycine to generate L-threonine.119 With this in mind, PLP 
was explored as a possible co-factor for the analogous transformation in S. cattleya 
(Scheme 1.6). Thus, incubation of L-threonine, fluoroacetaldehyde 26 and PLP in a cell-free 
extract of the bacterium120 led to the formation of 4-fluorothreonine 39, detected by 19F NMR 
spectroscopy, as illustrated below in Figure 1.6.121 
 
 
Scheme 1.6 Biotransformation of fluoroacetaldehyde 26 to fluoroacetate 17 catalysed by 
fluoroacetaldehyde dehydrogenase in S. cattleya. 
 
Figure 1.6 19F NMR spectrum showing production of 4-fluorothreonine 39 in a CFE of 
S. cattleya incubated with PLP, fluoroacetaldehyde 26 and L-threonine.121 
 
Assays with partially purified enzyme and a range of amino acids (glycine, L-serine, 
L-cysteine, L-aspartate, L-alanine, and L-allo-threonine) revealed the requirement for PLP and 
the aminoacid L-threonine 40 for the production of 4-fluorothreonine 39 in the bacterium.120 
These results indicated the presence of a novel threonine transaldolase enzyme. The proposed 
mechanism is shown in Scheme 1.7 (vide infra).  
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Scheme 1.7 Proposed mechanism for the enzymatic production of 4-FT 39 catalysed by the 
PLP-dependent threonine transaldolase (EC 2.2.1.8) from S. cattleya.  
 
The PLP-dependent threonine transaldolase was purified to homogeneity, showing a native 
molecular weight of 120 kDa and a monomer of approximately 60 kDa. This threonine 
transaldolase from S. cattleya does not use glycine as a substrate, which makes it distinct from 
more classical threonine aldolases.120  
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1.4.4 Identification of a fluorination enzyme from 
 Streptomyces cattleya 
The enzymatic synthesis of fluorophosphates in mammalian cells was first described by 
Ochoa,122 when pyruvate kinase was incubated with adenosine-triphosphate (ATP) and 
fluoride ion in the presence of magnesium ions.  
Experiments exploring fluorophosphate production in resting cell cultures of S. cattleya led to 
the detection of the cell-free production of an organofluorine compound.123 Small amounts of 
fluorophosphates were detected by 19F NMR spectroscopy (Figure 1.7, vide infra) in whole 
cell incubations supplemented with glycerol and KF, after 5 days at 28 ºC. 
 
-67 -68 -69 -70 -71 -72 -73 ppm  
Figure 1.7 19F NMR spectrum of supernatant of resting cells of S. cattleya after incubation with 
glycerol (5 mM) and KF (2 mM) for 5 days at 28 ºC. The major signal (d, 70 ppm, 
JFP 865.3 Hz) corresponds to monofluorophosphate 45 whereas the smaller one 
(d, 69.7 ppm, JFP 929.2 Hz) is assigned to   β-fluoroadenosine diphosphate 
(β-FADP) 44.123 
 
Initially it was considered that activated fluoride in the form of fluorophosphates may play a 
role in the fluorination process in S. cattleya towards the secondary metabolites 
fluoroacetate 17 and 4-fluorothreonine 39, since the production of fluorophosphates could 
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overcome some of the problems associated with water solvation of fluoride and provide an 
activated form of fluoride ion for further metabolism.124  
To investigate this hypothesis, cell-free extract experiments were carried out in which 
adenosine triphosphate (ATP) and several other phosphate sources such as 
uridine triphosphate (UTP), guanosine triphosphate (GTP) and cytidine triphosphate (CTP) 
were added with fluoride ion to a CFE of S. cattleya. From the analysis by 19F NMR 
spectroscopy no signal for fluorophosphate could be detected. However, the CFE incubation 
with ATP gave rise to the production of three organofluorine products, as shown by 
19F NMR analysis (Figure 1.8).123  
 
 
Figure 1.8 19F NMR spectrum of CFE incubation with ATP and fluoride ion at 37 ºC for 18 h. 
 
The 19F NMR spectrum showed three signals,123 one of which was assigned to 
FAc 17 (t, 215.8 ppm, 2J 48.3 Hz) and two were unknown (229.5 ppm and 229.7 ppm). 
The production of fluoroacetate 17 in the CFE of S. cattleya can only be explained by the 
enzymatic fluorination of an organic molecule which then proceeds through further enzymatic 
steps to 17. The presence of two additional signals raised the possibility of the identification 
of intermediates on the biosynthetic pathway. Both signals are doublets of triplets (dt) with 
identical JHF coupling constants (2JHF 47 Hz, 3JHF 29 Hz), indicating closely related structures. 
-231-230-229-228-227-226-225-224-223-222-221-220-219-218-217-216-215
-230.00-229.80-229.60-229.40-229.20
 
-231-230-229-228-227-226-225-224-223-222-221-220-219-218-217-216-215
-230.00-229.80-229.60-229.40-229.20
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Previously, labelling experiments with [2-2H1, 2-18O]glycerol had shown that the C-O bond is 
retained during the biosynthesis, as the isotope was found in both FAc 17 and 4-FT 39.125 
With this information, a minimal structure for the two potential intermediates was devised 
(Figure 1.9). 
 
Figure 1.9 Minimal structure devised from the signals of the unknown fluorometabolites. 
 
These experiments showed that ATP 46 supported fluorometabolite biosynthesis in 
S. cattleya. Thus, at this stage, it appeared reasonable that adenosine triphosphate 46 was 
involved in the fluorination reaction, being acted upon by a fluorinase enzyme that would 
displace the triphosphate group. The product of such enzymatic fluorination would clearly be 
5-deoxy-5-fluoroadenosine (5-FDA) 47, which is consistent with the minimal structure 
previously shown in Figure 1.9 (vide supra). 
 
 
 
However, further investigations into the enzymatic C-F bond formation using ATP 46 
revealed that the amino acid L-methionine 48 enhanced the production of fluoroacetate 17 and 
both the other two fluorinated compounds. These results suggested that 
S-adenosyl-L-methionine (SAM) 49, and not ATP 46, was involved in the biosynthesis of 
fluorometabolites in S. cattleya. 
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The formation of S-adenosyl-L-methionine 49 could be rationalised by the presence of 
SAM synthase in CFE of the bacterium, which mediates a reaction between ATP 46 and 
L-methionine 48.126  
When cell-free extracts of S. cattleya were incubated with ATP 46 and KF, the in situ 
production of SAM 49 by SAM synthase, proved in vitro fluorometabolite production to 
render 5-FDA 47. 
The fluorination process was studied in real time by incubating SAM 49 and KF in a CFE of 
S. cattleya. The progress of the biosynthesis was monitored by 19F NMR analysis. This 
experiment showed the production of FAc 17 and confirmed SAM 49 as the substrate of the 
fluorination enzyme, capable of supporting fluorometabolite biosynthesis.127 The resulting 
19F NMR spectra are shown in Figure 1.10 (vide infra). 
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13 h 
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Figure 1.10 19F NMR time course of CFE incubations with SAM 49 and fluoride ion showing 
production of FAc 17 and two fluorometabolites at 229.4 ppm (5-FDA 47) 
and 229.7 ppm (unknown). 
 
The preparation of a synthetic sample of 5-FDA 47 and subsequent CFE experiments, 
confirmed the role of 47 as an intermediate in the biosynthetic pathway to fluoroacetate 17. 
The 19F NMR time course clearly showed formation of 5-FDA 47 (229.4 ppm) followed by 
another metabolite with a 19F NMR signal at 229.7 ppm. 
The identity of this unknown fluorometabolite was determined by further incubations of CFE 
with SAM 49 and KF in the presence of iodoacetamide (Figure 1.11, vide infra). 
Iodoacetamide arrests fluoroacetate 17 biosynthesis by inhibiting one or more of the enzymes 
on the pathway.118 
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Figure 1.11 19F NMR time course of CFE incubations with SAM 49 and fluoride ion in the 
presence of iodoacetamide. Inset shows the 19F NMR signals for the two 
fluorometabolites formed. 
 
The spectra in Figure 1.11 show accumulation of two fluorometabolites without formation of 
FAc 17. Of the two fluorometabolites generated, one was identified as the product of the 
fluorination reaction, 5-FDA 47. The other (19F   NMR,   δF  229.7 ppm), had an identical 
coupling pattern (dt, 2JHF 47 Hz, 3JHF 29 Hz) to 5-FDA 47. Further analysis by 1H NMR and 
19F NMR spectroscopy on a purified sample of this unknown fluorometabolite indicated that 
it was a 5-deoxy-5-fluororibose nucleoside. ES-MS analysis gave a mass ion which was 
one atomic mass unit higher than 5-FDA 47 (MH+ = 269 amu versus MH+ = 268 amu). 
The presence of a deaminase activity128 in S. cattleya, converting the NH2 group of adenine to 
an OH of inosine, would account for this mass difference. To explore the possibility that 
5-FDA 47 was converted to 5-deoxy-5-fluoroinosine (5-FDI) 50, isotopic labelling 
experiments were carried out with [18O]-labelled water. ES-MS analysis showed a product 
which was now three atomic mass units higher than 5-FDA 47, indicating the incorporation 
of 18-oxygen during the biotransformation of 5-FDA 47 to 5-FDI 50 mediated by a 
deaminase. This result was confirmed by GC-MS analysis of the derivatised fluorometabolites 
with MSTFA,127,129 as shown in Figure 1.12 (vide infra).  
0 h 
17 h 
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Figure 1.12 Persilylated derivatives of 5-FDA 47 and 5-FDI 50 analysed by GC-MS (CI) after 
treatment with MSTFA. 
 
Incubations of cell-free extracts of S. cattleya with a purified sample of 5-FDI 50 showed no 
production of FAc 17 or 4-FT 39. Thus, the conversion of 5-FDA 47 to 5-FDI 50 is 
irreversible, and 5-FDI 50 does not support fluorometabolite biosynthesis,129 therefore it 
remains as a stable shunt product in the biotransformation of fluoride to fluoroacetate 17 
(Scheme 1.8, vide infra). 
 
 
Scheme 1.8 Enzymatic formation of 5-FDA 47 from SAM 49 generated in situ, leading to the 
production of the secondary metabolite FAc 17 and the shunt product 5-FDI 50. 
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1.4.4.1 Purification, crystal structure and properties 
With 5-deoxy-5-fluoroadenosine (5-FDA) 47 identified as the product of the fluorination 
enzyme and SAM 49 as the substrate,130 an HPLC assay was established to pursue 
purification of the fluorinating enzyme in Streptomyces cattleya. Purification of 
5-fluoro-5-deoxyadenosine synthase (5-FDAS, ‘fluorinase’;; EC 2.5.1.63) from S. cattleya 
was carried out by C. Schaffrath at the University of St Andrews and full details have been 
published.131 The molecular weight of the monomeric protein (Mr) was estimated to be around 
32 kDa by SDS-PAGE electrophoresis. The purified enzyme showed a native mass of 
approximately 180 kDa after gel filtration chromatography, indicating that it is a hexamer. 
The partial amino acid sequence of the wild-type enzyme was used to design polymerase 
chain reaction (PCR) primers. The gene of the fluorinase (flA) was then cloned by degenerate 
PCR using genomic DNA from S. cattleya as a template. The complete gene and the amino 
acid sequence for the fluorinase (flA) was obtained after sequencing the amplified DNA. 
The flA gene is 897 base pairs (bp) in size and encodes a protein containing 299 amino acids. 
The flA gene amplified by PCR was inserted into the pET28a(+) plasmid and expressed in 
Escherichia coli BL21(DE3) cells. The over-expressed and purified recombinant FlA protein 
showed a molecular weight in agreement with ESI-MS data for the wild-type enzyme.132  
Access to recombinant fluorinase allowed a fuller characterisation of its activity.132 The 
catalytic rate constant (kcat) of the fluorinase is 0.07 min-1 and the Michaelis constant (Km) for 
F- is 2 mM, and the Km for SAM 49 is 74 µM. 
The effect of temperature on the enzyme was investigated by conducting an assay over a 
range of temperatures from 25 ºC to 70 ºC. The optimum temperature was determined to be 
55 ºC. Addition of EDTA (1 mM) showed an increase activity by 25%, suggesting that the 
enzyme may be sensitive to trace amounts of metal ions. However, the presence of 
Mg2+ ion (1 mM) did not affect the activity. 
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Inhibitory studies were carried out with S-adenosyl-L-homocysteine (SAH) 51 and the 
antibiotic sinefungin 52, both previously reported to inhibit reactions of SAM-dependent 
enzymes.133,134 
 
 
 
SAH 51 was a competitive inhibitor of the fluorinase with a Ki value of 29 µM, whereas the 
presence of sinefungin 52 caused only 15% loss of enzyme activity, indicating much weaker 
inhibition. 
Crystallisation of the fluorinase was initiated with the wild type enzyme. However, the 
successful solution of the structure was completed with the cloning and over-expression of the 
fluorinase (EC 2.5.1.63), by Dr J. Spencer at Cambridge University, that allowed 
crystallisation trials to be carried out to obtain protein X-ray diffraction data.132,135 The 
fluorinase structure revealed a hexamer constructed as a dimer of trimers (Figure 1.13, 
vide infra). The fold of the monomeric unit was novel and had no obvious relationship to any 
other protein superfamily known at that time. 
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Figure 1.13 The structure of the fluorinase (EC 2.5.1.63). (a) Monomer  (b) Trimer with SAM 49 
bound at the subunit interfaces  (c) The overall hexamer structure showing a dimer of 
trimers. 
 
The crystal structure revealed that the trimer has three active sites where SAM 49 binds at the 
subunit interfaces. The substrate 49 binds tightly to the fluorinase, consistent with its 
co-purification with the protein. The three components of SAM 49: the adenine ring, the 
ribose ring and L-methionine are recognised by a combination of hydrogen bonds and van der 
Waals contacts. Of particular note is the ribose ring of 49, which is held in an unusually 
planar conformation by hydrogen bonding contacts between the 2- and 3-hydroxyl groups 
and the carboxylate group of Asp 16, as shown in Figure 1.14 (vide infra).  
(a) (b) 
(c) 
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Figure 1.14 Schematic representation of hydrogen bonding contacts of 5-FDA 47 and 
L-methionine 48 on the surface of the fluorinase as deduced from X-ray 
crystallography data.132 
 
The crystal structure revealed that most of the heteroatoms of the adenine ring are involved in 
hydrogen bonding, and the amino acid residues of the methionyl moiety are compensated by 
interactions to the surface of the protein. It is also noteworthy that the ribosyl ether oxygen is 
the only heteroatom of SAM 49 which is not involved as a hydrogen bond acceptor. 
Co-crystallisation of the fluorinase with SAM 49 in the presence of fluoride ion resulted in a 
bound product complex with 5-FDA 47 and L-methionine 48 at the active site. A comparison 
of this product structure with the wild-type (SAM-bound) protein was particularly informative 
in suggesting a mechanism for the reaction. Very small structural changes were observed 
between the two crystal structures, except in the bond forming/breaking region. The 
orientation of the new C-F bond (Figure 1.14, vide supra), approximately antiperiplanar to the 
old C-S bond, is indicative of a substitution reaction (SN2) occurring with an inversion of 
configuration.136 This conclusion is reinforced by the stereochemical studies described in 
Section 1.4.4.2. 
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Despite the high bond-dissociation energy of the C-F bond, assays with the FDAS, both in the 
forward and reverse directions, have suggested that the fluorinase enzyme is reversible and 
therefore, it also catalyses the conversion of 5-FDA 47 to SAM 49.137 This was proved by 
incubation of 5-FDA 47 with L-(13C-methyl)methionine, which resulted in the formation of 
13C-methyl-SAM, identified by HPLC-ES-MS analysis. Further experiments replacing 
fluoride ion with a chloride ion in the presence of SAM 49, showed the production of 
5-chloro-5-deoxyadenosine (5-ClDA) 53. Nevertheless, this was only possible when the 
reaction equilibrium was moved in favour of the organochlorine product by coupling the 
fluorinase to an L-amino acid oxidase that acts upon L-methionine 48, as shown in 
Scheme 1.9. 
 
 
Scheme 1.9 Coupled enzymatic strategy towards C-Cl bond formation catalysed by the fluorinase. 
 
The incorporation of bromine and iodine was explored using a similar coupled-enzyme 
system. However, no organohalogen products were detected.137 
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As a result, the fluorinase can catalyse the conversion of L-methionine 48 and either 
5-FDA 47 or the chlorinated analogue, 5-ClDA 53, to SAM 49, with the concomitant release 
of the corresponding halide ion, as illustrated in Scheme 1.10. 
 
 
Scheme 1.10 The fluorinase operates in reverse with both 5-FDA 47 and 5-ClDA 53. 
 
Experiments to explore the reaction catalysed by the fluorinase in the reverse direction 
showed that 5-ClDA 53 is the more efficient substrate, since chloride is a better leaving 
group. Also the selenomethionine analogue of 49, SeAM 55, is the more efficient substrate in 
the reverse direction, because Se is the better nucleophile. 
However, the fluorinase shows a preference for F over Cl by a factor of 120. This was 
demonstrated in a fluorinase-mediated trans-halogenation reaction as illustrated in 
Scheme 1.11 (vide infra). 
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Scheme 1.11 Trans-halogenation reaction of 5-ClDA 53 to 5-FDA 47 catalysed by the fluorinase. 
 
Interestingly, when a 2-deoxy-ribonucleoside (e.g., 2-deoxy-5-FDA) is presented to the 
enzyme, it is also turned over, although less efficiently than the natural substrate, 5-FDA 47 
(Scheme 1.12).138 
 
 
Scheme 1.12 The fluorinase can catalyse the conversion of 2d-FDA 57 and 2d-ClDA 58 substrates 
with L-SeMet 56 to generate 2d-SeAM 59. 
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It is clear from these studies that, although the 2-hydroxyl group of the ribose ring has been 
removed, the fluorinase accepts the 2-deoxy analogues, 2d-FDA 57 and 2d-ClDA 58, as 
substrates to generate 2d-SeAM 59. A crystal structure of the 2d-FDA-fluorinase 
co-complex confirmed that the 2-deoxy substrates bind at the active site, therefore retaining 
some level of activity.138 
 
1.4.4.2 Mechanism of the fluorinase 
The stereochemical course of biological fluorination was explored using deuterium isotope 
labelling, firstly in whole-cell incubations136 of S. cattleya and subsequently with the purified 
enzyme.139 This consisted of a set of feeding experiments with isotopically labelled glycerols 
in S. cattleya. In particular, (1R, 2R)- and (1S, 2R)-[1-2H1]glycerol, 60a and 60b 
(Scheme 1.13, vide infra), were incubated with washed cells of the bacterium. These glycerols 
were labelled with a single deuterium atom only on the pro-R hydroxymethyl group of 
glycerol, the pro-chiral arm which was already established to undergo fluorination.117 The OH 
group is formally replaced by fluorine during fluorometabolite biosynthesis in S. cattleya. The 
incorporation of these chiral glycerols, 60a and 60b, resulted in the production of chiral 
fluoromethyl groups on the resultant fluoroacetates, 17a and 17b, generated in vivo during 
incubations with washed resting cells of the bacterium, as illustrated below in Scheme 1.13. 
 
 
Scheme 1.13 Incorporation of chiral deuterium labelled glycerols in whole-cell incubations of 
S. cattleya.136 
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This set of feeding experiments demonstrated that the biosynthetic process is stereospecific. 
The fact that the in vivo-generated fluoroacetates 17a and 17b showed the same 
stereochemistry as their respective incubated labelled glycerols, suggested that the enzymatic 
C-F bond formation occurs with an inversion of configuration between SAM 49 and 
fluoroacetate 17. 
With the purified and over-expressed fluorinase available, a study was carried out to examine 
the stereochemical course of the fluorination event on the enzyme directly.139 With this as an 
objective, synthetically prepared (5R)-[5-2H1]ATP 46a was incubated with purified 
SAM synthase to generate a sample of (5S)-[5-2H1]SAM 49a (vide infra Scheme 1.14). 
Treatment of this isotopically labelled SAM with fluoride ion in the presence of the fluorinase 
provided a sample of [5-2H1]-5-FDA 47a, stereospecifically labelled at the C5 position. The 
entire strategy is illustrated in Scheme 1.14. 
 
 
Scheme 1.14 Coupled-enzyme assay involving SAM synthase and the fluorinase, indicating that 
there are two sequential inversions of configuration resulting in an overall retention of 
configuration. 
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Since SAM synthase operates via a SN2 mechanism,140 the resultant configuration at C5 of 
[5-2H1]-5-FDA 47a indicated that the fluorination reaction also occurs with an inversion of 
the configuration. Thus, the stereochemical study suggests that the enzyme catalyses the SN2 
displacement of L-methionine 48 by nucleophilic attack at C5 of SAM 49, a process which 
requires at least partial desolvation of fluoride ion.139 However, computational studies showed 
that stripping the fluoride ion of its last two remaining water molecules requires significantly 
more than half of the overall desolvation energy,141 suggesting a mechanism that leaves at 
least two hydrogen bonds to F– to be favoured. Two recent theoretical studies shed light on 
possible mechanisms.141,142 Quantum mechanical/molecular mechanical (QM/MM) 
calculations142 indicated that the fluorinase accelerates the reaction by between 106 to 108 in 
comparison with the uncatalysed process, activation energy of which is approximately 
100 kJmol1. On the other hand, a theoretical study in the gas phase indicated that only partial 
desolvation of the fluoride ion was required to make F– a potent nucleophile.141 This latter 
study also highlighted a role of the charge on the organic moiety in stabilising the fluoride ion 
as it becomes partially desolvated, and in giving a reactant conformation appropriate for 
nucleophilic attack at the substitution centre. 
Although the structure of the fluorinase bound to both SAM 49 and the products were solved, 
and the theoretical studies revealed possible mechanisms, it was only very recently that the 
molecular mechanism of enzymatic fluorination was elucidated. Site-directed mutagenesis 
studies, structural analyses and isothermal calorimetry (ITC) experiments provided the 
necessary data to establish the key residues required for catalysis and the order of substrate 
binding.143 As fluoride ion is not easily distinguished from water by protein X-ray 
crystallography, chloride ion was used in combination with a mutant of low activity. Thus, it 
was possible to locate the halide ion in non-productive co-complexes with SAM 49 and 
SAH 51. The kinetic data revealed that the positively charged sulfur atom of SAM 49 plays a 
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key role in stabilising the transition state. These experiments also allowed the order of binding 
of the reactants to be determined and thus, a detailed molecular mechanism for the fluorinase 
was proposed as illustrated in Figure 1.15.  
 
Figure 1.15 Schematic illustration of the sequential mechanism of the fluorinase.143 
 
The molecular mechanism for FDAS is explained in the following manner. The solvated 
fluoride ion binds to an unoccupied binding site of the fluorinase. The affinity of binding is 
increased by exchanging two water molecules for hydrogen bonds to polar residues of the 
protein (a process that is entropically favoured). Then a molecule of SAM 49 binds tightly 
and specifically to the enzyme forcing the release of water and trapping the fluoride ion in a 
reactive position, stabilised by the positive charge on SAM 49. The partially desolvated 
fluoride ion acts now as a nucleophile attacking at the C5 of SAM 49 via a SN2 mechanism. 
After that, L-methionine 48 is then released by the enzyme followed by 5-FDA 47. 
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1.4.5 Identification of 5-deoxy-5-fluoro-,D-ribose-1-
 phosphate as an intermediate 
In order to decipher the next step in the fluorometabolite pathway in S. cattleya, the role of a 
putative purine-nucleoside phosphorylase (PNPase)144,145 was investigated using 
a CFE of the bacterium.146 The action of such enzyme would then generate 
5-deoxy-5-fluoro-,D-ribose-1-phosphate (5-FDRP) 61 and adenine 62, as a result of a 
specific reaction for -nucleosides to give only the -anomer of the phosphorylated sugar, as 
shown below in Scheme 1.15. 
 
 
Scheme 1.15 A putative purine-nucleoside phosphorylase in S. cattleya catalyses the cleavage of the 
C-N glycosidic bond of 5-FDA 47 by a phosphorolysis reaction to render 5-FDRP 61 
and adenine 62. 
 
To this end, a sample of 5-FDRP 61 was prepared to explore its role as an intermediate during 
fluorometabolite biosynthesis in S. cattleya. This was achieved using a chemo-enzymatic 
approach with two commercially available enzymes: a 5'-adenylic acid deaminase 
(EC 3.5.4.6; Aspergillus species) and a bacterial PNPase (EC 2.4.2.1; unknown source). 
Incubation of this sample of 5-FDRP 61 in a cell free extract of S. cattleya resulted in the 
accumulation of the secondary metabolite FAc 17, as determined by 19F NMR spectroscopy. 
Thus, it was shown that 5-deoxy-5-fluoro-,D-ribose-1-phosphate (5-FDRP) 61 supported the 
biosynthesis of fluorometabolites in S. cattleya, being the next formed intermediate after 
5-FDA 47 on the biosynthetic pathway to FAc 17 and 4-FT 39.147 
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The identification of 5-FDRP 61 and the phosphorylase activity responsible for its formation, 
led to a partially purified PNPase from S. cattleya.148 Feeding experiments with 5-FDA 47 
were carried out with a partially purified protein fraction after ammonium sulfate 
precipitation, hydrophobic interaction chromatography and ion exchange chromatography. 
The bioconversion of 5-FDA 47 to 5-FDRP 61 was then monitored by 
19F NMR spectroscopy (Figure 1.16, vide infra), and the formation of 61 demonstrated the 
ability of this partially purified PNPase from S. cattleya to catalyse the phosphorolysis 
reaction on the fluorinase product.147 
 
 
Figure 1.16 19F {1H} NMR time course, recorded every hour for 8 h, showing the production of 
5-FDRP 61 from 5-FDA 47, catalysed by a purine nucleotide phosphorylase 
contained in a partially purified extract from S. cattleya. 
 
This set of experiments confirmed 5-deoxy-5-fluoro-,D-ribose-1-phosphate (5-FDRP) 61 as 
the second intermediate in fluorometabolite biosynthesis in S. cattleya, and also the presence 
ppm (f1)
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of a purine-nucleoside phosphorylase (PNPase), which is responsible for the reversible 
phosphorolysis of the glycosidic bond of 5-FDA 47 to 5-FDRP 61 (Scheme 1.15, vide supra). 
The partially purified PNPase has revealed narrow substrate specificity and similarities to 
bacterial 5'-methylthioadenosine phosphorylases (MTAPs).148  
With the identification of the flB gene encoding a putative purine nucleoside 
phosphorylase,149 over-expression and purification of the PNPase from S. cattleya was 
possible, with subsequent work on crystallisation trials. The purified over-expressed PNPase 
from S. cattleya showed an estimated mass of 33 kDa by SDS-PAGE electrophoresis.148 
 
1.4.6 Fluorometabolite gene cluster in S.  cattleya 
Recently, in the search of the genes encoding the enzymes involved in fluorometabolite 
biosynthesis in S. cattleya, a 10 kb gene cluster has been identified in Cambridge from a 
genomic DNA cosmid library of the bacterium.149 In total, a further eleven open reading 
frames (ORF) have been located around the previously characterised fluorinase gene (flA) of 
S. cattleya. Contiguous to flA was found a putative ORF (flB) which encodes for the purine 
nucleoside phosphorylase (PNPase) enzyme responsible for the transformation of 5-FDA 47 
to 5-FDRP 61 (as previously described in Section 1.4.5, vide supra). The functions of these 
genes contained in the fl locus (Figure 1.17, vide infra) have been tentatively assigned based 
on other known protein sequences, and most of them are likely to play a role in regulation. 
Interestingly, the gene flK has been shown to encode a thioesterase responsible for the 
breakdown of fluoroacetyl-CoA 21 but not acetyl-CoA. The presence of such selective 
thioesterase activity suggests a resistance mechanism to fluoroacetate 17 in the organism. In 
this way, any fluoroacetyl-CoA 21 formed is hydrolysed, avoiding its entry into the 
tricarboxylic acid cycle.  
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flE flD flC flB  flA flF flG flH flI flJ flK flL 
ORF StartStop (bp) Length (aa) Function / Homology 
     flE 127795c 222 DNA binding regulatory protein 
     flD 8541504c 216 Dehalogenase / Phosphatase 
     flC 18453038 397 MFS permease 
     flB 30533952c 299 5-FDA phosphorylase 
     flA 41725071 299 5-FDA synthase (fluorinase) 
     flF 51965753 185 DNA binding regulatory protein 
     flG 59476651c 234 DNA binding regulatory protein 
     flH 66488051c 467 Na+ / H+ antiporter 
     flI 83179786 489 Adenosylhomocysteine hydrolase 
     flJ 980210197 131 Regulatory protein 
     flK 1017210591c 139 Fluoroacetyl-CoA thioesterase 
     flL 1069611373c 225 DNA binding regulatory protein 
 
 
Figure 1.17 The Spencer cluster: map of the fl gene locus and possible functions for the proteins 
encoded by the open reading frames.149 
 
However, the genes encoding for the previously characterised enzymes, responsible of the 
later steps in fluorometabolite biosynthesis in S. cattleya, were not located in the Spencer 
cluster. Thus, it is unclear whether there is a second locus containing these missing genes or 
whether the enzymes catalysing similar reactions in primary metabolism may also accept the 
fluorinated substrates.149 
 
1.4.7 Overview of fluorometabolite biosynthesis              
 in Streptomyces cattleya 
As discussed so far, isotope labelling experiments and biochemical studies led to the 
rationalisation of the biosynthetic pathway in the fluorometabolite-producer S. cattleya.32,95 
An illustration of the metabolites and enzymes involved in the biosynthesis of 
fluoroacetate 17 and 4-fluorothreonine 39, prior to the work carried out in this thesis, is 
illustrated in Scheme 1.16 (vide infra). 
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Scheme 1.16 Overview of the biosynthetic pathway in S. cattleya showing the relationships between 
primary metabolites and fluorinated secondary metabolites and the enzymes involved 
in such transformations. The dot traces the fate of the pro-R hydroxymethyl group of 
glycerol through to FAc 17 and 4-FT 39. 
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5-Deoxy-5-fluoro-α,D-ribose-1-phosphate (5-FDRP) 61 has been identified as the second 
intermediate on the fluorometabolite biosynthetic pathway in S. cattleya.1 It arises by the 
action of a purine-nucleoside phosphorylase (PNPase) on 5-deoxy-5-fluoroadenosine 
(5-FDA) 47. Fluoroacetaldehyde 26 was already known to be the last common intermediate 
to both fluoroacetate 17 and 4-fluorothreonine 39.2 However, metabolic intermediates that 
exist between 5-FDRP 61 and fluoroacetaldehyde 26 remained to be characterised. It was the 
focus of this work to identify these intermediates.  
The results described in this chapter indicate that 5-deoxy-5-fluoro-D-ribulose-1-phosphate 
(5-FDRulP) 69 is the next formed fluorometabolite after 5-FDRP 61.3 The enzyme 
responsible for the conversion of 5-FDRP 61 to 5-FDRulP 69 has been identified as an 
isomerase. In order to understand the metabolic fate of 5-FDA 47 and the next fluorinated 
intermediates on the pathway, a short overview of biochemical processes involving the 
metabolism of structurally similar nucleosides is given below. 
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2.1 L-Methionine salvage pathway 
The methionine salvage pathway is universally used to regenerate the amino acid 
L-methionine 48, crucial in many cellular functions, and to maintain its levels in vivo. Most 
organisms, from bacteria through plants to mammals, have evolved this route to surmount the 
energy consuming assimilation of sulfur.4 In this way, organic sulfur is recovered from 
5-methylthioribose (MTR) 64, which is derived from the S-methylthioadenosine (MTA) 63 
that is a by-product of other reactions involving SAM 49 (Scheme 2.1, vide infra). This 
metabolic pathway has been the subject of study due to its role in a variety of human tumour 
tissues.5,6,7 Also some analogs of MTR 64 have been shown to be growth inhibitors of the 
malarial protozoan, Plasmodium falciparum.8,9,10 
This metabolic route has been extensively studied in the gram-negative bacterium Klebsiella 
pneumoniae, where all of the genes and reactions have been revealed.11,12,13,14,15,16 
Very recently, the genes encoding the enzymes of all steps in this cycle have been also 
identified in the commonly used eukaryotic model system, the yeast Saccharomyces 
cerevisiae,17 as well as in the non-photosynthetic bacterium Bacillus subtilis.18 Scheme 2.1 
illustrates the methionine salvage pathway, as revealed in Bacillus subtilis.19  
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Scheme 2.1 Methionine salvage pathway in Bacillus subtilis.19 
 
The beginning of the pathway is variable, even in phytogenetically related organisms. Briefly, 
MTA 63, a product of spermidine metabolism, is converted into MTR 64 by the action of a 
MTA nucleosidase. Then, a MTR kinase acts upon MTR 64 to yield 5-methylthio-α,D-ribose-
1-phosphate (MTR-1-P) 65, a compound that is isomerised to 5-methylthio-ribulose-1-
phosphate (MTRu-1-P) 66  by a MTR-1-P isomerase (encoded in B. subtilis by gene mtnA). 
Remarkably, it has been observed that this gene, expressed at a level similar to that of the 
MTR kinase (mtnK), codes for a protein with a sequence as similar to that of the eukaryotic 
initiation factor eIF2B. Then, MTRu-1-P 66 is further metabolised by a dehydratase (encoded 
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by gene mtnW), an enzyme sharing high similarities to ribulose 1,5-bisphosphate 
carboxylase/oxygenase (RuBisCO), the most abundant naturally occurring protein.4,18,20,21 
Further along the pathway, MTR 64 can accumulate and becomes extremely toxic to the cell 
in the absence of mtnW, opening an unexpected target for new antimicrobial drugs.18 
 
 
2.1.1 5-Deoxy-5-methylthio-,D-ribose-1-phosphate 
 isomerases 
Abeles and co-workers11 first identified the action of 5-deoxy-5-methylthio-,D-ribose-1-
phosphate isomerase (MTR-1-P isomerase) in Klebsiella pneumoniae, where it was shown 
that 5-S-methyl-5-thio-,D-ribose-1-phosphate (MTR-1-P) 65 undergoes an isomerisation to 
(3R,4S)-5-methylthioribulose-1-phosphate (MTRul-1-P) 66 (as illustrated for B. subtilis in 
Scheme 2.1, vide supra). A number of MTR-1-P isomerases have since been purified from 
bacteria20 and yeast22 after gene cloning, and the yeast structure has been solved by X-ray 
analysis.22  
As previously mentioned, the gene (mtnA) of the MTR-1-P isomerase from Bacillus subtilis 
codes for a protein with a sequence annotated as similar to a family of eukaryotic initiation 
factors, eIF2B.4,23 Consequently, the amino acid sequence similarity between the B. subtilis 
MTR-1-P isomerase and related protein sequences, assigned as putative translation initiation 
factor eIF2B, from Streptomyces coelicolor, Streptomyces avermitilis, Klebsiella pneumoniae 
and Saccharomyces cerevisiae shows a high degree of homology (Figure 2.l, vide infra).  
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Figure 2.1 MTRP isomerase sequence alignments. 
 
Figure 2.1 illustrates this homology. For example, the S. coelicolor eIF2B shows a 32% 
identity and 52% similarity to the MTR-1-P isomerase from B. subtilis. This observation 
tentatively suggests that these putative translation initiation factors have been misassigned, 
and they are actually related to MTR-1-P isomerases. Recently, one of these proteins from 
S. cerevisiae (Ypr118w) was crystallised and characterised as a MTR-1-P isomerase.22 It was 
shown that Ypr118w is required for yeast cells to grow on MTA 63 in the absence of 
L-methionine 48, thus confirming the role of Ypr118w in the methionine salvage pathway in 
S. cerevisiae. This yeast isomerase shares 37% sequence identity to that from B. subtilis and a 
26-28% identity to the eIF2B from Schizosaccharomyces pombe and S. cerevisiae.22 
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2.2 The metabolism of 5-FDA in S. cattleya 
Work developed by C. Schaffrath in 2003 (University of St Andrews) focused on the 
metabolic fate of 5-FDA 47 in S. cattleya.24 It was shown that 47 supports fluorometabolite 
biosynthesis in S. cattleya when incubated in CFEs of the bacterium, generating 
fluoroacetate 17 and 4-fluorothreonine 39 with other fluorinated intermediates. 
 
 
 
 
Figure 2.2 19F{1H}NMR time course of production of fluorinated intermediates in a CFE of 
S. cattleya when incubated with 5-FDA 47 (20 mM) at 25 ºC for 19 h. 
 
As shown in Figure 2.2 (vide supra), the incubation of 5-FDA 47 in a CFE of S. cattleya also 
led to the formation of a complex between fluoroacetaldehyde 26 and 
tris(hydroxymethyl)aminoethane 68, the constituent of Tris buffer.  
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Surprisingly, fluoroethanol 67 was detected in such incubations, indicating the capacity of the 
CFE to reduce fluoroacetaldehyde 26 to fluoroethanol 67 (Scheme 2.2) 
 
 
Scheme 2.2 Biotransformation of fluoroacetaldehyde 26 to fluoroethanol 67 catalysed by an 
alcohol dehydrogenase in S. cattleya. 
 
The fact that 4-fluorothreonine 39 is generated implies that all of the enzymes and co-factors 
are present in the CFE for its biosynthesis from 5-FDA 47. Further work was carried out to 
investigate the fluorinated intermediates on the biosynthetic pathway to 
fluoroacetaldehyde 26. To this end, the biotransformation of 5-FDA 47 in CFEs of S. cattleya 
was followed in real time by 19F NMR spectroscopy.25 Thus, 5-FDA 47 (100  μl,  18.6  mM)  
was  incubated  in  an  active  CFE  (500  μl)  at  37  ºC  and  followed  by  19F{1H}NMR hourly. The 
time course spectra are shown in Figure 2.3 (vide infra). 
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Figure 2.3 19F{1H}NMR spectra of 5-FDA 47 incubation in a CFE of S. cattleya at 37 ºC for 9 h. 
 
The resultant 19F{1H}NMR spectra shown in Figure 2.3 clearly indicates a number of fluoro-
organic compounds derived from the incubation of 5-FDA 47. The time course showed the 
generation of fluoroacetate 17 and 4-fluorothreonine 39, consistent with the intermediacy of 
5-FDA 47. Production of 5-FDRP 61, the next intermediate after 5-FDA 47 in the 
fluorometabolite biosynthetic pathway, was also observed due to the action of a 
purine-nucleoside phosphorylase (PNPase). The rapid conversion of 5-FDA 47 to 5-FDI 50 
is apparent by the action of adenosine deaminase present in the CFE. The transformation of 
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5-FDRP 61 is shown to proceed to compound 69 (231.34 ppm) which appears after 2 h of 
incubation and accumulates over time. Production of fluoroacetaldehyde 26 is transient during 
the time course with later formation of compound 70. In order to gain an insight into the 
biosynthesis of the next fluorometabolite in the pathway, the metabolism of 5-FDRP 61 was 
studied. 
 
 
2.3 The metabolism of 5-FDRP in S. cattleya 
2.3.2 Preparation of 5-FDRP 61 
5-Deoxy-5-fluoro-α,D-ribose-1-phosphate (5-FDRP) 61 was already established as an 
intermediate on the fluorometabolite pathway.1 The metabolism of 5-FDRP 61 in a CFE of 
S. cattleya was studied in order to explore the hypothesis that an isomerase enzyme is 
operating in S. cattleya, and to elucidate the remaining fluorinated intermediates on the 
biosynthetic pathway. With this objective, it was necessary to prepare a sample of 61 for 
incubation studies with cell free extracts of the bacterium. This was achieved following a 
chemo-enzymatic approach, as outlined in Scheme 2.3 (vide infra). 
 
CHAPTER 2 
71 
 
Scheme 2.3 Chemo-enzymatic preparation of 5-FDRP 61. 
 
A synthetic sample of 5'-FDA 47 (synthetic procedure described in Chapter 3) was treated 
with 5'-adenylic acid deaminase (EC 3.5.4.6, from Aspergillus sp. Bacterium, Aldrich™) to 
generate 5'-FDI 50, the fluorinated unnatural substrate for a purine-nucleoside phosphorylase 
(supplied by GlaxoSmithKline), as previously described.1 This PNPase enzyme (EC 2.4.2.1) 
mediates the reversible phosphorolysis reaction to generate 5-FDRP 61 along with 5-FDR 71, 
as a result of a contaminating phytase activity present in the immobilised enzyme preparation. 
As a consequence, this chemo-enzymatically prepared sample of 61 contains residual 
5'-FDI 50 and 5-FDR 71. However, both 50 and 71 have been studied previously and are not 
biotransformed to the fluorometabolites in S. cattleya. They are recovered intact in CFE 
incubations of the bacterium.1,26 
This chemo-enzymatic preparation of 5-FDRP 61 was used in CFE incubations of the 
bacterium. 
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2.3.3 The effect of EDTA on fluorometabolite production 
Previous studies showed that the production of FAc 17 was arrested when EDTA was present 
in CFE incubations. EDTA is a well known chelator of metal ions and it appears to inhibit a 
zinc-dependent aldolase in the cell-free extract, operating later on in the pathway.25 
Accordingly, an experiment was conducted in which an active CFE (500   μl)   was  
pre-incubated with EDTA (30 mM) at 37 ºC for 30 min. After this time, the 5-FDRP 61 
preparation, also containing 5-FDI 50 and 5-FDR 71, was added to the pre-incubated 
cell-free extract. The reaction was monitored by 19F NMR spectroscopy at hourly intervals, 
and the resultant time course is shown in Figure 2.4 (vide infra). 
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Figure 2.4 (a) 19F{1H} NMR time course of a CFE of S. cattleya incubated with 5-FDRP 61 and 
EDTA at 37 ºC for 6 h.  (b) 19F-1H NMR spectrum after 6 h, expansion of region 
231.10 ppm to 231.80 ppm. 
 
The production of FAc 17 was arrested and this led to the accumulation of a new 
fluorometabolite clearly evident by 19F NMR (231.34 ppm, dt, 2JF-H 47.0 Hz and 
3JF-H 20.9Hz) as shown in Figure 2.4 (vide supra), alongside residual 5´-FDI 50 and 
contaminating 5-FDR 71. 
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2.3.4 Isomerisation of 5-FDRP to 5-FDRulP 
The MTR-1-P isomerase offered a model in metabolism to make the link in the 
fluorometabolite pathway in S. cattleya, where fluorine replaces the methylthio substituent at 
C-5. An analogous isomerisation on 5-deoxy-5-fluoro-α,D-ribose-1-phosphate (5-FDRP) 61 
would generate 5-deoxy-5-fluoro-D-ribulose-1-phosphate (5-FDRulP) 69, as outlined in 
Scheme 2.4 (vide infra). 
 
 
Scheme 2.4 Putative isomerisation of 5-FDRP 61 to 5-FDRulP 69 in S. cattleya. 
 
The presence of an isomerase enzyme in S. cattleya yielding 5-FDRulP 69 is an attractive 
hypothesis, as ribulose phosphates are classical products/substrates of DHAP-dependent 
aldolase enzymes.27,28,29 An aldolase could then mediate a reverse aldol reaction to give 
dihydroxyacetone phosphate (DHAP) 72 and fluoroacetaldehyde 26, which has been already 
established as a biosynthetic intermediate.2 Such an isomerase to aldolase sequence represents 
a realistic metabolic pathway that could account for the conversion of 5-FDRP 61 to FAd 26, 
as outlined in Scheme 2.5. 
 
 
Scheme 2.5 Putative enzymes for the conversion of 5-FDRP 61 to FAd 26 in S. cattleya. 
 
In order to test this hypothesis, the stepwise metabolism of 5-FDRP 61 in S. cattleya was 
investigated.  
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2.3.4.1 5-FDRulP as a biosynthetic intermediate 
The product mixture of 5-FDRP 61 (100  μl)  was  incubated  in  a  cell-free extract of S. cattleya 
(500  μl)  at  37  °C,  and  the  biosynthetic  fate  of  61 was followed by 19F NMR spectroscopy at 
hourly intervals for 6 h. The 19F{1H} NMR time course of this incubation is shown in 
Figure 2.5. 
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Figure 2.5 19F{1H}NMR time course of a CFE of S. cattleya incubated with a sample of 
5-FDRP 61 at 37 ºC for 6 h. 
 
The incubation of 61 showed the accumulation of FAc 17, consistent with its conversion in 
the cell free extract. The production of fluoroacetate 17 is consistent with the previously 
reported ability of 5-FDRP 61 to support fluorometabolite biosynthesis in S. cattleya.1 
However, a new signal corresponding to the next formed fluorometabolite was also observed 
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in this experiment. It was initially attributed to 5-deoxy-5-fluoro-D-ribulose-1-phosphate 
(5-FDRulP) 69, the product of a putative isomerase operating in S. cattleya. 
A product mixture of 5-FDRulP 69 was also analysed by GC-MS after derivatisation with 
N-methyl-N-(trimethylsilyl)trifluoacetamide (MSTFA) following the method described by 
Hamilton et al.30 to generate the persilylated ribulose phosphate derivative. Control 
experiments with GC-MS (CI -ve ion mode) were carried out on the substrate and the product 
mixtures as their persilylated derivates, illustrated in Figure 2.6.  
 
 
Figure 2.6 Persilylated derivatives of 5-FDRP 61 and 5-FDRulP 69 analysed by GC-MS (CI) 
after treatment with MSTFA. 
 
Despite the identical molecular masses for these isomers, the product 5-FDRulP 69 was 
clearly distinguished from the incubated 5-FDRP 61 by very different retention times. 
A molecular ion on 521 amu was the predominant ion and the location of the phosphate at the 
C-1 position was confirmed by the presence of  a mass ion at 283 amu. 
 
A. Preparation of 5-FDRul 73 
Immobilised glucose isomerase (EC 5.3.1.5, Sweetzyme T) has been reported to convert 
(2R,3R)-configured aldotetrose as well as D-ribofuranoses, modified at C-5, into the 
CHAPTER 2 
77 
corresponding open-chain 2-ketoses, the latter being the predominant products of the 
isomerisation reactions.31,32 
The product of the isomerisation reaction on 5-FDR 71 is 5-deoxy-5-fluoro-D-ribulose 
(5-FDRul) 73, the de-phosphorylated analogue of 5-FDRulP 69, a postulated biosynthetic 
intermediate in the fluorometabolite pathway. Scheme 2.6 illustrates this enzyme-catalysed 
isomerisation reaction.31  
 
 
Scheme 2.6 Chemo-enzymatic synthesis of 5-FDRul 73 with commercial glucose isomerase.  
 
Therefore, to further secure the identity of 5-FDRulP 69, it was envisaged that the 
stereochemistry of 5-FDRulP 69 could be established by correlation, by investigating the 
stereochemistry of 5-FDRul 73. The strategy is shown in Scheme 2.7. 
 
 
Scheme 2.7 Strategy to establish the stereochemistry of the intermediate 5-FDRulP 69 in 
S. cattleya by dephosphorylation and cross reference to 5-FDRul 73. 
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Accordingly, each of the resulting samples of 5-FDRulP 69 from the experiment illustrated in 
Figure 2.5 (vide supra), was treated with a commercial phosphatase (EC 3.1.3.8, from 
Aspergillus ficuum, Aldrich™) (100  μl,  10  mg/ml). This resulted in an immediate change of 
the 19F NMR chemical shift of the fluorinated metabolite 69 from   −231.34 ppm to 
−231.22 ppm, indicating that a chemical transformation had occurred, consistent with 
phosphate cleavage. The results are presented in Figure 2.7. 
 
 
Figure 2.7 19F{1H} NMR spectra after addition of a phytase to the samples from time course in 
Figure 2.5. Insets are 19F NMR expansions of the product peaks without {1H} 
decoupling. 
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This set of experiments supported the conversion of 5-FDRP 61 to 5-FDRulP 69, and then to 
the free sugar 5-deoxy-5-fluoro-D-ribulose (5-FDRul) 73 by the action of the added 
phosphatase. 
For further confirmation, a sample of 5-deoxy-5-fluoro-D-ribose (5-FDR) 71 was prepared 
independently as a reference compound to cross reference the product generated from the 
sequence of biotransformations described above. Open-chain 2-keto sugars have been 
synthesised from glucose isomerase catalysed isomerisation of the corresponding D-ribo and 
D-xylofuranoses as shown in Scheme 2.6 (vide supra).31,32 
Therefore, a sterochemically pure sample of 5-FDR 71 was prepared by synthesis as 
described in Chapter 3. Immobilised glucose isomerase (EC 5.3.1.5, Sweetzyme T from 
S. murinus) was used for the production of 5-FDRul 73 from 5-FDR 71. Accordingly, an 
aqueous solution of 5-FDR 71 (4.7 mM) was incubated with immobilised glucose isomerase 
(30 mg) at 37 ºC. The reaction was monitored by 19F NMR spectroscopy and a time course is 
illustrated in Figure 2.8 (vide infra). 
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Figure 2.8 19F{1H} NMR time course of 5-FDR 71 (4.7 mM) incubated with a commercial 
immobilised glucose isomerase at 37 ºC. Insets are non-decoupled 19F NMR 
expansions of the product signals. Traces of product 5-FDRul 73 are detected by 
19F NMR in the 0 h sample due to the initial running time of the experiment 
(approx. 30 min.). 
 
The two anomers of the 5-FDR 71 starting   material,   (β-anomer: 228.53 ppm, dt, 
2JF-H 46.5 Hz and 3JF-H 26.0  Hz;;  α-anomer: 230.83 ppm, dt, 2JF-H 46.5 Hz and 3JF-H 27.9 Hz) 
dominated at the outset and over time the 5-FDRul 73 product signal at 231.22 ppm (dt, 
2JFH 46.9 Hz and 3JF-H 20.5 Hz) accumulates. Incubation times longer than 6 h did not result 
in further accumulation of product due to the reversible reaction reaching an equilibrium.  
Notably the 19F NMR product signal at –231.22 ppm for 73 has an identical chemical shift 
and coupling pattern to the product observed after incubating 5-FDRP 61 and EDTA with the 
cell free extract of S. cattleya, followed by phosphatase treatment.  
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Co-addition of the glucose isomerase reaction product to that of the EDTA-cell-free 
extract/phosphatase reaction gave identical products as judged by 19F NMR as shown in 
Figure 2.9. 
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Figure 2.9 19F{1H} NMR spectra of :  (a) S. cattleya cell-free extract incubation of 
5-FDRP 61/5-FDI 50 and subsequent treatment with phosphatase.  (b) 5-FDRul 73 
generated by incubation of synthetic 5-FDR 71 with glucose isomerase.  (c) Co-
addition of these samples indicating that the 19F{1H} NMR signal for 73 perfectly 
overlaps. 
 
For comparison, a sample of 5-deoxy-5-fluoro-D-xylose (5-FDX) 74 was also prepared by 
synthesis (outlined in Chapter 3) in a stereospecific manner. Incubation of this furanose 
isomer with glucose isomerase would then generate 5-deoxy-5-fluoro-D-xylulose 
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(5-FDXul) 75. The strategy for the chemo-enzymatic preparation of the diasteroisomer of 73 
is illustrated in Scheme 2.8. 
 
 
Scheme 2.8 Chemo-enzymatic synthesis of 5-FDXul 75. 
 
The synthesis of 5-FDX 74 was achieved via the synthetic procedure described in Chapter 3. 
With 74 in hand, a glucose isomerase catalysed isomerisation reaction was carried out by 
incubating an aqueous solution of 5-FDX 74 (1 ml, 4.7 mM) with glucose isomerase (30 mg) 
at 37 ºC for 3 h. The reaction was monitored by 19F NMR spectroscopy every hour. The 
resultant 19F NMR time course is illustrated in Figure 2.10 (vide infra). 
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Figure 2.10 19F {1H} NMR time course of 5-FDX 74 (4.7 mM) incubated with a commercial 
immobilised glucose isomerase at 37 ºC for 3 h. Traces of product 5-FDXul 75 are 
detected by 19F NMR in the 0 h sample due to the initial running time of the 
experiment (approx. 30 min.). 
 
After 1 h of incubation, the 19F NMR spectrum showed the production of 75 with a new 
fluorine signal at 228.55 ppm (dt, 2JF-H 46.2 Hz and 3JF-H 15.3 Hz). The product of this 
reaction, 5-FDXul 75 does not correlate with the product of the cell-free extract plus phytase 
treatment. These results confirm that the product of the cell-free extract is indeed 
diastereoisomer 73, as expected, and not diastereoisomer 75. 
Taken together, this set of complementary biotransformations secures 5-FDRulP 69 as an 
intermediate formed immediately after 5-FDRP 61 on the pathway to the secondary 
fluorometabolites FAc 17 and 4-FT 39 in S. cattleya. The reaction involves an isomerisation, 
which finds precedent in the isomeration of the methylthiosugars in the methionine salvage 
pathway. 
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B. The role of 5-FDRul 73 
The capability of 5-FDRul 73, the dephosphorylated product of 5-FDRulP 69, to support 
fluoroacetate 17 and 4-fluorothreonine 39 production was explored. The aforementioned 
chemo-enzymatic approach was used to prepare a sample of 5-FDRul 73 for incubation 
studies. Accordingly, 5-deoxy-5-fluoro-D-ribose 71 was prepared by synthesis (as described 
in Chapter 3) and incubated with the enzyme. This preparation of 5-FDRul 73 also contained 
5-FDR 71, which has already shown to be metabolically inert within S. cattleya. 
Consequently,  an  active  CFE  (500  μl)  was  incubated  with  this  5-FDRul 73 preparation (100 
μl)  for  16  h  at  37 ºC. The resulting spectra of the biotransformation are shown in Figure 2.11. 
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Figure 2.11 19F {1H} NMR spectra of 5-FDRul 73 incubated in a CFE of S. cattleya. 
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The 19F {1H} NMR spectra clearly show that no biotransformation occurred when the product 
of the glucose isomerase reaction on 5-FDR 71, 5-FDRul 73, was incubated in a CFE of 
S. cattleya, indicating that 5-FDRul 73 does not support the biosynthesis of fluoroacetate 17 
and 4-fluorothreonine 39. 
 
 
2.3.4.2 Purification of the isomerase 
A. Assay for isomerase activity 
In order to purify the isomerase enzyme from S. cattleya, a suitable assay was required. Thus, 
the conversion of 5-FDRP 61 to 5-FDRulP 69 catalysed by the isomerase was monitored by 
19F NMR spectroscopy. The assay is described in detail in Chapter 5, and was used at each 
purification stage. 
 
B. Step 1: Ammonium sulfate precipitation 
In the first stage of the isomerase purification, the crude cell-free extract was subjected to 
ammonium sulfate precipitation to salt out the desired protein. Accordingly, ammonium 
sulfate (NH4)2SO4 was added to an active CFE and the solution was left to stir for 20 min at 
4 oC. Protein precipitations were carried out using four (NH4)2SO4  cuts (0-35%, 35-50%, 
50-60%, 60-80%). After this time the precipitated protein was removed by centrifugation 
(14000 rpm, 20 min) and the supernatant used for the next (NH4)2SO4 cut. Each of the 
(NH4)2SO4 cuts was assayed in the following manner. Partially purified CFE (200 µl) was 
supplemented with 5-FDRP 61 prepared by the method outlined in Chapter 5 and incubated 
for 16 h at 37 oC. The resulting samples were then analysed by 19F NMR spectroscopy. The 
resultant 19F NMR spectra are shown in Figure 2.12 (vide infra).  
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Figure 2.12 19F {1H} NMR spectra of ammonium sulfate cuts of the isomerase incubated with 
5-FDRP 61. 
 
Analysis of the ammonium sulfate cuts actually revealed that the 35-60% cut contained all of 
the biosynthetic enzymes and co-factors required to support fluoroacetate 17 and 
4-fluorothreonine 39 biosynthesis. The isomerase activity is found predominantly in the 
35-50% cut with a less activity in the 50-60 % cut. No isomerase activity was detected in any 
of the other fractions, which only showed presence of 5-FDRP 61 and 5-FDI 50. 
The isomeration of 5-FDRP 61 to 5-FDRulP 69 could not be detected in real time because 
assay of the samples involved pre-incubation with EDTA. The 35-50% cut (100 µl) was 
pre-incubated with EDTA for 25 min at 37 oC. After this time, the pre-incubated sample was 
supplemented with 5-FDRP 61 and incubated for 16 h at 37 oC. Analysis by 19F NMR 
spectroscopy (Figure 2.13) showed that the 35-50% cut was able to support the synthesis of 
5-FDRulP 69, implying that the addition of a metal ion co-factor is not required for the 
isomerisation reaction. 
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-231,273
-231,317
-231,373
-231,418
5-FDI 50 
 
Figure 2.13 19F {1H} NMR spectrum of 35-50% (NH4)2SO4 cut incubated with 5-FDRP 61 and 
EDTA for 16 h at 37 ºC. Inset shows a non-decoupled 19F NMR expansion of the 
product signals. 
 
The generation of 5-FDI 50 was confirmed by comparison with a reference sample on 
admixing. 
 
 
C. Step 2: Hydrophobic interaction chromatography 
A hydrophobic interaction chromatography (HIC) column (Phenyl HP, 40 ml) was 
equilibrated with phosphate buffer (50 mM, pH 6.8) supplemented with 1 M (NH4)2SO4. The 
35-50% (NH4)2SO4 precipitate was re-dissolved in equilibration buffer (6 ml, 20 mg / ml). 
The sample was injected and eluted under a (NH4)2SO4 gradient following the protocol 
detailed in Chapter 5. Figure 2.14 shows the resulting protein elution chromatogram 
(vide infra). 
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Figure 2.14 Protein elution chromatogram at step 2 of the isomerase purication protocol after 
ammonium sulfate precipitation and the HIC column.  
 
Each of the protein fractions collected after this second step of purification was assayed for 
isomerase activity. Thus, a small volume of protein solution (200 µl) was incubated with 
5-FDRP 61 at 37 oC for 16 h and then analysed by 19F NMR spectroscopy. It was found that 
the partially purified isomerase elutes at the end of the gradient (highlighted area). This 
indicates a strong affinity to the resin. It is clear from the chromatogram that purification by 
hydrophobic interaction eliminated a substantial amount of undesired protein. 
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D. Step 3: Size exclusion chromatography 
Size exclusion chromatography was the next step chosen for the purification of the isomerase. 
After the HIC step, there is no ammonium sulfate in the partially purified isomerase, which 
allows direct injection of this sample onto a size exclusion column. Thus, after concentration 
of the sample, the partially purified isomerase (2 ml, ~8 mg / ml) was applied to a pre-
equilibrated Superdex 200 column. Figure 2.15 shows the resulting protein elution 
chromatogram. 
 
 
Figure 2.15 Step 3 for the purification of the isomerase enzyme from S. cattleya. 
 
As previously carried out, protein fractions were assayed for isomerase activity. The 
isomerase enzyme was found to be in the 7280 ml fraction (highlighted area) with a protein 
concentration of ~ 0.5 mg/ml. Baseline separation was not achieved and therefore a further 
purification step was clearly required. 
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 E. Step 4: Anion exchange chromatography 
Anion exchange chromatography was now explored to purify further the active fractions 
following the protocol detailed in Chapter 5. The active fractions after step 3 were combined 
(8 ml) and concentrated (2 ml) by centrifugation. The concentrated protein was then passed 
through a desalting column (HiTrap™ desalting, 5 ml) and re-concentrated again (~ 2 ml). 
This sample was loaded onto a strong anion exchange column (Q, 5 ml, Amersham 
Biosciences) and was pre-equilibrated with Tris buffer (50 mM, pH 7.2). Elution was 
achieved using a stepwise gradient following the protocol described in Chapter 5. The protein 
elution profile is shown in Figure 2.16. 
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80
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157.10
     
Figure 2.16 Step 4:  Protein elution chromatogram obtained by anion exchange using a Q, 5 ml 
column after injection of sample (2 ml) after size exclusion purification. Active 
fraction is highlighted in the chromatogram. 
 
Each fraction was assayed for isomerase activity using the assay outlined in Chapter 5. It 
emerged that the desired activity eluted after 250 mM KCl addition with a total protein 
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concentration of 1.5 mg / ml. It is clear from the trace in Figure 2.16 that the isomerase 
enzyme is still not homogenous and further purification is required. 
 
 F. Isomerase analysis by SDS-PAGE 
Each stage of the isomerase purification was monitored by SDS-PAGE and the resultant gel is 
shown in Figure 2.17.  
 
Figure 2.17 SDS-PAGE gel (4-12% acrylamide) showing active protein fractions containing 
isomerase activity during each purification step. Lanes: 0, molecular markers; 
1, hydrophobic interaction chromatography; 2, size exclusion chromatography; 
3, anion exchange chromatography. 
 
Finally, the partially purified isomerase was shown to catalyse the biotransformation of 
5-FDRP 61 to 5-FDRulP 69, confirming purification of the isomerase enzyme operating in 
S. cattleya. 
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2.3.4.3 Identification of the isomerase gene in S. cattleya 
Contemporaneous work carried out by Dr H. Deng in the research group led to the 
identification of the analogous isomerase gene in S. cattleya.33 The protein sequences of 
S. coelicolor and S. avermitilis genomes highlighted 2 genes SCO3014 (S. coelicolor) and 
SAV6658 (S. avermitilis), previously annotated as ‘eukaryotic  translation  initiation  factors  2’  
(eIF2B). The amino acid sequences had a 35% amino acid identity to the B. subtilis MTRP 
isomerase and therefore these genes probably code related isomerases. The SCO3014 gene 
was amplified by PCR from S. coelicolor genomic DNA and the protein was over-expressed 
in E. coli for evaluation. After examination of the conserved domains of SCO3014 and 
SAV6658, DNA primers were designed for PCR amplification using S. cattleya genomic 
DNA as a template. This proved successful. The resulted sequenced open reading 
frame (ORF), with ~75% identity to the putative isomerase from S. coelicolor, was 
over-expressed in E. coli. The purified protein showed a molecular weight of approximately 
40 kDa by SDS-PAGE, and the sequence was confirmed by MS-MS analysis. 
Biotransformation assays of this S. cattleya isomerase revealed that this enzyme also catalyses 
the conversion of 5-FDRP 61 to 5-FDRulP 69.33 
Analysis of the sequence similarity between the MTRP isomerase from Bacillus subtilis, 
Saccharomyces cerevisiae and Kebsiella pneumoniae, and related protein sequences from 
Streptomyces avermitilis, Streptomyces coelicolor and Streptomyces cattleya are shown in 
Figure 2.18 (vide infra). 
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Figure 2.18 MTR-1P isomerase sequence alignments for B. subtilis, K. pneumoniae, S. cerevisae, 
S. avermitilis, S. cattleya and S. coelicolor. 
 
There is clearly a high level of conserved residues between the genes from the Streptomyces 
species. This high homology suggests that the gene from S. cattleya is likely to have the same 
function as that of SCO3014 and SAV6658. The fact that the S. cattleya enzyme has the 
ability also to catalyse the isomerisation of 5-FDRP 61 to 5-FDRulP 69 suggests a possible 
dual function, which is consistent with the observation that no obvious isomerase gene has 
been found in the gene cluster associated with the fluorinase (flA) and PNP (flB) genes.33,34 
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2.3.4.4 Mechanism of the isomerase enzyme 
Recently the crystal structure of the 5-methylthioribose-1-phosphate isomerase (EC 5.3.1.23) 
from Bacillus subtilis has been solved in a complex with its product, MTRu-1-P 68.35 This 
finding has shed some light on possible mechanisms for the isomerisation reaction. The 
putative catalytic mechanisms for such an aldose-ketose isomerisation are shown in 
Scheme 2.9.  
 
 
Scheme 2.9 Mechanisms for the isomerisation of an aldose to a ketose. 
 
Unlike the substrates of other aldose-ketose isomerases, that normally bear hydroxyl groups 
on the cyclic C-1, MTR-1-P 67 has a phosphate group on the corresponding C-1 position. The 
crystal structure of the B. subtilis isomerase with MTRu-1-P 68 (Figure 2.19, vide infra) 
shows binding of the phosphate group at the active site, suggesting its requirement and 
involvement in the catalysis of the isomerisation reaction. 
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Figure 2.19 Active-site structure of Bs-M1Pi. (a) Close-up stereoview of the MTR-1-P isomerase 
active site in complex with MTRu-1-P 68 showing the interactions with the phosphate 
group (in orange and red). (b) Schematic representation deduced from X-ray 
crystallography data of hydrogen bonding contacts of MTRu-1-P 68 in the active site 
structure. Dashed lines: hydrogen bonds with the distance (Å); cyan semicircles: the 
hydrophobic interactions; the residues involved in the binding of the phosphate group 
(highlighted in orange) and the backbone oxygens of MTRu-1-P (shown in green). 
 
In S. cattleya it has been shown that such a phosphate group is a requirement for the 
isomerisation of FDRP 61, since FDR 71 is not further biotransformed and remains 
metabolically inert in CFEs of the bacterium.1 Scheme 2.10 illustrates two possible but 
distinct mechanisms for the isomerisation reaction of MTR-1-P 67 based on crystallographic 
data.35 
(a) (b) 
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Scheme 2.10 Two possible mechanisms. The cis-enediol proton transfer (upper site in yellow box) 
and 1,2-hydride shift (underside in purple box) reaction of M1Pi based on the crystal 
structure of its product complex. D240 protonates the ring oxygen of MTR-1-P. C1-O 
bond cleavage could be accompanied by a hydride shift to quench the generating 
carbocation. 
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In a similar manner to the mechanism of xylose isomerase 36,37,38,39 the side chain of Asp240 
donates a proton to the ring oxygen to promote the ring-opening step during catalysis 
(Scheme 2.10, vide supra). In addition, previous NMR and mass spectrometry studies of 
BsM1Pi in D2O showed some analogy with those of xylose isomerase, which adopts the 
hydride transfer mechanism.37 However, it remains to be elucidated whether the mechanism 
of this reaction proceeds via a direct hydride transfer or via a cis-enediol intermediate, since 
the crystal structure does not discriminate between these mechanisms.35 
Currently work is being undertaken within our research group to shed some light on this 
mechanism. 
 
 
2.4 The metabolism of 5-FDRulP in S. cattleya 
2.4.1 Aldolases in S. cattleya 
Aldolases (EC 4.1.2.X) are an ubiquitous class of enzymes that catalyse in vivo the reversible 
asymmetric addition of dihydroxyacetone phosphate (DHAP) 72 to D-glyceraldehyde-3-
phosphate (G3P) or L-lactaldehyde. These enzymes have attracted particular attention because 
of their application in organic synthesis (i.e., chiral synthetic processes), since they catalyse 
the regio- and stereospecific aldol addition of DHAP 72 with a wide range of acceptor 
aldehydes to generate products with two new stereogenic centres.40,41,42 
There are four different types of DHAP-dependent aldolase enzymes and each one mediates 
the formation of a distinct stereoisomer.27,28,29 The stereochemistry of the products formed 
during each enzymatic aldol reaction has been extensively studied, and is shown in 
Scheme 2.11 (vide infra). 
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Scheme 2.11 The four DHAP-dependent aldolases: L-fuculose-1-phosphate aldolase (L-FucA, 
EC 4.1.2.17), L-rhamnulose-1-phosphate aldolase (L-RhuA, EC 4.1.2.19), tagatose-
1,6-bisphosphate aldolase (TagA, EC 4.1.2.40) and fructose-1,6-bisphosphate aldolase 
(FruA, EC 4.1.2.13) 
 
Aldolases have been divided into two classes according to their mode of donor activation. 
These two types of aldolases also vary in structure, since they are phylogenetically distinct.43 
Class I aldolases, which are present in all groups of living organisms, from prokaryotes to 
eukaryotes, achieve stereospecific deprotonation of the substrate by means of covalent linkage 
to an active site lysine residue (imine/enamine formation).44,45 Class II aldolases occur only in 
prokaryotes and lower eukaryotes such as bacteria, yeast, algae and fungi; and they utilise 
transition metal ions (usually Zn2+) as essential Lewis acid co-factors to facilitate 
deprotonation.29,46 Type I aldolases are inactivated by treatment with sodium borohydride, 
while type II aldolases are inactivated by chelating compounds such as EDTA. 
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Scheme 2.12 illustrates the general mechanism for class I DHAP-dependent aldolases.44 The 
mechanism for catalysis by class II DHAP-dependent aldolases is shown in Scheme 2.13.46 
 
 
Scheme 2.12 General mechanism for Class I DHAP-dependent aldolase. 
 
 
Scheme 2.13 Mechanism of Class II DHAP-dependent aldolase. 
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Previous work identified two DHAP-dependent aldolases,25 one of which, a class II 
L-fuculose aldolase (L-FucA), is involved in fluorometabolite biosynthesis in S. cattleya and 
generates fluoroacetaldehyde 26 from 5-deoxy-5-fluoro-D-ribulose-1-phosphate (5-FDRulP) 
69. The other one, a L-fructose 1,6-bisphosphate aldolase (L-FruA) was purified to 
homogeneity and appears to be responsible for the formation of intermediate 70 (Figure 2.3, 
vide supra). The product of this L-FruA has been tentatively assigned as 5-deoxy-5-fluoro-D-
xylulose-1-phosphate (5-FDXulP) 70 after comparison studies with 5-FDXul 75. 
 
 
 
This L-FruA was shown to catalyse an aldol reaction between DHAP 72 and 
fluoroacetaldehyde 26 to generate 5-FDXulP 70. This enzyme is also a class II aldolase, 
requiring a divalent metal ion such as Zn2+, Mg2+, Mn2+, Co2+, Ni2+, Fe2+ or Ca2+ for catalytic 
activity. L-FruA was purified to homogeneity and showed homology to a L-FruA from 
Streptomyces galbus.25,47 The purified protein showed a molecular weight of approximately 
40 kDa by SDS-PAGE, and a native mass of 160 kDa was observed by gel filtration, 
indicating a tetramer. The amino acid sequence showed similarity to other bacterial 
L-FruAs.25 Biotransformation assays of this S. cattleya aldolase suggested its relationship to 
primary metabolism and the formation of 5-FDXulP 70 as a shunt product. Scheme 2.14 
outlines the formation of 69 and 70 from fluoroacetaldehyde 26 in S. cattleya. 
 
 
Scheme 2.14 The stereochemical relationships of the two aldolases in the S. cattleya CFE. 
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Purification of the L-FucA operating in S. cattleya proved to be unsuccessful.25 Recent work 
by S. Cross focused on the isolation of the gene for L-FucA, putatively involved in 
fluorometabolite production in S. cattleya. Unfortunately, all attempts to isolate such gene 
from S. cattleya genomic DNA were also unsuccessful.33 
The metabolic relationships and enzymes involved in the biosynthesis of fluoroacetate 17 and 
4-fluorothreonine 39 in S. cattleya are summarised in Scheme 2.15. 
 
 
Scheme 2.15 Overview of the fluorometabolite biosynthetic pathway in S. cattleya. 
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2.5 Conclusions 
(3R,4S)-5-Deoxy-5-fluoro-D-ribulose-1-phosphate (5-FDRulP) 69 has been identified as the 
third fluorinated intermediate on the biosynthetic pathway to fluoroacetate 17 and 
4-fluorothreonine 39. 5-FDRulP 69 is generated after formation of 5-deoxy-5-
fluoroadenosine (5-FDA) 47 and then phosphorolysis of 5-FDA 47 to 5-fluoro-5-deoxy-α,D-
ribose-1-phosphate (5-FDRP) 61 occurs by the action of a purine-nucleoside phosphorylase. 
An isomerase mediates the conversion of 5-FDRP 61 to 5-FDRulP 69. The identity of the 
(3R,4S) diastereoisomer of 5-FDRulP 69 was established by comparative 19F{1H} NMR 
studies whereby 5-FDRulP 69 that accumulated in a cell free extract of S. cattleya, was 
treated with a phytase to generate the non-phosphorylated sugar, 5-deoxy-5-fluoro-D-ribulose 
(5-FDRul) 73. 
This S. cattleya product was compared to the product of an in vitro biotransformation where 
separately 5-deoxy-5-fluoro-D-ribose (5-FDR) 71 and 5-deoxy-5-fluoro-D-xylose (5-FDX) 74 
were converted to 5-deoxy-5-fluoro-D-ribulose (5-FDRul) 73 and 5-deoxy-5-fluoro-D-
xylulose (5-FDXul) 75, respectively, by the action of a glucose isomerase. It was 
demonstrated that 5-FDR 71 gave the identical diastereoisomer to that observed from 
5-FDRulP 69. 
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Synthesis of key molecules 
 
 
 
 
3.1 Synthesis  of  5’-deoxy-5’-fluoroadenosine 47 
As described in Chapter 1, 5-deoxy-5-fluoroadenosine (5-FDA) 47 is the product of the 
fluorinase in S. cattleya. This metabolic intermediate is capable of supporting the biosynthesis 
of fluoroacetate (FAc) 17 and 4-fluorothreonine (4-FT) 39 when incubated in a cell-free 
extract. Consequently, 5-FDA 47 is a key intermediate for detailed studies on the 
fluorometabolite pathway, and it is continually required in this research project. Therefore, a 
straightforward synthesis of 5-FDA 47 was necessary to carry out cell-free extract incubation 
experiments to support the research programme.  
Few examples of the synthesis of mono-fluorinated nucleosides at C-5 are found in the 
literature. Moreover, there was only one reported synthesis of the target molecule 5-FDA 47, 
at the outset of this work.1 The synthesis is illustrated in Scheme 3.1 (vide infra). 
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Scheme 3.1 The synthesis of 5-FDA 47 reported by Kissman and Weiss.1   
 Reagents and conditions: (a) Pyridine / MsCl, 3 ºC, 71%  (b) KF / MeOH, 160 ºC, 
68%  (c) 0.02 N H2SO4, 100 ºC, 100%  (d) Pyridine / acetic anhydride, 21%  
(e) Acetyl choride, HCl / ether, 3 ºC  (f) Chloromercuri-6-chloropurine / xylene, 
140 ºC, 54%  (g) NH3 / MeOH, 100 ºC, 64%. 
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The overall yield for this synthesis as reported by Kissman and Weiss, was 4% without 
including the additional step that is required for the preparation of 82, a starting material 
prepared from ribose 81. The fluorinated intermediate 84 is obtained by nucleophilic 
displacement of a mesylate group using anhydrous KF.1 Although the yield of the reaction is 
quite good (68%), the required reaction conditions are fairly harsh (Scheme 3.1, step b). 
Other reported 5-fluorinated nucleosides have been generated as a result of an attempt to 
synthesise molecules resistant to phosphorylation at C-5.2 Among those are the fluorinated 
derivatives of toyocamycin 91 and the antibiotics, sangivamycin 92 and thiosangivamycin 93, 
shown in Scheme 3.2 (vide infra). 
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Scheme 3.2 The synthesis of 5-fluoro-nucleosides 91, 92 and 93 as reported by Sharma et al.2 
Reagents and conditions: (a) DAST, benzene, 80 ºC, 3 h, 35%  (b) MsCl, pyridine, 
0 ºC, 24 h, 78%  (c) TBAF, MeCN, reflux, 24 h, 90%  (d) Formic acid (60% crude)  
(e) Pyridine, benzoyl chloride, 0 ºC, 95%  (f) Acetic acid / acetic anhydride, 78%  
(g) 4-Amino-6-bromo-5-cyanopyrrolo[2,3-d]pyrimidine / hexamethyldisilazane, 
TMSTF, 77%  (h) Et3N, Pd charcoal / H2, 90%  (i) NH3 / MeOH, 91%  (j) NH4OH, 
H2O2, 75%  (k) Hydrogen sulfide / pyridine, then  NH3 / MeOH, 27% (over two 
steps). 
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The synthesis of 47, 91, 92 and 93, derive from 5-deoxy-5-fluoro-2,3-O-isopropylidene-β-D-
ribofuranoside 83 (Schemes 3.1 and 3.2, vide supra). 
Sharma et al. improved the yield of the fluorination step to 84 to 90% by employing 
tetrabutylammonium fluoride (TBAF) as the fluorinating reagent (Scheme 3.2, step c). They 
also showed the practicality of direct fluorination of the C-5 hydroxyl group using DAST as a 
fluorinating agent (Scheme 3.2, step a). However, the reaction yield is lower than that 
achieved with TBAF, even when taking the mesylation step into consideration.2  
As illustrated in Schemes 3.1 and 3.2, the synthesis of 5-fluorinated nucleosides involves the 
incorporation of a fluorine atom into a suitably protected sugar and subsequent coupling to the 
desired base by a ribosylation reaction.3,4 Such a synthetic approach allowed the preparation 
of 5-fluoro analogs of several purine and pyrimidine nucleosides.1 However, the 
condensation reaction between the 5-fluorinated protected sugar and the base often presents 
some disadvantages, such as a low reaction yield, formation of undesired nucleosides and also 
the use of toxic mercury based reagents.1 
In order to overcome these inconveniences, a new synthetic route to 5-FDA 47 was 
developed at St Andrews by S. Cobb.5 The route involved a combination of the procedures 
detailed in Schemes 3.1 and 3.2, and was especially designed to avoid the glycosylation step. 
Thereby, the synthesis of 5-FDA 47 was initially carried out following this new procedure. 
The synthetic sequence is shown in Scheme 3.3. 
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Scheme 3.3 Reagents and conditions: (a) MsCl, pyridine, RT, 4 h  (b) TBAF.3H2O, MeCN, 
reflux, 17 h  (c) 0.02 M H2SO4, reflux, 5 h. 
 
The starting material 94 can be easily prepared from adenosine using a standard protection 
protocol using acetone and 2,3-dimethoxypropane with an acid catalyst.6 However, 
widespread application for the preparation of modified nucleosides has resulted in 94 
becoming commercially available. The first step of the synthesis involves the activation of the 
C-5 hydroxyl group in 94 via a mesylation reaction. Therefore, 2,3-O-isopropylidene-5-O-
mesyl-adenosine 95 was prepared according to known procedures.7 The mesylation reaction 
furnished the desired product in good yield (68%), and the analytical and spectroscopic data 
for the compound were in full agreement with the literature. 
Fluorination of 95 used tetrabutylammonium fluoride (TBAF) as the fluorinating reagent. 
TBAF is available as its trihydrate form (TBAF.3H2O), and although there are procedures 
detailed to prepare anhydrous TBAF 8 there are problems associated with the stability of 
anhydrous TBAF and there is evidence that its use increases the formation of elimination 
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products due to the increased basicity of dry fluoride ion and the presence of hydroxide ion.9 
Therefore, mesylate 95 was subjected to fluoride substitution conditions using 2.5 equivalents 
of TBAF.3H2O in refluxing acetonitrile for 16 h. The fluorination, although successful, 
resulted in a significant decrease of the yield (31%). It is worth noting that the free amine at 
the C-6 position of the adenine base in 94 did not participate in, or complicate, the reaction 
and only the 5-O-mesyl compound 95 was isolated. Thus, no formation of unwanted 
3,5-cyclo-nucleoside 97 was observed, a compound previously identified in C-5 activation 
protocols.7  
 
 
Finally, the 2,3-isopropylidenated-5-FDA 96 was deprotected under acidic conditions. 
However, this synthesis resulted in a poor yield of the desired 5-fluorinated product 47. The 
mesylate is generally prepared in good yield (68%), but once subjected to fluoride substitution 
conditions the yield decreased significantly. Consequently, the recovery of 5-FDA 47 is poor.  
While this work was in progress, an improved synthesis of 5-deoxy-5-fluoroadenosines was 
reported in the literature by Ashton and Scammells.10 So far, the synthesis of 5-FDA 47 and 
related compounds involved the conversion of the 5-OH group to the corresponding sulfonate 
leaving group, i.e., the tosylate or mesylate. This is then followed by substitution using a 
suitable fluoride nucleophile under SN2 conditions. However, such synthetic sequences 
typically result in poor yields. Different factors contribute to the decreased efficiency of this 
synthetic method, including the instability of the sulfonated intermediates. The 5-sulfonates 
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are regarded as poor precursors for nucleophilic substitution due to a competing 
intramolecular reaction between N-3 of the adenine ring and C-5 of the ribose moiety to give 
undesired cyclic nucleosides (e.g., 97). This process is activated by the lone pair on the 
exo-cyclic N6-nitrogen of the adenine ring. Protection of that N6-nitrogen would reduce the 
effect of the lone pair but would also lengthen the synthetic route.11,12,13 
Ashton and Scammells envisaged that an electron withdrawing group at N-6 of the adenine 
ring would negate the formation of any intramolecular cyclised product. Besides, using a 
6-chloropurine moiety would also have the advantage of being a good starting point for the 
preparation of a range of N6-substitution adenosine derivatives.10 
This new synthetic route to 5-FDA 47 was therefore explored for the first time in the lab 
following the literature as outlined in Scheme 3.4 (vide infra).  
 
 
Scheme 3.4 Reagents and conditions: (a) Acetone, 2,2-dimethoxypropane, p-toluenesulfonic 
acid monohydrate, RT, 4 h, 73%  (b) TsF, TBAF, THF, 66 ºC, 22 h, 81%  (c) NH3, 
t-BuOH, sealed tube, 90 ºC, 24 h, 92%  (d) TFA (90%), RT, 25 min, 85%. 
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The synthesis starts with 2,3-isopropylidene-6-chloropurine riboside 99 (Scheme 3.4, 
vide supra), which, although commercially available, is easily prepared from 6-chloropurine 
riboside 98.14 Then, the free 5-OH is dehydroxyfluorinated by refluxing in THF with tosyl 
fluoride (TsF) and tetrabutylamonium fluoride (TBAF) following the method previously 
described by Shimizu.15 The generation of the tosylate in the presence of excess fluoride was 
predicted to minimise the formation of any undesired cyclic nucleoside 97. However, under 
such conditions, fluorine substitution at the N6-position of 99 was also observed, giving rise to 
the resultant aryl fluoride 100b. Therefore 100a and 100b were obtained as a mixture and 
carried through to the next step. The mixture of 100a and 100b was then aminated smoothly 
by heating in a t-BuOH solution saturated with NH3(g). The desired 2,3-isopropylidenated-5-
deoxy-5-fluoroadenosine 96 was formed in excellent yield (92%). Deprotection to give 47 
was then achieved in good yield using 90% trifluoroacetic acid (TFA).16 
This new synthetic route to 5-FDA 47 proved very successful in our hands, showing good 
yields in all of the steps and it has emerged as our route of choice to 5-FDA 47. 
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3.2 Synthesis of 5-deoxy-5-fluoro-D-ribose 71 
Two potential synthetic routes to 5-FDR 71 have previously been outlined and are illustrated 
in Schemes 3.1 and 3.2.1,2 In addition to these two synthesis, Ebner and Stütz reported another 
method as illustrated in Scheme 3.5.17  
 
 
Scheme 3.5 Synthesis of 5-FDR 71 reported by Ebner and Stütz.17    
 Reagents and conditions: (a) Ph3CCl, dry pyridine, 40 ºC  (b) Ac2O  (c) BF3·Et2O, 
MeOH, CHCl3  (d) Tf2O, pyridine, 48% overall  (e) TBAF.3H2O, MeCN, 73%  
(f) NaOMe, MeOH, 0 ºC, 92%. 
 
A comparison of the three synthetic routes suggested that 5-FDR 71 could be synthesised in 
only three steps following the strategy described by Sharma et al. for the synthesis of 
5-fluoronucleosides (see Scheme 3.2). It was also reported that methyl-2,3-O-isopropylidene-
β-D-ribofuranoside 81 is directly fluorinated using DAST.2 Scheme 3.6 outlines the potential 
synthetic sequence for the synthesis of 5-FDR 71 combining both synthetic routes. 
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Scheme 3.6 Potential synthetic approaches to 5-FDR 71. 
 
With D-ribose 81 as starting material, the synthetic route involved formation of the dimethyl 
acetal and then a selective protection of the 2,3-hydroxyl groups, leaving the 5-OH free, 
generating methyl-2,3-O-isopropylidene-β-D-ribofuranoside 82.18 This was easily achieved by 
using BF3 in ether as the catalyst and a mixture of 2,2-dimethoxypropane and acetone.19 With 
82 in hand, direct fluorination with DAST was attempted. Despite Sharma et al. reporting a 
35% yield for this fluorination reaction, it was found that the desired fluorinated 
ribofuranoside 84 was formed in only very low yield. Instead, the major product of the 
reaction was found to be 2,3-O-isopropylidene-5-O-methyl-ribofuranosyl fluoride 103. 
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This result is consistent with the findings previously published by Lloyd and co-workers.20 
They investigated the migration of the methoxyl group from C-1 to C-5 in different 
carbohydrates when treated with DAST and they also proposed a mechanism, illustrated 
below in Scheme 3.7. 
 
Scheme 3. 7 Proposed mechanism for the 1,5-migration of the -OCH3 group in furanosides 
treated with DAST.20 
 
Despite the existence of these reported synthetic routes, the procedure of choice to produce 
5-FDR 71 involved a modification of the first route reported by Kissman (Scheme 3.1), 
following the sequence protectionactivationfluorinationdeprotection. As previously 
described, fluorination reactions are usually carried out on reactive sulfonates. Thus, it was 
envisaged that activation of 82 via the formation of a 5-O-tosylate 102 could facilitate the 
subsequent nucleophilic displacement by fluoride using TBAF. Having prepared the 
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fluorinated protected sugar 83, removal of the methyl ether and the isopropylidene protecting 
groups would then furnish 5-FDR 71. Scheme 3.8 outlines this synthetic route to 5-FDR 71. 
 
 
Scheme 3.8 Reagents and conditions: (a) MeOH, acetone, 2,2-dimethoxypropane, BF3·ether, 
RT, 20 h, 57%  (b) TsCl, pyridine, RT, 3 h, 76%  (c) TBAF.3H2O, MeCN, reflux, 
22 h, 59%  (d) 0.02 M H2SO4, reflux, 5 h, 95%. 
 
Accodingly, after generation of methyl-2,3-O-isopropylidene-β-D-ribofuranoside 82, the 
5-hydroxyl group was then activated via the corresponding tosylate 102. It was found that 102 
could easily be prepared under standard reaction conditions in very good yield.21 Treatment of 
102 with TBAF.3H2O (2.5 molar eq.) in acetonitrile and under reflux, resulted in the 
formation of the desired product methyl-2,3-O-isopropylidene-5-deoxy-5-fluoro-β-D-
ribofuranoside 84 in moderate yield. Analytical and spectroscopic data for 84 were in good 
agreement with the literature.1,2 Removal of the methyl ether and isopropylidene protecting 
groups of the fluorinated and protected sugar 84 was easily achieved under acidic conditions.1 
As expected, the product was the free fluorinated ribose 71. Analysis by 19F NMR 
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(D2O, 25 ºC) showed an anomeric mixture in 2:1 ratio, in which the major anomer was 
determined to be the -anomer, by comparison with the literature.  
 
 
3.3 Synthesis of 5-deoxy-5-fluoro-D-xylose 74 
The synthesis of 5-deoxy-5-fluoro-D-xylose (5-FDX) 74 has also been reported in the 
literature. The first route was published by Kent and Young,22 however it is a lengthy and not 
convenient synthetic method to 5-FDX 74. Later, another synthetic approach to 74 was 
reported by Hadwiger and co-workers.23,24 This synthetic procedure is outlined in Scheme 3.9. 
 
 
Scheme 3.9 Synthesis of 5-FDX 74 reported by Hadwiger et al.23,24    
 Reagents and conditions: (a) 0.66 M H2SO4, acetone, 20 ºC, 2.5 h, 80%  (b) DAST, 
CH2Cl2, 40 ºC, 34%  (c) IR 120,  H2O/MeCN, 50 ºC, 48%. 
 
The first step of the synthesis involved the selective protection of the hydroxyl groups at C-1 
and C-2 of xylose. This can be easily achieved following a standard one-pot procedure.25 
However, 1,2-di-O-isopropylidene-,D-xylofuranose 105 is a common intermediate in the 
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syntheses of different biologically active compounds (i.e., antibiotics, nucleosides, herbicides, 
anti-HIV agents) and is nowadays commercially available. 
With 1,2-di-O-isopropylidene-,D-xylofuranose 105 in hand, direct fluorination of the free 
5-OH was attempted using DAST as the fluorinating reagent, as reported by Hadwiger et al. 
The poor yield of the reaction, together with the formation of by-products rendered it 
unsuitable. Thus, another synthetic strategy was explored for the preparation of 5-FDX 74, 
based on the previous strategy: protection  activation  fluorination  deprotection. 
Scheme 3.10 illustrates the synthetic route that eventually gave 74. All of the reactions steps 
proceeded in moderate to good yields. 
 
 
Scheme 3.10 Reagents and conditions: (a) TsCl, pyridine, RT, 3 h, 80%  (b) TBAF.3H2O, 
MeCN, reflux, 24 h, 57%  (c) 0.02 M H2SO4, reflux, 4 h, 90%. 
 
Starting with commercially available 1,2-di-O-isopropylidene-,D-xylofuranose 105, 
introduction of the fluorine atom at C-5 was envisaged using a suitably protected 5-sulfonate. 
Consequently, 107 was prepared by tosylation of 105 with p-toluenesulfonyl chloride in the 
usual manner.26 The reaction gave 1,2-di-O-isopropylidene-5-O-tosyl-,D-xylofuranose 107 
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exclusively, with no side-product formation or undesired tosylates. Thereby, tosylate 107 was 
then subjected to fluoride substitution using TBAF as the fluorine source. The fluorination 
reaction was found to proceed successfully and in a moderate yield to furnish 5-deoxy-5-
fluoro-1,2-di-O-isopropylidene-,D-xylofuranose 106. Analytical and spectroscopic data were 
in good agreement with the literature.22,23,24 Finally, fluorinated xylofuranose 106 was 
hydrolysed under acidic conditions to afford 5-FDX 74, as a mixture of anomers. 
 
 
3.4 Synthesis of fluoroacetaldehyde 26 
The synthesis of fluoroacetaldehyde (FAd) 26 was carried out using the previously described 
procedure as outlined in Scheme 3.11.27 Fluoroethanol 67 is oxidised using pyridinium 
dichromate (PDC) in dichloromethane (DCM) to generate fluoroacetaldehyde 26 which is 
collected as its hydrate by distillation directly into water. The oxidation reaction never goes to 
completion and 19F NMR analysis of the resultant FAd 26 (231.0 ppm, dt, 2JF-H 46.7 and 
3JF-H 10.0 Hz) typically shows 54% residual fluoroethanol 67 (224.5 ppm, tt, 2JF-H 47.6 and 
3JF-H 32.1 Hz). This preparation has been used in cell-free studies by previous co-workers and 
in this thesis. The contaminating fluoroethanol 67 is metabolically inert and does not 
generally prove problematic. 
 
 
Scheme 3.11 Reagents and conditions: (a) PDC, DCM, reflux, 16 h. 
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The fluorinase as a tool for the 
synthesis of new fluorine-18 
labelled sugars for positron 
emission tomography 
 
 
 
 
There is an increasing interest in the preparation of [18F]-labelled radiopharmaceuticals with 
potential application in positron emission tomography (PET), one of the most common 
techniques in medical imaging. This requires an efficient route to incorporate fluorine-18 into 
a drug molecule. However, the incorporation of fluorine-18 into a radiotracer is not always 
easy to achieve. 
A possibility for the synthesis and formation of C-18F bonds from [18F]fluoride ion became 
available with the discovery of the fluorinase from S. cattleya (EC 2.5.1.63). In this project 
the enzymatic preparation of [18F]-labelled sugars using the fluorinase, as potential 
radiotracers for positron emission tomography, has been investigated. In addition, imaging 
studies with human cancer cell lines and small rodents have been accomplished. 
Because of the requirement for fluorine-18 and some human cancer cell lines, this work has 
been carried out in collaboration, initially with Dr Christophe Plisson at GlaxoSmithKline 
(PET Laboratory at Mount Vernon Hospital in Northwood, U.K.), and more recently with 
Dr Lutz Schweiger, Dr Juozas Domarkas and Dr Timothy A. D. Smith at the University of 
Aberdeen (John Mallard PET Centre in Aberdeen, U.K.). 
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4.1 Introduction to positron emission tomography 
Positron emission tomography (PET) is a high-resolution, sensitive, non-invasive imaging 
technique in nuclear medicine that permits the assessment and quantification of specific 
biological and pharmacological processes at the molecular level in humans and animals. This 
medical imaging method can measure the spatial and temporal concentration of a positron 
emitting isotope in a volume element of tissue. It was developed in the mid-1970s by Phelps 
et al.,1 and is the most advanced technology currently available for studying in vivo molecular 
interactions in terms of distribution, pharmacokinetics and pharmacodynamics.2,3 Its 
applications are very varied, and a growing number of diverse physiological parameters in 
humans and animals (i.e., blood flow, glucose metabolism, receptor properties, enzyme 
activity and drug distribution and mechanisms) have been investigated using this technique. 
Although PET has been extensively applied to studies of the brain, heart and tumours, its use 
goes beyond these systems.3,4 Within the last few years, it has been increasingly implemented 
in clinical diagnosis,5 becoming the main technique in the study of the brain6,7 heart disease,8 
and neurological and psychiatric disorders. Diseases such as Alzheimer’s   disease,9 
dementia,10 epilepsy,11 depression,12,13 and schizophrenia14 have all benefitted from PET. In 
recent years, PET imaging has been applied in drug abuse research, providing information on 
the mechanisms responsible for substance abuse, addiction, and dependence.15,16,17 
However, the outstanding feature of PET is that it allows the visualization of tissue 
malfunction in vivo, thereby representing an important technique for the development of 
anticancer strategies and for assessing the response to cancer therapy.18,19,20,21 In addition to 
the major role that PET plays in oncology research,22,23 it is also used to perform 
pharmacokinetic studies in vivo, providing information on functional activity, biochemical 
transformations and distribution of organic compounds in the body.24 Such studies may be 
among the most valuable research applications of PET, and leave open the future possibility 
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of testing drug effectiveness on humans to obtain data much more quickly than is currently 
possible.25  
PET employs mainly short-lived positron-emitting radiopharmaceuticals. The common 
positron emitting isotopes (18F, 11C, 13N, 15O) are those of the common elements in organic 
chemistry (Table 4.1, vide infra). The availability of such isotopes offers a wide range of 
possibilities for the investigation of various biochemical pathways, since they are constituents 
of the physiological substrates, proteins, and neurochemicals that regulate and sustain 
biological processes. The use of positron-emitting isotopes of these natural elements allows 
the preparation of labelled tracer molecules that have chemical and biological behaviour 
identical to the authentic, unlabelled molecules.3 
 
Table 4.1 Comparative physical properties of radionuclides for PET imaging.3,26 
 
 
 
The four most widely used positron emitters are carbon-11, nitrogen-13, oxygen-15 and 
fluorine-18. Three properties of all of these isotopes: the short half-life, the chemistry which 
is applicable to labelling organic molecules, and the high specific activity, contribute to their 
implementation to tracer studies in humans. Nevertheless, among those properties is the short 
Nuclide Half-life Maximum Energy (MeV) Decay 
11C        20.4 min 0.96 β+ (99%) 
13N        9.96 min 1.19 β+ (99%) 
15O        2.07 min 1.723 β+ (99.9%) 
18F      109.7 min 0.635 β+ (97%) 
76Br        16.1 h 3.98 β+ (57%) 
124I        4.18 days 2.13 β+ (24%) 
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half-life of the positron which dominates the research and application for PET, since isotope 
production and tracer preparation and analysis must be carried out within a restricted time 
frame. For this reason, fluorine-18, with the longest half-life and the lowest positron energy 
(Table 4.1, vide supra), is the most suitable positron emitting radionuclide for clinical 
investigations in PET.3,26 
Although there are different methods for its production, fluorine-18 is usually generated in a 
cyclotron through the proton irradiation of [18O]-enriched water (i.e., 18O(p,n)18F). Several 
Curies (Ci) may be produced in a single irradiation whereas only 5–15 mCi of radiotracer 
need to be injected into a human subject for a PET examination. Fluorine-18 is obtained as a 
solution of [18F]fluoride ion in the irradiated target water, and the fact that it is obtained as 
‘no-carrier   added’ increases its specific radioactivity (i.e., the ratio of [18F]fluoride ion 
radioactivity to its mass of carrier or total fluoride ion). This enables the administration of 
radiotracers to human subjects in low mass doses (typically less than 1–10 nmol), with no 
toxicity or pharmacological effects involved.27  
The chemistry of fluorine-18 presents, however, several difficulties. First of all, isotopic 
labelling is theoretically limited to molecules having an atom of fluorine in their structure. 
Nevertheless, approximately 30% of molecules of therapeutic interest contain at least one 
fluorine atom.28 New candidate molecules for 18F PET studies may be synthesised by 
substituting one of the atoms of a non-fluorinated molecule by a fluorine atom but, in this 
case, the biological properties of this new radiotracer have to be assessed independently. 
From a chemical point of view, methods for the introduction of a fluorine-18 atom into a 
chemical structure rely on either electrophilic (i.e., starting from molecular fluorine [18F]F2) or 
nucleophilic (i.e., starting from the fluoride ion [18F]F-) fluorination reactions.3,26,27,29 
Many useful positron-emitting radiotracers have been developed and have proven to be 
attractive candidates for extensive clinical application. The first produced 
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radiopharmaceutical for PET studies, and the most widely used today, is 2-deoxy-2-
[18F]fluoro-D-glucose, [18F]FDG, [18F]108; a fluorinated analog of 2-deoxy-D-glucose 
(2DG).30 Its major application is as radiotracer of glucose utilisation and metabolism in 
oncology and neurology.31,32 It is also the major PET tracer for examining the effect of a drug 
on glucose metabolism in tumours,33,34 since the ability to sustain high rates of glycolysis is a 
common feature of rapidly proliferating malignant cells.35 The increased rates of glucose 
metabolism in cancer cells, compared to healthy cells, is the biochemical principle on which 
PET is based, making it a molecular imaging technique for the detection and staging of 
tumours.36 Glucose enters the cell via carrier proteins of the GLUT family. It is 
phosphorylated at O-6 and then undergoes complex metabolism. The modified and 
radiolabelled glucose analogue, [18F]FDG [18F]108, is transported into the cell in the same 
way and is also phosphorylated by hexokinase to [18F]FDG-6-P (Figure 4.1, vide infra). By 
contrast to phosphorylated glucose, [18F]FDG-6-P undergoes limited metabolism in most 
tissues and its permeability is quite low. Thus, [18F]FDG [18F]108 is essentially trapped inside 
the cell, and its accumulation can be measured non-invasively using PET.37,38,39 
 
 
Figure 4.1 Intracellular uptake of [18F]FDG [18F]108 (‘metabolic  trapping’). 
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The radiosynthesis of [18F]FDG [18F]108 is based on the nuclephilic substitution of a 
modified mannose precursor with [18F]fluoride ion acting as a nucleophile,40 as illustrated in 
Scheme 4.1. 
 
 
Scheme 4.1 Radiosynthesis of [18F]FDG [18F]108 (K222: Kryptofix® 2.2.2) 
 
The successful use of [18F]FDG [18F]108 in PET imaging has prompted the design and 
synthesis of other [18F]-labelled molecules.41 Some of these fluorinated radiotracers are shown 
in Table 4.2 (vide infra). 
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Table 4.2 Selected [18F]-labelled PET radiotracers.27  
 
Radiotracer Structure Applications to measurement of: 
[18F]Altanserin 
 
Brain 5-HT2 receptors 
[18F]Fallypride 
 
Brain D2 receptors 
[18F]FBR 
 
Brain  “peripheral”  benzodiazepine  receptors 
[18F]FCWAY 
 
Brain 5-HT1A receptors 
[18F]FDG 
 
Glucose metabolism 
[18F]FDOPA 
 
Brain dopamine metabolism 
[18F]FECNT 
 
Brain dopamine transporters 
[18F]FET 
 
Tumour location 
[18F]FLT 
 
Cellular proliferation 
[18F]Flumazenil 
 
Brain benzodiazepine receptors 
[18F]FMeNER-d2 
 
Noradrenaline transport 
[18F]FMISO 
 
Hypoxia 
[18F]FMTEB 
 
Brain mGluR5 receptors 
[18F]SP203 
 
Brain mGluR5 receptors 
[18F]SPA-RQ 
 
Brain neurokinin type-1 receptors 
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There is an increasing interest in the synthesis of [18F]-labelled sugars and derivatives for 
clinical investigations.42 Among other PET labelled probes which may have potential for the 
imaging of tumours or receptors in the brain, are the adenosine derivatives.43 The 
radiolabelled analogue of 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine, [18F]FAD 
[18F]111, has shown promise in imaging tumour cell proliferation by PET.44  
 
 
 
 
With the stated aim of imaging adenosine receptor systems by the PET technique, the 
synthesis of 5-deoxy-5-[18F]fluoroadenosine, [18F]FDA [18F]47, was attempted for the first 
time in 2000 by Lehel and co-workers.45 However, the introduction of the radioisotope into 
the molecule proved to be especially difficult, giving extremely low radiochemical yields 
(1%). Further unsuccessful efforts to synthesise [18F]FDA [18F]47 led to the conclusion that: 
“5-deoxy-5-[18F]fluoroadenosine cannot be synthesised in preparatively acceptable amounts 
starting from a precursor of adenosine structure”.46  
In spite of its sometimes difficult chemistry, fluorine-18 remains the most attractive PET 
nuclide because of its convenient half-life and low positron energy. The current challenge for 
[18F]-labelled pharmaceuticals is to develop rapid and clean synthesis methods with 
straightforward purification protocols for new in vivo imaging probes. Enzymatic methods are 
in principle attractive because of the chemospecificity and low generation of side products. 
So far there are only a few examples in PET synthesis where enzymes have been used to 
introduce isotopically labelled atoms, largely because suitable enzymes are not 
available.47,48,49,50  
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4.2 Application of the fluorinase enzyme in PET 
Studies towards the synthesis of the adenosine derivative 5-deoxy-5-[18F]fluoroadenosine, 
[18F]FDA [18F]47, highlighted the difficulty of introducing [18F]fluoride in the 5-position of 
the nucleoside; when a series of 5-halo and 5-sulfonic acid alkyl and aryl esters failed to 
produce the expected radiolabelled adenosine derivatives in sufficient yield under the 
commonly used nucleophilic substitution reaction conditions with [18F]fluoride ion.46 
With the fluorinase in hand, there was the prospect of the synthesis of [18F]FDA [18F]47 in 
one chemical step. 
In 2003, the St Andrews lab in collaboration with GlaxoSmithKline reported the first 
enzymatic radiolabelling method for the production of 5-deoxy-5-[18F]fluoroadenosine,51 
[18F]FDA [18F]47, by incubating purified wild-type fluorinase from S. cattleya with SAM 49 
and [18F]F- (Scheme 4.2).  
 
 
 
Scheme 4.2 Enzymatic radiolabelling of 5-deoxy-5-[18F]fluoroadenosine, [18F]47. 
 
In these experiments, the fluorinase enzyme was partially purified by ammonium sulfate 
precipitation and anion exchange chromatography.52 Interestingly, it was shown that the 
purity of the enzyme had no measurable effect on the radiochemical yield (RCY) of the 
reaction or the radiochemical purity of [18F]FDA [18F]47. Although the radiochemical yield of 
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the reaction was very low (ca. 1%), the successful enzymatic fluorination at the first attempt 
was significant and provided a foundation for future optimisation. 
The subsequent realisation that the fluorination reaction is reversible,53 and that the 
equilibrium of the reaction must be pulled over towards [18F]FDA [18F]47 formation for 
efficient conversion, led to more satisfactory results. In these latter experiments,54 the 
radiosynthesis of [18F]47 was improved by using a different coupled enzyme strategy 
(Scheme 4.3, vide infra). This involved over-expressed fluorinase in mg/ml concentrations 
and the introduction of a second enzyme, an L-amino-acid oxidase (EC 1.4.3.2), which 
catalyses the oxidation of L-methionine 48 to a 2-oxo-acid, improving the rate of synthesis 
and the overall conversion to [18F]FDA [18F]47 up to 95% under optimum conditions. 
 
 
 
Scheme 4.3 Fluorinase coupled reactions for the synthesis of various [18F]-labelled compounds. 
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The second approach (vide supra Scheme 4.3) involved coupling the fluorinase to an 
5-adenylic acid deaminase (AMP deaminase, EC 3.5.4.6) enzyme to generate [18F]FDI 
[18F]50 with a RCY of 75% from [18F]fluoride, achieved over 4 h. Finally, combining the 
fluorinase reaction with a purine-nucleoside phosphorylase (PNPase, EC 2.4.2.1) and then an 
alkaline phosphatase (EC 3.1.3.1) resulted in the sequential depurination and phosphate 
hydrolysis to produce the free ribose sugar [18F]FDR [18F]71 in an overall radiochemical yield 
of 45% obtained after a 4 h reaction. 
These experiments also revealed information about how temperature and fluorinase 
concentration affect the process. A modest increase in temperature (from 25 ºC to 35 ºC) had 
a significant influence on the radiochemical yield, and when increasing the fluorinase 
concentration (from 8 mg/ml to 24 mg/ml), higher RCY were also obtained and the reaction 
time could be shortened. 
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4.2.1 New enzymatic method                                         
for the synthesis of [18F]FDR 
The bioconversion of SAM 49 and [18F]fluoride to [18F]FDR [18F]71 was accomplished in a 
three enzyme system consisting of the fluorinase (EC 2.5.1.63), an immobilised PNPase 
(EC 2.4.2.1) and a phosphatase (EC 3.1.3.1). An efficient radiolabelled synthesis of a ribose 
sugar became a key research objective, given the role that [18F]FDG [18F]108 has in PET.55 
Thereby, it was attractive to develop a protocol for the synthesis of [18F]FDR [18F]71 via a 
shorter route starting from SAM 49. This envisaged approach for the synthesis of [18F]71 
involved coupling the fluorinase to an enzyme which acts upon [18F]FDA [18F]47 by direct 
hydrolysis of the N-glycosidic bond, generating [18F]FDR [18F]71 and adenine 62 in a two 
step protocol, as illustrated in Scheme 4.4. 
 
 
Scheme 4.4 Potential two step route for the synthesis of [18F]FDR [18F]71 starting from SAM 49. 
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Ideally, this new route to [18F]FDR [18F]71 from SAM 49, coupling the fluorinase to a 
nucleoside hydrolase, could be carried out as a one-pot reaction. With this objective, the best 
conditions for each enzyme had to be investigated in order to find optimal conditions for a 
one-pot reaction. 
 
4.2.1.1 Development of the “cold” experiment 
A. Nucleoside hydrolases 
Nucleoside hydrolases (or nucleoside N-ribohydrolases; NHs) are a group of enzymes that 
catalyse the hydrolysis of the N-glycosidic bond (glycosidases, EC 3.2.2.-) between the 
anomeric carbon atom of ribose and the purine (EC 3.2.2.1) or pyrimidine (EC 3.2.2.8) base 
of  β-ribonucleosides, forming the free nucleic acid base and ribose 81 (Scheme 4.5).56 
 
 
Scheme 4.5 The NH-catalysed hydrolysis of a ribonucleoside exemplified by adenosine 
N-glycosidic bond cleavage. 
 
NHs are widely distributed in nature. These enzymes have been isolated, or the genes of the 
enzymes have been identified, from a variety of sources, including bacteria,57,58,59,60 yeast,61 
protozoa,62,63 insects,64 mesozoa,65 plants.66 Although found in most organisms, their 
physiological role is only well understood in certain parasitic protozoa (e.g., Trypanosoma) 
where they are involved in the purine salvage pathways. Since neither nucleoside hydrolase 
activity, nor the encoding genes have been found in mammals, they constitute an attractive 
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target for drug design against a variety of pathogens.67,68,69 In addition, nucleoside hydrolases 
have also been proposed for use as pro-drug activators in chemotherapy.70,71 
All characterised nucleoside hydrolases show high specificity for the ribose moiety, but 
exhibit variability in their preferences for the nature of the nucleoside base. On the basis of 
the substrate specificity, NHs have been grouped into three subclasses: the inosine-uridine 
preferring nucleoside hydrolases (IU-NHs),72,73 the purine specific 
inosine-adenosine-guanosine preferring nucleoside hydrolases (IAG-NHs)74,75 and the 
6-oxo-purine specific inosine-guanosine preferring nucleoside hydrolases (IG-NHs).76 
The nucleoside hydrolase from Trypanosoma vivax (TvNH) has been well characterised 
kinetically and structurally. This NH catalyses the hydrolysis of the N-glycosidic bond of 
inosine, adenosine and guanosine most efficiently.74 The rates for these reactions are very 
similar, and the kcat values   for   these   substrates   are   rather   low   (≈  4   s-1 at pH 7.0). The first 
crystal structure of the T. vivax IAG-NH enzyme shows that the enzyme forms hydrogen 
bonds with all three hydroxyl groups of the ribose moiety. A Ca2+ ion is tightly bound at the 
bottom of the active site (Figure 4.2, vide infra).74  
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Figure 4.2 (a) Close-up stereoview of the T. vivax IAG-NH active site in complex with 
3-deaza-adenosine. The calcium ion and the catalytic water molecule are depicted as 
dark and light blue spheres, respectively. The residues interacting with ribose or the 
calcium ion are colored light grey. The residues interacting with the 3-deaza-adenine 
base are colored dark grey. Asp10 (in yellow) is the proposed catalytic base. Asp40 (in 
yellow) could act as leaving group activator.  (b) Schematic representation of 
interactions in the active site of the T. vivax IAG-NH (distances are given in Å). 
 
It was previously shown for the NH from T. brucei brucei that interactions with the 
5-OH group mainly contribute to substrate binding, while interactions with the 2-OH and the 
3-OH groups are important for the stabilisation of the oxocarbenium ion in the transition 
state.75  
Studies on substrates or inhibitors of the T. vivax NH with the 5-OH group of the ribose 
moiety replaced for another atom have not been published so far. This led to a first 
investigation of 5-FDA 47 as a potential substrate for TvNH.  
(a) (b) 
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Recombinant NH was purified from extracts of E.coli strain BL21(DE3)Gold, transformed 
with the pQE30-IAGNH plasmid (which became available thanks to Dr J. Steyaert, Vrije 
Universiteit Brussel) according to the procedure outlined in Chapter 5. 
A cell-free extract (300 l) containing NH activity was incubated with synthetic 5-FDA 47 
(30 l, 18.6 mM) in phosphate buffer (400 l, 50 mM, 1 mM CaCl2) at 37 ºC for 16 h, and the 
assay solution was subsequently analysed by 19F NMR spectroscopy. The presence of 
5-FDR 71 (alongside other fluorinated furanoses, due to different activities present in the 
CFE) confirmed that the T. vivax NH catalyses the hydrolysis of the N-glycosidic bond of 
5-FDA 47, producing 5-FDR 71 as shown below in Figure 4.3 (vide infra). 
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Figure 4.3 19F{1H} NMR spectra of:  (a) Control sample for the incubation of a CFE of TvNH 
with synthetic 5-FDA 47 at time zero.  (b) 5-FDR 71 generated after an overnight 
incubation of a CFE of TvNH with synthetic 5-FDA 47. 
 
The initial published studies on TvNH stated that the catalytic power of the enzyme is related 
to the interactions with the purine base, provided by multiple aromatic stacking interactions 
with enzyme residues.74 It was also found that two functional groups with a pKa of 5.5 and 8.5 
are required to be protonated. Accordingly, Asp10 (Figure 4.2, vide supra) acts as the general 
base in the reaction mechanism, while Asp40 is proposed as a general acid. It was then 
suggested that the optimum pH of the TvNH is around pH 5.74 
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Experiments on pH profile and temperature were performed in order to investigate the best 
conditions for the TvNH to catalyse the hydrolysis of 5-FDA 47 (Scheme 4.6). 
 
 
Scheme 4.6 Hydrolysis of the N-glycosidic bond of 5-FDA 47 catalysed by the 
T. vivax nucleoside hydrolase. 
 
The enzyme was purified from E. coli bearing the pQE30-IAGNH plasmid encoding IAG-NH 
from T. vivax. This partially purified IAG-NH was taken directly after nickel column 
purification and separated into three fractions. Each fraction was dialysed in three different 
buffers (50 mM MES, pH 5.5; 50 mM PBS, pH 7.0 and 50 mM TRIS, pH 8.5). Experiments 
were carried out by incubating the TvNH (500 l, 0.5 mg/ml) with synthetic 5-FDA 47 
(30 l, 18.6 mM) in the corresponding buffer (170 l) supplemented with CaCl2 (1mM) at 
37 ºC and 55 ºC. The hydrolysis of 5-FDA 47 was followed by 19F{1H} NMR analysis, every 
two hours. These studies showed a clear influence of the pH on the reaction rate. At pH 5.5 
formation of 5-FDR 71 is detected at 0 h time, accumulating due to the running time of the 
experiment (approximately 30 min), whereas incubation times of 4 h and 2 h respectively, are 
needed at pH 7.0 and pH 8.5 as shown in Figure 4.4. 
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(a) (b) 
(c) (d) 
 
Figure 4.4 19F{1H} NMR spectra of partially purified TvNH incubated with synthetic 5-FDA 47 
at 37 ºC:  (a) In 50 mM MES buffer pH 5.5 and time zero (time the spectrum is 
acquired)  (b) In 50 mM MES buffer pH 5.5 after 2 h  (c) In 50 mM PBS buffer pH 
7.0 after 4 h  (d) In TRIS buffer pH 8.5 for 2 h. 
 
The hydrolysis of the N-glycosidic bond of 5-FDA 47 is more rapid when catalysed under 
acidic conditions by TvNH. These results are consistent with the previous report that sets the 
optimum pH for T. vivax NH around pH 5. However, it is important to note that the reduction 
in activity at pH 7.0 may be attributed to a partial sequestering of the calcium by the 
phosphate ions in the PBS buffer, rather than just a direct action of pH 7.0.  
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B. Coupling the fluorinase to a nucleoside hydrolase 
The next step in the study involved exploring the fluorinase reaction at pH 5.5 and 37 ºC. 
Previous studies on the fluorinase52 have shown that the optimal temperature for the 
production of 5-FDA 47 is 55 ºC. It is also known from those studies that addition of 
EDTA (1mM) increases enzyme activity by 25%, suggesting that the fluorinase may be 
sensitive to trace ammounts of metal ions. Nevertheless, there was little known about the 
optimum pH profile for enzymatic fluorination, and to date all incubations of the fluorinase 
enzyme had been carried out at neutral or slightly basic pH. A set of experiments was 
explored by incubating partially purified fluorinase (280 l, 1.5 mg/ml) with SAM 49 
(10 l, 20 mM), KF (10 l, 500 mM) and D2O (100 l) in the three buffers (170 l; 
50 mM MES, pH 5.5; 50 mM PBS, pH 7.0 and 50 mM TRIS, pH 8.5) at 37 ºC. The 
production of 5-FDA 47, was followed by 19F{1H} NMR analysis, every two hours. The 
results of these experiments indicated that the fluorinase is inactive at pH 5.5, and 5-FDA 47 
was observed only at neutral or more basic pH (pH 8.5). 
In the light of these results, a two phase experiment was explored. The fluorinase 
(280 l, 1.5 mg/ml) was incubated with SAM 49 (10 l, 20 mM) and KF (10 l, 500 mM) for 
a period of 4 h at 37 ºC and pH 7.0. After 4 h, production of 5-FDA 47 was observed by 
19F{1H} NMR analysis as shown in Figure 4.5a (vide infra). This sample was then 
supplemented with a freshly prepared CFE (400 l) of TvNH in MES buffer (50 mM, pH 5.5; 
1 mM CaCl2) and incubated for a further 30 min. The sample was analysed by 19F{1H} NMR 
and the spectrum clearly showed two signals at 228.45 ppm and 230.77 ppm corresponding 
to the  and   α   anomers of 5-deoxy-5-fluoro-D-ribose, 5-FDR 71. Thus, the sequential 
fluorinase and then nucleoside hydrolase reaction was successful in a two-phased one-pot 
reaction (Figure 4.5b, vide infra). 
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Figure 4.5 19F{1H} NMR spectra of:  (a) Incubation of the fluorinase with SAM 49 and KF 
showing production of 5-FDA 47 at pH 7.0.  (b) Addition of T. vivax IAG-NH and 
further incubation of the mixture for 30 min shows 5-FDR 71 formation at pH 5.5. 
 
A similar experiment was then carried out to explore the combination of these two enzymes 
under more basic conditions. Accordingly, the fluorinase (280 l, 1.5 mg/ml) was incubated 
with SAM 49 (10 l, 20 mM) and KF (10 l, 500 mM) at pH 7.8 for a period of 3 h at 37 ºC. 
19F{1H} NMR analysis clearly showed the production of 5-FDA 47 (Figure 4.6a, vide infra). 
To this sample was added a freshly prepared CFE (400 l) of the over-expressed T. vivax 
nucleoside hydrolase in phosphate buffer (50 mM, pH 7.8; 1 mM CaCl2) and the resulting 
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mixture was then incubated for a further 30 min. After this time, the sample was analysed by 
19F{1H} NMR and the spectrum clearly showed two signals at 228.45 ppm and 230.77 ppm 
corresponding to the  and  α  anomers,  respectively,  of  5-deoxy-5-fluoro-D-ribose, 5-FDR 71, 
indicating a successful reaction (Figure 4.6b, vide infra). 
 
(a)  
(b)  
Figure 4.6 19F{1H} NMR spectra of:  (a) Incubation at 37 ºC and pH 7.8 of the fluorinase with 
SAM 49 and KF showing production of 5-FDA 47 after 3 h.  (b) Addition of TvNH 
and further incubation of the mixture for 30 min at pH 7.8 shows formation of 
-FDR 71 and -FDR 71. 
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The next phase in the development of the cold experiment for the enzymatic synthesis of 
5-FDR 71 was focused on establishing optimum conditions for coupling both enzymes 
together in a one-pot reaction. The experiments carried out so far have provided valuable 
information about the optimum conditions for the fluorinase and for the T. vivax nucleoside 
hydrolase. However, the fluorinase and the TvNH show very different preferences in terms of 
pH and temperature and the presence of metal ions in the reaction mixture. The fluorinase 
catalyses the fluorination reaction at neutral or basic pH, whereas the TvNH proved to be 
faster under more acidic conditions. The optimal temperature for the fluorinase is 55 ºC, 
whereas T. vivax NH shows no catalytic activity at this temperature. Finally, the fluorinase is 
known to be sensitive to trace amounts of metal ions, increasing its activity up to 25% with 
EDTA, while the nucleoside hydrolase requires the presence of Ca2+ as a co-factor to catalyse 
the hydrolysis reaction. So the prospects did not look good. A summary of the required 
conditions for each enzyme for good functioning is represented in Table 4.3. 
 
Table 4.3 Comparative conditions for activity of the enzymes involved in the coupled enzymatic 
synthesis of 5-FDR 71. 
 
 
Fluorinase 
(EC 2.5.1.63) 
TvNH 
(EC 3.2.2.1) 
pH 
< 7   
= 7   
> 7    
Tª 
37 ºC   
55 ºC   
EDTA 1 mM   
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A reaction was explored at pH 8.5 and at 37 ºC. For that, the fluorinase (280 l, 1.5 mg/ml) 
was incubated with SAM 49 (10 l, 20 mM), KF (10 l, 500 mM) and a freshly prepared CFE 
(400 l) of the over-expressed T. vivax nucleoside hydrolase in phosphate buffer (50 mM, 
pH 7.8; 1 mM CaCl2) at 37 ºC. After 2 h incubation, the reaction mixture was analysed by 
19F{1H} NMR. The characteristic 19F{1H} NMR signals for the α  and  anomers of 5-deoxy-
5-fluoro-D-ribose, 5-FDR 71 showed that the product had formed (Figure 4.7a, vide infra). 
One hour later, at a total incubation time of 3 h, the 19F{1H} NMR spectrum showed the same 
two signals for the production of 5-FDR 71, in a ratio 2:1 :α  (Figure  4.7b, vide infra). 
 
(a) 
(b) 
 
Figure 4.7 19F{1H} NMR spectra following incubation of the fluorinase with SAM 49, KF and 
TvNH (CFE in PB pH 7.8) at 37 ºC showing production of 5-FDR 71 at: (a) 2 h and 
(b) 3 h. 
CHAPTER 4 
 
151 
This experiment confirmed that 5-deoxy-5-fluoro-D-ribose, 5-FDR 71, can be synthesised 
from SAM 49 in two steps via a fluorinase-NH coupled enzymatic reaction under basic 
conditions, as shown in Scheme 4.7. 
 
 
Scheme 4.7 Enzymatic coupled system for the synthesis of 5-FDR 71. 
 
In order to study the fluorinase-NH coupled reaction in real time, a 19F{1H} NMR time course 
experiment was carried out in a NMR tube. Accordingly, a cell free extract containing 
T. vivax IAG-NH (400 l) in phosphate buffer (50 mM, pH 7.8, 1 mM CaCl2) was 
supplemented with fluorinase (280 l, 1.5 mg/ml), SAM 49 (10 l, 20 mM), KF (10 l, 
500 mM) and D2O (100 l), and incubated at 37 ºC. The progress of the reaction was 
monitored by recording 19F{1H} NMR (470 MHz) spectra at 30 min intervals over 4 h. 
Figure 4.8 displays the stacked 19F{1H} NMR time course spectra resulting from the 
biotransformation. 
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Figure 4.8 19F{1H} NMR time course spectra of TvNH cell free extract incubated with fluorinase, 
KF and SAM 49 in phosphate buffer (50 mM, pH 7.8) at 37 ºC for 4 h. 
 
The resultant 19F{1H} NMR data show a product signal at 228.03 ppm corresponding to the 
 anomer of 5-FDR 71, appearing just after 30 min of incubation, while the NMR spectrum 
was being recorded. After 1 h, both anomers of 5-FDR 71 are observed in a 2:1 ratio of : 
and no 5-FDA 47 is detected. This suggests that the fluorinase is rate limiting and that the 
TvNH hydrolyses the fluorinase-generated 5-FDA 47 faster than it is being formed. 
With this coupled reaction in place, experiments with radiolabelled [18F]fluoride ion were 
explored. 
 
 
 
 
 
 
 
 
1 h 
2 h 
3 h 
4 h 
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4.2.1.2 Development  of  the  “hot”  experiment 
The fluorinase enzyme was over-expressed in E. coli and purified following the protocol 
described in Chapter 5. Initially, an experiment was carried out to explore the production of 
[18F]FDA [18F]47 in a single step enzyme reaction involving only the fluorinase. The 
fluorinase enzyme (70 l, 35.3 mg/ml) was incubated with SAM 49 (30 l, 20 mM) and 
aqueous [18F]fluoride (50 l, solution in [18O]H2O, 72 MBq) at 37 ºC for 15 h. Aliquots were 
collected at time intervals and analysed by analytical HPLC under the conditions described in 
Chapter 5. The HPLC system was coupled to a diode array detector followed by a radioactive 
detector. An aliquot of the reaction mixture was then analysed by radio-HPLC after 3.8 h, 
showing a radiolabelled compound with a retention time of 5.21 min. The sample was loaded 
onto a carbohydrate column (Agilent), and formation of [18F]FDA [18F]47 was detected as 
shown in Figure 4.9 (vide infra). A contemporaneous aliquot from the same mixture was 
analysed by HPLC on a Hypersyl ODS column (Figure 4.10, vide infra), confirming 
production of radiolabelled 5-FDA [18F]47 after 4 h incubation at 37 ºC. 
 
Figure 4.9 HPLC Chromatogram obtained from radioactive detector after injection of a sample 
collected after 3.8 h of incubation ( 85:15 ACN/H2O as mobile phase). 
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Figure 4.10 HPLC Chromatogram showing both UV (trace in red) and radioactivity (trace in 
green) detector outputs for the production of [18F]FDA [18F]47 (90:10 NaH2PO4/ACN 
as mobile phase). The first radioactive signal corresponds to unreacted [18F]fluoride. 
 
Production of [18F]FDA [18F]47 was clearly observed after 4 h of incubation and a preparation 
of purified nucleoside hydrolase in HEPES buffer (100 L, 16 mg/mL) was added to the 
remaining fluorinase reaction mixture, as well as a small volume of the buffer (50 L, 50 mM 
HEPES, 1 mM CaCl2) containing the enzyme co-factor (Ca2+) necessary for the hydrolase 
reaction. Following the addition of TvNH, the enzyme cocktail was incubated for a further 45 
min at 37 ºC, and an aliquot was taken for HPLC analysis. Incubation of the mixture 
containing [18F]FDA [18F]47 with the TvNH enzyme resulted in the formation of a new 
radiolabelled compound. This was [18F]FDR [18F]71, which had a retention time of 7.2 min as 
shown by HPLC analysis (Figure 4.11). The ratio between [18F]FDA [18F]47 and 
[18F]FDR [18F]71 was approximately 9:1, and thus, although successful, the conversion was 
modest. 
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Figure 4.11 HPLC Chromatogram obtained from the radioactivity detector following injection of 
an aliquot collected after 4.5 h incubation, showing production of [18F]FDA [18F]47 
and [18F]FDR [18F]71. 
 
The production of [18F]FDR [18F]71 increased when the reaction mixture was incubated for a 
further 4 h, as shown by radio-HPLC analysis in Figure 4.12. 
 
 
 
Figure 4.12 HPLC Chromatogram obtained from the radioactivity detector following injection of 
an aliquot collected after 4.5 h incubation with the fluorinase and additional 4 h 
incubation with the TvNH, showing production of [18F]47 and [18F]71. 
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Another aliquot from the same mixture was also analysed by HPLC on a Hypersyl ODS 
column (Figure 4.13), confirming production of radiolabelled 5-FDR [18F]71 after 3.5 h of 
incubation followed TvNH addition. The three detected radioactive signals correspond to 
unreacted [18F]fluoride, [18F]FDR [18F]71 and [18F]FDA [18F]47, as shown in Figure 4.13. 
 
 
Figure 4.13 HPLC Chromatogram showing both UV (trace in red) and radioactivity (trace in 
green) detector outputs for the production of [18F]FDA [18F]47 and [18F]FDR [18F]71. 
 
In a second experiment, both enzymes were combined in a one-pot reaction as designed in the 
cold experiment approach (Section 4.2.1.1, B). The fluorinase enzyme was over-expressed in 
E. coli and purified following the procedure described in Chapter 5. The TvNH plasmid was 
transformed into BL21 or C43(DE3) E. coli cells for protein expression and the protein was 
also purified according to the protocol described in Chapter 5. 
A one-pot experiment coupling both enzymes for [18F]FDR [18F]71 production was carried 
out as follows: the fluorinase enzyme (70 l, 35.3 mg/ml) was incubated with SAM 49 (30 l, 
20 mM), TvNH (100 l, 12 mg/ml) and aqueous [18F]fluoride (100 l, solution in [18O]H2O, 
137 MBq) in HEPES buffer (50 L, 50 mM HEPES pH 8.0, 1 mM CaCl2) at 37 ºC. After a 
4 h incubation time an aliquot was taken and loaded onto a carbohydrate column (Agilent) for 
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HPLC analysis. Two radiochemical peaks were evident in this one-pot reaction mixture, one 
of which is [18F]FDA [18F]47 and the other [18F]FDR [18F]71, with retention times of 
5.22 min and 7.20 min, respectively, as shown in Figure 4.14.  
 
 
Figure 4.14 HPLC Chromatogram obtained from the radioactivity detector following injection of 
an aliquot collected from the fluorinase-NH one-pot reaction mixture after 4 h 
incubation, showing production of [18F]FDA [18F]47 and [18F]FDR [18F]71. 
 
The formation of radiolabelled 5-FDR [18F]71 after 6 h incubation was also confirmed by 
HPLC analysis when an aliquot of the enzyme cocktail was loaded on a Hypersyl ODS 
column using NaH2PO4/ACN (90:10) as the mobile phase. These are conditions under which 
[18F]FDR [18F]71 elutes before [18F]FDA [18F]47, and the unreacted [18F]fluoride and polar 
products elute first (Figure 4.15). 
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Figure 4.15 HPLC Chromatogram showing both UV (trace in red) and radioactivity (trace in 
green) detector outputs for the production of [18F]FDA [18F]47 and [18F]FDR [18F]71 
after 6 h of combined incubation of fluorinase and TvNH. 
 
Another experiment was carried out coupling the fluorinase and the TvNH, but in this case 
with a higher concentration of TvNH. Thus, the fluorinase enzyme (70 l, 35.3 mg/ml) was 
incubated with SAM 49 (30 l, 20 mM), TvNH (100 l, 16 mg/ml) and aqueous [18F]fluoride 
(100 l, solution in [18O]H2O, 136 MBq) in HEPES buffer (50 L, 50 mM HEPES pH 8.0, 
1 mM CaCl2) at 37 ºC. After 4.5 h of incubation, analysis by HPLC of the reaction mixture 
containing the fluorinase and the NH showed an increased conversion to [18F]FDR [18F]71 in 
the reaction mixture (Figure 4.16, vide infra). The formation of radiolabelled 5-FDR [18F]71 
related to [18F]FDA [18F]47 is higher than in the previous experiment after a similar 
incubation time (Figure 4.14, vide supra). This is most probably due to the fact that the TvNH 
enzyme is more concentrated in this latter experiment. 
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Figure 4.16 HPLC Chromatogram obtained from the radioactivity detector following injection of 
an aliquot collected from the fluorinase-NH one-pot reaction mixture after 4.5 h 
incubation, showing production of [18F]FDR [18F]71, which represents approximately 
20% of the total radioactivity observed. 
 
Longer incubation times resulted in a increased of [18F]FDR [18F]71 formation, as shown by 
HPLC analysis (Figure 4.17, vide infra), reaching an approximately 7:3 [18F]FDA [18F]47 to 
[18F]FDR [18F]71 ratio after 8.25 hours (Figure 4.18, vide infra). 
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Figure 4.17 HPLC Chromatogram showing both UV (trace in red) and radioactivity (trace in 
green) detector outputs for the production of [18F]FDA [18F]47 and [18F]FDR [18F]71 
after 7 h of combined incubation of fluorinase and TvNH. The first radioactive signal 
corresponds to unreacted [18F]fluoride. 
 
 
 
 
Figure 4.18 HPLC Chromatogram obtained from the radioactivity detector following injection of 
an aliquot collected from the fluorinase-NH one-pot reaction mixture after 8.25 h of 
incubation, showing production of [18F]FDR [18F]71, which represents approximately 
31% of the total radioactivity observed ([18F]fluoride does not elute from the column 
under these conditions). 
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An experiment coupling the fluorinase to a L-amino acid oxidase (EC 1.4.3.2) was also 
performed, in which a preparation of purified fluorinase (70 µl, 35.26 mg/ml) was incubated 
with SAM 49 (30 µl, 20 mM), L-amino acid oxidase (0.15 units) and aqueous [18F]fluoride 
(50 l, solution in [18O]H2O, 70 MBq) at 37 ºC for 4 h. The HPLC analysis showed 
production of [18F]FDA [18F]47 but there was not a real improvement in the synthesis of the 
radiolabelled nucleoside. 
A summary of the reactions explored is illustrated in Scheme 4.8. 
 
 
 
Scheme 4.8 Fluorinase coupled enzyme systems for the synthesis of [18F]FDR [18F]71. 
 
The experiments demonstrate, for the first time, a two-step enzymatic approach to 
[18F]FDR [18F]71 that can be carried out either in a sequential one-pot reaction or in one-pot 
reaction system. 
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4.2.2 Enzymatic synthesis of [18F]FDA 
With an improved protocol in hand for the synthesis of [18F]FDA [18F]47 using the fluorinase, 
it was attractive to generate a sample for investigating its incorporation into cancer cells. 
In a typical reaction, the fluorinase enzyme (25 l, 30 mg/ml) was incubated with SAM 49 
(20 l, 20 mM) and aqueous [18F]fluoride (70 l, solution in [18O]H2O, 163 MBq) at 37 ºC for 
1 h. After this time, an aliquot was collected and the protein was denatured by heating (95 ºC, 
1 min) and removed by centrifugation (14,500 rpm, 5 min). The supernatant was then analysed 
by analytical HPLC under the conditions described in Chapter 5. The HPLC system was 
coupled to a diode array detector followed by a radioactive detector. The radio-HPLC 
chromatogram of the reaction mixture showed production of a radiolabelled compound with a 
retention time of 9 min and 99% conversion. Such product was confirmed to be [18F]FDA 
[18F]47 when compared with a standard. Figure 4.19 illustrates the HPLC chromatogram 
obtained.  
 
Figure 4.19 Radio-HPLC chromatogram for the production of [18F]47 after a 1 h incubation 
 
Biological studies with [18F]FDA [18F]47 will be discussed in Section 4.3. 
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4.2.3 Enzymatic synthesis of [18F]FDI 
The enzymatic synthesis of [18F]FDI [18F]50 was achieved by first incubating the fluorinase 
enzyme (25 l, 30 mg/ml), SAM 49 (20 l, 20 mM) and aqueous [18F]fluoride (60 l, solution 
in [18O]H2O, 397 MBq) at 37 ºC. After 1 h incubation, an aliquot of the reaction mixture was 
analysed by HPLC and checked for [18F]FDA [18F]47 production against a standard following 
the procedure described in Chapter 5. In most cases almost complete conversion to [18F]FDA 
[18F]47 was observed and the fluorinase enzyme in the reaction mixture was denatured by 
heating (95 ºC, 1 min) and removed by centrifugation (14,500 rpm, 5 min). Then 5-adenylic 
acid deaminase (3 mg, 0.11 units/mg) was added to the supernatant and incubated for a further 
1 h. After this time, an aliquot was collected and the protein was denatured by heating (95 ºC, 
1 min) and removed by centrifugation (14,500 rpm, 5 min). Radio-HPLC analysis against a 
standard confirmed the generation of [18F]FDI [18F]50 with 85% conversion from 
[18F]fluoride and quantitative conversion from [18F]FDA [18F]47, as shown in Figure 4.20. 
 
 
Figure 4.20 Radio-HPLC chromatogram of the enzymatic synthesis of [18F]FDI [18F]50 after 1 h 
incubation with fluorinase and then 1 h incubation with deaminase. 
CHAPTER 4 
 
164 
4.3 Adenosine analogues as potential radiotracers for 
investigating adenosine receptors by PET 
Adenosine is a natural metabolite, ubiquitous in mammalian cell types. It is related both 
structurally and metabolically to the bioactive nucleotides adenosine triphosphate (ATP), 
adenosine diphosphate (ADP), adenosine monophosphate (AMP) and cyclic adenosine 
monophosphate (cAMP); to the biochemical methylating agent S-adenosyl-L-methionine 
(SAM); and structurally to the co-enzymes NAD, FAD and co-enzyme A; and to RNA. 
Adenosine, with these related compounds, plays an important role in the regulation of cellular 
metabolism.77 The major pathways reponsible for the metabolism (biosynthesis and 
degradation) and transport of adenosine are shown in Figure 4.21.77 
 
 
Figure 4.21 Formation, metabolism and uptake of adenosine. EN, ecto-5-nucleotidase; 
NT, nucleoside transport; AR, adenosine receptor; AK, adenosine kinase; 
SAH, S-adenosylhomocystein; ADA, adenosine deaminase. 
Extracellular
Intracellular
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The physiological effects of adenosine are mediated by activation of specific cell surface 
receptors. To date, four adenosine receptors (ARs), namely A1AR, A2BAR, A2AAR and 
A3AR, have been characterised pharmacologically.77,78 
Adenosine is reported to be present at high concentrations in solid tumours, with 
accumulation in the intracellular and extracellular tumour microenvironments. It has also been 
shown to promote tumour growth and to be involved in the stimulation of angiogenesis and 
inhibition of inflammatory processes at the site of injury. In addition, a number of 
observations strongly suggest that adenosine may have a role in cancer. Due to rapid growth, 
solid tumours routinely experience severe hypoxia and necrosis, which causes adenine 
nucleotide degradation and adenosine release.79 Recent studies have revealed the role that 
adenosine plays in tumour growth and metastasis.80 The activation of the A3 adenosine 
receptor (A3AR) by its natural ligand adenosine, or by synthetic agonists, induces an 
inhibitory effect on tumour cell growth, attributed to different expression levels of the 
receptor in tumour and in normal cells.81,82 Both the adenosine and the agonists inhibit the 
growth of various tumour cell types such as melanoma, colon or prostate carcinoma,83 
lymphoma,84,85 and human breast cancer.86 However, the clinical efficacy of anticancer 
nucleoside drugs is strictly determined by the nucleoside transporters (NTs), which are 
implicated in the entry of nucleoside drugs into the cells, as all of the nucleoside drugs 
commonly employed for cancer therapy are hydrophilic molecules and in the absence of 
transporter-mediated uptake, their access to intracellular targets would be slow.87,88,89,90 
Since these transporters are the route of entry for cytotoxic nucleoside analogues used in 
cancer and viral chemotherapy, imaging adenosine receptors and transporters may be of 
clinical importance for the investigation of nucleoside metabolism in pathological conditions 
where adenosine uptake and/or release from certain tissues and organs may be altered (e.g., 
malignant cell proliferation, cancer, inflammation, hypoxia, asthma).91,92 With this objective, 
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several analogues of adenosine have been synthesised and studied as potential antitumor and 
antiviral agents.93,94,95 In addition, the [18F]-labelled analogues of adenosine have potential for 
PET imaging of cell proliferation and/or viral infection.96,97 
It has been proposed that 5-deoxy-5-[18F]fluoroadenosine [18F]47 and its derivatives could 
possibly serve as PET isotope-labelled agonist ligands, specific for adenosine receptors, as the 
modification of the adenine moiety leads to increased selectivity towards receptor 
subtypes.45,46 However, as previously stated, the preparation of 
5-deoxy-5-[18F]fluoroadenosine [18F]47 by synthetic-chemical procedures proved to be 
unsatisfactory.45,46 
The application of the fluorinase enzyme from S. cattleya (EC 2.5.1.63) as a catalyst to 
incorporate [18F]fluoride, and the subsequent successful preparation of [18F]FDA [18F]47 
permitted further exploration of its role as a potential PET radiotracer. 
 
4.3.1 PET imaging studies in vitro  
4.3.1.1 5’-Deoxy-5’-[18F]fluoroadenosine, [18F]FDA 
A. [18F]FDA uptake in human cancer cells 
If FDA 47 is to act as an analogue of adenosine for imaging studies, cell uptake may occur via 
adenosine transporters. In order to investigate this hypothesis, cell uptake studies were carried 
out with enzymatically prepared [18F]FDA [18F]47. The incorporation of [18F]FDA [18F]47 in 
human cancer cells was determined in the absence and presence of high concentration of 
adenosine (10 mM). Reactions were carried out in triplicate to ensure reproducibility, 
following the procedure detailed below.  
Human breast cancer cells (MDA-MB-453) were seeded in tissue culture flasks 
(6 x 25 ml flasks) and cultured to 10% confluence level. A sample of [18F]FDA [18F]47 was 
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collected (0.75 mL, 2 MBq) and an aliquot (100   μl) was added to (a) Dubbelco´s modified 
Eagle medium (DMEM) culture medium (7.5 ml) and (b) DMEM containing 10 mM 
adenosine (7.5 ml). A small volume (2 ml) of (a) was added to 3 flasks and of (b) to the other 
3 flasks, and the cells were incubated at 37 °C for 30 min. The cells were then washed with 
phosphate buffered saline (PBS) at 4 °C (5 times) and harvested with trypsin. Uptake of 
[18F]FDA [18F]47 was determined in a cell counter. The cells were then centrifuged and 
washed once with PBS; the cell pellet was resuspended in aqueous NaOH (100  μl, 1 M) and 
left overnight at 37 °C. They were then neutralised with HCl. The protein content was 
determined using a bicinchoninic acid protein (BCA) assay kit (Sigma-Aldrich™). 
The cell count showed that adenosine does not decrease cell viability during the time period 
of the assay (i.e., the number of cells in flasks with and without adenosine was similar). 
However, the addition of adenosine decreased the uptake of [18F]FDA [18F]47 into the cells 
significantly (>99%), as shown in Figure 4.22.  
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Figure 4.22 [18F]FDA [18F]47 uptake by human breast cancer cells (MDA-MB-453) in the absence 
and presence of a competing concentration of adenosine (10 mM). 
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These results clearly indicate that [18F]FDA [18F]47 uptake into the cells takes place via the 
adenosine transporters, suggesting that [18F]47 may be useful for imaging adenosine 
transport/metabolism by positron emission tomography.  
 
 
B. [18F]FDA transport 
In order to investigate whether the cells are also engaged in the reverse process, promoting the 
release of [18F]FDA [18F]47 out of the cell via the adenosine transporters, a cell uptake/efflux 
experiment was performed.  
The same procedure for cell culturing was carried out following the aforementioned protocol. 
Two set of flasks (6 in total) of human breast cancer cells (MDA-MB-468) were seeded as 
before. This time, the  culture  medium  was  replaced  with  Dubelcco’s  modified  Eagle  medium  
(DMEM) containing [18F]FDA [18F]47 (2 ml, 1.5 MBq) and the cells were incubated at 37 °C 
for 30 min. After this time, one set of flasks was used for determining [18F]47 uptake 
following the procedure described above. The other set had the radioactive medium replaced 
with new fresh DMEM (2 ml), which was added to each flask. The cells were then incubated 
at 37 °C for a further 15 min. The residual [18F]FDA [18F]47 and the number of cells and 
counts per minute (cpm) were determined. The results obtained are illustrated in Figure 4.23 
(vide infra). 
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Figure 4.23 [18F]FDA [18F]47 uptake and efflux by human breast cancer cells (MDA-MB-468). 
 
The [18F]FDA [18F]47 uptake and efflux, expressed as counts per minute (cpm) per milligram 
of protein, shows that not all [18F]FDA [18F]47 that is incorporated remains inside the cell. 
This indicates the existance of an efflux process. Nevertheless, the results demonstrate that 
more than 60% of the radiolabelled FDA is retained inside the cell. These findings further 
support the potential for [18F]FDA [18F]47 as a radiotracer for PET imaging. 
 
4.3.1.2 5’-Deoxy-5’-[18F]fluoroinosine, [18F]FDI 
A. [18F]FDI uptake in human cancer cells 
The incorporation of [18F]FDI [18F]50 in human cancer cells (MDA-MB-468) was determined 
following the aformentioned protocol for [18F]FDA [18F]47 uptake. Reactions were also 
carried out in triplicate to ensure reproducibility. Cell culture and counting were performed 
following the same procedure. In this case, incubation of [18F]FDI [18F]50 in human breast 
cancer cells (MDA-MB-468) was carried out in the absence and presence of a competing 
concentration of inosine (20 mM) as encountered in vivo. The results obtained after a 10 min 
incubation are illustrated in Figure 4.24 (vide infra). 
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Figure 4. 24 [18F]FDI 50 uptake by human breast cancer cells (MDA-MB-468) in the absence and 
presence of inosine. 
 
The results showed that the addition of inosine decreased significantly the uptake of [18F]FDI 
[18F]50 into the cells.  
 
 
4.3.2 PET imaging studies in vivo:                                    
 a small animal study with [18F]FDA 
Molecular imaging in small animals has emerged as a powerful technique for investigating 
disease processes at the molecular and cellular levels.98,99 As such, small-animal PET 
(‘microPET’)  has  opened  the  way  for   imaging  tissue  biodistribution and metabolism of new 
markers in nude and genetically-modified rodents.100,101,102 
With the purpose of investigating [18F]FDA [18F]47 uptake in vivo, an experiment was carried 
out with a healthy nude rat. After injection (i.v. tail) of a small dose of [18F]FDA [18F]47, 
uptake of [18F]47 was determined by microPET scanning. 
Sagittal and coronal images were acquired after a period of 15 min following intravenous 
administration of [18F]FDA [18F]47 (1 ml, 18.68 MBq), and are depicted in Figure 4.25 and 
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Figure 4.26, respectively. A contrast-enhanced microCT scan is shown in both images for 
anatomic reference. 
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Figure 4.25 Fused CT-PET sagittal view of [18F]FDA [18F]47 uptake in the brain of a male 
Winstar Han rat following injection of 18.68 Mq, 15 min post-injection. A mixture of 
ketamine and xylazine was used as an anesthetic agent. 
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shoulders
 
Figure 4.26 Fused CT-PET coronal view through the thorax of a male Winstar Han rat following 
injection of 18.68 MBq of [18F]FDA [18F]47. Animal was anesthesised with a mixture 
of ketamine and xylazine. 
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Uptake of [18F]FDA [18F]47 (Figure 4.25, vide supra) is mainly observed in the olfactory 
bulb. Very low levels of uptake of [18F]FDA [18F]47 are observed in the brain area, with very 
little definition, indicating virtually no uptake in the brain or spinal cord. This finding 
suggests that [18F]FDA [18F]47 does not cross the blood brain barrier. However, these are 
very preliminary results, with not enough information about the pharmacokinetics of [18F]47. 
Therefore, the possibility that there was insuffient clearance of [18F]FDA [18F]47 from the 
blood at the time of imaging cannot be discarded. 
The experiment demonstrates some accumulation of [18F]FDA [18F]47 in a healthy nude rat 
with clear concentration in some tissues. [18F]FDA [18F]47 has been generated via the 
fluorinase reaction and in an adequate formulation for a small animal imaging. In vivo uptake 
of [18F]47 has been observed after non-invasive microPET imaging, and happily the animal 
survived the study. 
In order to reduce stress and motion, most small-animal PET scans are carried out with 
anaesthesia. This may present a problem in PET imaging studies, since the pharmacological 
action of anaesthetics affect some neuroreceptor systems. However, not only anesthetic agents 
but also the mode of anesthesia can affect the results of PET studies in small animals. 
Recently, it has been shown that dietary conditions and temperature during the uptake of the 
radiotracer influence [18F]FDG [18F]108 biodistribution in mice.103,104 
In this context, investigations to gain a deeper knowledge of [18F]FDA [18F]47 
biodistribution, and particularly its metabolism, as well as temperature and anesthesia effects, 
need to be undertaken. Future work will also focus on the exploration of [18F]FDA [18F]47 in 
tumour and inflammation models. 
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4.4 Preliminary results of [18F]FDR as a radiotracer     
of potential diagnostic interest 
As aforementioned, nucleoside and sugar tracers have been actively investigated as PET 
imaging agents for use in tumour detection and/or to monitor response to chemotherapy.42,105  
Taking into account the metabolic role of ribose in energy production and recent studies that 
have reported its benefits in some cardiovascular diseases,106,107,108 the development of 
fluorine-18 labelled ribose, [18F]FDR [18F]71, could offer a new approach to study human 
energy metabolism and clinical disorders by PET techniques. 
To this end, cell uptake studies in human breast cancer cells (MDA-MB-468) were carried out 
with enzymatically prepared [18F]FDR [18F]71 following the protocol already described for 
[18F]FDA [18F]47. 
The preliminary studies involving incubation of [18F]FDR [18F]71 in breast cancer cells, 
showed high uptake values when compared to those for [18F]FDG [18F]108 reported for the 
same cancer cell line, as illustrated in Figure 4.27. 
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Figure 4.27 Incorporation of [18F]FDG [18F]108 and [18F]FDR [18F]71 in breast cancer cell line 
MDA-MB-468. 
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However,   the   ‘metabolic   trapping’   of   [18F]FDR [18F]71 needs to be further investigated. 
Future studies will also focus on the application of [18F]FDR [18F]71 for the evaluation of 
ribose determination in biological systems. 
 
4.5 Conclusions 
The main purpose of this work was to develop a shorter route to [18F]FDR [18F]71 using the 
fluorinase enzyme as a catalyst for 18F-C bond formation.  
A second aim was to develop radiofluorinated FDA [18F]47 and other analogues for non-
invasive assessment of adenosine receptors by positron emission tomography (PET). 
Human cancer cell lines evaluated in vitro showed significant uptake of these radiotracers 
produced by fluorinase-coupled enzymatic reactions, as summarised in Figure 4.28. 
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Figure 4.28 Comparative uptake of radiotracers produced by fluorinase reaction with [18F]FDG in 
human breast cancer cell lines. 
 
These observations stimulated further research on the uptake of [18F]FDA [18F]47, with in 
vivo microPET imaging studies in anesthetised rat. Nevertheless, further investigations are 
needed to evaluate the biodistribution and pharmacokinetics of [18F]FDA [18F]47 and these 
studies should characterise the mode of uptake of these [18F]-labelled sugars and their 
potential role as radiotracers with clinical use in PET. 
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5.1 Chemical syntheses 
5.1.1 General experimental procedures 
5.1.1.1 Reagents and solvents 
Commercially available reagents and solvents were used when available and purchased from 
Acros, Aldrich®, Alfa Aesar®, Fluka, Lancaster and VWR®.  
All reagents were of synthetic grade and used as supplied, unless otherwise stated. If further 
purification was required, the procedures detailed by Perrin and Armarego were followed.1  
Diethyl ether (Et2O) and dry tetrahydrofuran (THF) were dried by refluxing with 
benzophenone over sodium wire under an atmosphere of nitrogen, and were distilled and 
collected by syringe as required. Dry methanol (MeOH) and dry dichloromethane (DCM) 
were dried by refluxing with calcium hydride, they were then distilled and collected by dry 
syringe as required, or from Pure-Solv™ Solvent Purification Systems from Innovative 
Technology, Inc. Dry acetonitrile (MeCN) and dry pyridine were used as supplied by 
Aldrich®. Acetone was used as reagent grade. Light petroleum refers to the fraction boiling 
between 40−60 ºC. 
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5.1.1.2 Reaction conditions 
Air and moisture sensitive reactions were carried out under a positive pressure of nitrogen 
using oven-dried glassware (140 ºC). Room temperature (RT)   refers   to  20−25   ºC. Reaction 
temperatures   of   −78   ºC   to   −40   ºC   were   obtained   using a bath cooling apparatus 
LP Technology RP-100-CD. For those at 0 °C, an ice bath was employed. Reactions requiring 
reflux or heating were carried out using an oil bath equipped with a contact thermometer. 
Reaction progress was monitored by thin layer chromatography (TLC). 
 
5.1.1.3 Chromatography 
Thin layer chromatography (TLC) was carried out on pre-coated aluminium backed silica gel 
plates (Machery-Nagel Alugram® SIL G, 0.20 mm silica gel) or on pre-coated plastic sheets 
with silica gel (Machery-Nagel Polygram® SIL G/UV254, 0.20 mm silica gel). Compounds 
were   visualised   using   UV   light   (λ, 254 nm), potassium permanganate, vanillin or a 
molybdenum based staining agent. 
Flash column chromatography was performed using silica gel (Apollo Scientific Ltd, silica 
gel,   40−63  micron  grade). The crude samples were either applied directly to the top of the 
silica/solvent column or applied as a dry silica gel slurry. 
High-performance liquid chromatography (HPLC) analysis was carried out using a Varian 
series 9012 pump/9050 UV-lamp; analytical HPLC was performed using a Hypersil ODS 
C-18  column,  5  μm  (250  mm;;  4.6  mm  ID). 
GC-MS analyses were obtained using an Agilent 6890 gas chromatograph equipped with an 
Agilent 5973N mass-selective detector. 
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5.1.1.4 Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectra were recorded on either Bruker Avance 300 
(1H, 300 MHz; 13C, 75 MHz; 19F, 282 MHz), or Bruker Avance 400 (1H, 400 MHz; 13C, 100 
MHz; 19F, 376 MHz), or Bruker Avance 500 (1H, 500 MHz; 19F, 470 MHz) using GPE Ltd  
NMR tubes (GPE-S-5-300 NMR tubes). 13C NMR spectra were acquired using the 
PENDANT sequence. 
Chemical shifts for 1H and 13C NMR spectra were recorded using deuterated solvent as the 
lock and residual solvent as the internal standard. Where CDCl3 was employed as the solvent, 
calibration was carried out on this solvent signal at 7.26 ppm (1H) and 77.16 (13C).2 When 
D2O was used, the water signal was designated the internal reference at 4.79 ppm (1H). 
19F NMR spectra were referenced to CFCl3 as the external standard. 
NMR spectra are described in parts per million (ppm) and are reported consecutively as 
chemical shift (δH,  δC or δF), relative integral, multiplicity (s, singlet; d, doublet; dd, doublet of 
doublets; dt, doublet of triplets; t, triplet; m, multiplet; br.s, broad singlet), coupling constant 
(J) in Herzt (Hz) and assignment. The abbreviation Ar in the assignment of both 1H and 13C is 
used to denote aromatic. 
All NMR spectra were recorded at 25 ºC, unless otherwise stated and were analysed using 
Bruker TopSpin (Version 2.0 Bruker BioSpin 2006) software. 
 
5.1.1.5 Mass spectrometry  
Low resolution mass spectrometry (MS) were performed using a Micromass LCT 
(Manchester, UK) mass spectrometer with electrospray ionization (ESI) operating in both 
positive and negative mode. High resolution mass analysis was carried out by Caroline 
Horsburgh, spectra were recorded on a Micromass LCT TOF mass spectrometer using ES 
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ionization in +ve ion mode. Where this method was not adequate CI was employed using a 
Micromass GCT instrument 
 
5.1.1.6 Melting point analyses 
Melting points were obtained using Pyrex® capillaries and were measured on a Gallenkamp 
Griffin MPA350.BM2.5 melting point apparatus. 
 
5.1.1.7 GC-MS 
Low resolution GC-MS analysis was carried out using an Agilent 6890 plus gas 
chromatograph coupled to a 5973N mass selective detector in EI mode, with helium carrier 
gas. Automatic injections using a 7683 series injector were made into both non-chiral and 
chiral columns. Separations were achieved with an Agilent HP 19091S-433, 5% phenyl 
methyl siloxane, 30 m x 250 µm, film thickness 0.25 µm, non-chiral column and a β-DEX 
120 Superco chiral column. The HP 6890 chemstation software was used for data processing.  
 
5.1.1.8 LC-MS 
Low resolution LC-MS analysis was carried out on a Supelcosil ABZ+PLUS column (3 μm, 
3.3 cm x 4.6 mm ID) eluting with 0.1% HCO2H and 0.01 M ammonium acetate in water 
(solvent A), and 95% CH3CN and 5% water (containing 0.5% HCO2H) (solvent B). The 
elution gradient was as follows: 0–0.7 min 0% B, 0.7–4.2 min 0–100% B, 4.2–4.6 min 100% 
B with a flow rate of 3 cm3 / min. Three modes of detection were used: electrospray in 
positive mode, electrospray in negative mode which were recorded on a Waters ZQ mass 
spectrometer and diode array UV detection which was carried out in the range 215–330 nm. 
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5.1.2 Synthesis  of  5’-deoxy-5’-fluoroadenosine 47  
5.1.2.1 2’,3’-O-Isopropylidene-5’-O-mesyladenosine 95 3 
 
 
Methanesulfonyl chloride (2.5 cm3, 31.6 mmol) was added dropwise to a stirred solution of 
2,3-O-isopropylidene-adenosine 94 (5 g, 15.8 mmol) in anhydrous pyridine (40 cm3) at 0 ºC. 
The reaction was warmed to RT and stirred for 4 h.  Ice-cold water (20 cm3) and 2 M KOH 
were then added until a neutral pH was reached. The reaction mixture was then concentrated 
under reduced pressure to give a yellow oil, which was partitioned between chloroform 
(50 cm3) and water (40 cm3). The organic layer was washed with water (2 x 25 cm3), dried, 
filtered and concentrated. Purification over silica eluting with CHCl3:EtOH (10:1) gave 95 
(8.27 g, 68%) as an off white powder.  
M.p. 225-227 oC (lit.,4 235-236 oC dec.). δH (300 MHz; CDCl3): 1.40 (3 H, s, CCH3), 1.63 
(3 H, s, CCH3), 2.92 (3 H, s, SO2CH3), 4.40-4.47 (2 H, m, 2 x H-5’), 4.51-4.56 (1 H, m, 
H-4’), 5.16 (1 H, dd, J 6.3 and  2.9,  3’-H), 5.44 (1 H, dd, J 6.3 and 2.0, H-2’),  5.89 (2 H, br s, 
NH2), 6.13 (1 H, d, J 2.0, H-1’),   7.95   (1  H,   s,   H-8) and 8.34 (1 H, s, H-2); δC (75 MHz; 
CDCl3): 27.5 (CH3), 25.7 (CH3), 21.5 (SO2-CH3), 68.8 (CH2), 81.8 (CH), 84.4 (CH), 85.2 
(CH), 91.3 (CH), 115.2 (C), 119.1 (C), 140.5 (C-2), 150.0 (C), 153.2 (C-8) and 155.7 (C). 
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5.1.2.2 2’,3’-O-Isopropylidene-5’-deoxy-5’-fluoroadenosine 96 4 
 
 
Procedure A 4 
TBAF.3H2O (9.31 g, 29.5 mmol) in anhydrous MeCN (20 cm3) was added to a solution of 
2,3-O-isopropylidene-5-O-mesyl-adenosine 95 (4.54 g, 11.8 mmol) in anhydrous MeCN 
(80 cm3) at RT and the solution was heated under reflux for 17 h. The reaction was cooled to 
RT and concentrated under reduced pressure to afford a brown oil, that was partitioned 
between chloroform (150 cm3) and water (50 cm3). The organic layer was washed with water 
(2 x 50 cm3), dried, filtered and concentrated. Purification over silica eluting with 
CHCl3:EtOH (10:1) furnished 96 (1.12 g, 31%) as an off-white powder. M.p. 156-157 oC 
(lit.,4 159-160 oC). δH (300 MHz; CDCl3): 1.38 (3 H, s, CCH3), 1.60 (3 H, s, CCH3), 4.52 
(1 H, dm, H-4’),  4.68 (2 H, dm, 2JH,F  47.0, 2 x H-5’),  5.10  (1  H,  dd,  J 6.3 and 3.0, H-3’), 5.34 
(1 H, dd, J 6.3 and 2.2, H-2’),  6.18 (1 H, d, J 2.2, H-1’),  6.37 (2 H, brs,  NH2), 7.91 (1 H, s, 
H-8) and 8.31 (1H, s, H-2); δF (282 MHz; CDCl3): 229.29 (dt, 2JF-H 46.9 and 3JF-H 23.5). 
 
 
Procedure B 5 
A sealeable tube was charged with 100a:100b (0.188 g, 0.582 mmol) dissolved in t-BuOH 
(6 cm3). A flow of NH3(g) was then bubbled through the solution for 5 min, after which time 
the tube was sealed and heated at 90 ºC for 24 h. The solvent was removed at reduced 
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pressure, then taken up in CHCl3 (40 cm3) and washed using H2O (30 cm3) which was 
extracted further with CHCl3 (40 cm3). The combined organic phase was then dried (MgSO4), 
filtered and concentrated under reduced pressure to give 96 (0.166 g, 92%)  as an off white 
solid. 
Physical and spectroscopic properties were identical to those previously given for 96. 
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5.1.2.3 Chloro-9-(2’,3’-O-isopropylidene--D-ribofuranosyl)-
 purine 99 6 
 
 
To a stirred suspension of 6-chloro-9--D-ribofuranosylpurine 98 (0.5 g, 1.74 mmol) in 
anhydrous acetone (15 cm3) and 2,2-dimethoxypropane (1.2 cm3, 0.87 mmol) was added 
p-toluensulfonic acid monohydrate (0.34 g, 1.74 mmol). After 4 h the resulting solution was 
poured slowly into stirred aqueous 0.5 M NaHCO3 (30 cm3). The solution was concentrated 
under reduced pressure and extracted with CHCl3 (4 x 20 cm3). The combined organic 
extracts were washed with brine, dried over MgSO4 and the solvent was evaporated under 
reduced pressure. The residual off-white solid was crystallised from MeOH to give 99 
(0.41 g, 73%) as white crystals; M.p. 158-159 ºC (lit.6 159-160). δH (300 MHz, CDCl3): 1.39 
(3H, s, -CH3), 1.65 (3H, s, -CH3), 3.83 (1H, dd, J 12.6 and 2.1, H-5’),  3.98 (1H, dd, J 12.6 and 
1.79, H-5’), 4.55-4.58 (1H, m, H-4’),  5.11 (1H, dd, J 6.0 and 1.4, H-3’),  5.20  (1H,  dd,  J 6.0 
and 4.6, H-2’),   5.98 (1H, d, J 4.6, H-1), 8.25 (1H, s, H-8), 8.77 (1H, s, H-2). m/z (ES-): 
325.04 [M-H] (100%). m/z (ES+): 348.95 [M+Na]+ (100%). HRMS (ES): Found 349.0671. 
Calcd. for C13H15N4O4NaCl, 349.0680. 
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5.1.2.4 2’,3’-O-Isopropylidene-5’-deoxy-5’-fluoro-6-chloropurine 
 riboside 100a 5 
  2’,3’-O-Isopropylidene-5’-deoxy-5’,6-difluoropurine  
  riboside 100b 5 
 
 
 
To a stirred solution containing 0.300 g (0.92 mmol) of 99 in dry THF (8.5 cm3) was added 
TsF (0.320 g, 1.84 mmol; 2 eq) followed by 1 M TBAF in THF (2.8 cm3, 2.8 mmol; 3.0 eq) 
the resultant solution was heated under reflux. After 22 h the reaction mixture was filtered 
rinsing with EtOAc. Concentration of this solution under reduced pressure and subsequent 
purification by column chromatography (hexane:EtOAc, 1:1) gave 0.24 g (0.75 mmol, 81% 
conversion to primary fluoride) of 100a:100b as a yellow oil (10:1 mixture). δH (300 MHz, 
CDCl3): 1.35 (3H, s, CH3), 1.59 (3H, s, CH3), 4.68-4.44 (3H, m, H-4’,  5a’-H,  5b’-H), 5.03 
(1H, dd, J 6.3 and 2.7 ,  3’-H), 5.30-5.28 (1H, m, H-2’), 6.26 (1H, d, J 2.4 , H-1’), 8.24 (s, H-
8/2), 8.27 and 8.24 (s, H-8/2, 1:2.2, 1H), 8.71 and 8.60 (s, H-2/8, 1:2.2, 1H). δF (282 MHz, 
CDCl3, H-F decoupled): 230.3. 
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5.1.2.5 5’-Deoxy-5’-fluoroadenosine 47 7 
 
Procedure A 
2,3-O-Isopropylidene-5-deoxy-5-fluoroadenosine 96 (0.075 g, 0.242 mmol) was suspended 
in 0.02 M sulfuric acid (5 cm3) with stirring. The reaction slurry was then heated (100 oC) and 
the reaction was monitored by 19F NMR spectroscopy until such time that no starting material 
could be detected (5 h). The reaction mixture was cooled and the solvent co-evaporated 
several times with ethanol to give the title compound as a pale yellow oil which was identified 
as 47 by HPLC analysis.  
 
Procedure B 5 
A sample of 100a and 100b (0.152 g, 0.491 mmol) was stirred in TFA:H2O (9:1, 8 cm3) for 
25 min at RT, after which time the reaction mixture was cooled and the solvent removed 
under reduced pressure to afford a pale yellow oil. Recrystallisation in MeOH:Et2O gave 
0.094 g (77%) of 47 as a white solid. M.p. 203-204 oC (lit.,7 204-205 oC); δH (300 MHz; 
D2O): 4.11 (1 H, dm 3JH-F 23.8, H-4’),  4.21-4.30 (1 H, m, H-3’), 4.47-4.63 (1 H, m, H-2’),  
4.64 (2 H, dm, 2JH-F 47.8, 2 x H-5’),  5.46  (1  H,  brs,  OH), 5.65 (1 H, brs, OH), 6.01 (1 H, d, J 
4.8, H-1’),  7.30 (2 H, brs, NH2), 8.06 (1 H, s, H-8) and 8.15 (1 H, s, H-2); δC (75 MHz; D2O): 
69.8 (d, 3JC-F 6.1, C-3’),  74.3  (C-2’),  81.7 (d, 2JC-F 17.8, C-4’),  83.3  (d,  1JC-F 171.8, C-5’),  88.0  
(C-1’),  119.4  (C-5), 139.7 (C-8), 149.7 (C), 153.1 (C-2) and 156.4 (C-6); δF (282 MHz; D2O): 
230.00 (dt, 2JF-H 47.4, 3JF-H 23.8). m/z (ES+): 270.04 [M+H]+ (100%). HRMS (ES): Found 
270.1001. Calcd. for C10H12FN5O3, 270.1002. 
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5.1.3 Synthesis of 5-deoxy-5-fluoro-D-ribose 71  
5.1.3.1 Methyl-2,3-O-isopropylidene-β-D-ribofuranoside 82 8,9 
 
 
A solution of 2,2-dimethoxypropane (45 cm3) was added to D-(-)-ribose 81 (15.04 g, 
100.21 mmol) in a mixture of anhydrous methanol (55 cm3) and anhydrous acetone (70 cm3) 
at RT with stirring followed by BF3·Et2O (3.6 cm3, cat.) and the resulting yellow solution was 
allowed to stir for 24 h at RT. Sodium bicarbonate was then added until neutral pH was 
achieved. The reaction mixture was then filtered and concentrated under reduced pressure to 
afford the crude product as a yellow oil. Vacuum distillation gave the title compound 82 
(11.67 g, 57%) as a colourless oil. δH (300 MHz; CDCl3): 1.32 (3 H, s, -CH3), 1.49 (3 H, s, -
CH3), 3.44 (3 H, s, -OCH3), 3.48 (1 H, brs, -OH), 3.58 (1 H, dd, 2JH-H 12.5 and J 2.6, H-5), 
3.66 (1 H, dd, 2JH-H 12.5 and J 3.5, H-5), 4.44 (1 H, t, J 2.7, H-4), 4.59 (1 H, d, J 6.0, H-2), 
4.84 (1 H, d, J 6.0, H-3) and 4.98 (1 H, s, H-1); δC (75 MHz; CDCl3): 24.7 (CH3), 26.4 (CH3), 
55.5 (OCH3), 64.0 (C-5), 81.5 (C-3), 85.8 (C-2), 88.4 (C-4), 110.0 (C-1) and 112.5 (C). 
m/z (GC-MS, EI):189 (M+-CH3, 52%), 173 (M+-OCH3, 38), 59 (100), 43 (67). 
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5.1.3.2 Methyl-2,3-O-isopropylidene-5-O-tosyl-β-D-
 ribofuranoside 102 10 
 
 
Purified p-tosylchloride (6.9 g, 36.2 mmol) was added portion wise to a solution of methyl-
2,3-O-isopropylidene-β-D-ribofuranoside 82 (5.0 g, 24.5 mmol) in anhydrous pyridine 
(13 cm3) at 0 ºC. After 4 h at RT the reaction was found to be complete by TLC analysis. The 
reaction mixture was quenched into ice water (25 cm3) and the resulting white precipitate was 
filtered and washed with ice water (3 x 15 cm3) to remove the excess of pyridine. The white 
precipitate collected was dissolved in diethyl ether (15 cm3), dried over MgSO4 and the 
solvent removed under pressure. Subsequent drying under reduced pressure afforded the 
tosylate 102 (5.17 g, 76%) as a white solid. M.p. 78-79 ºC. (lit.,10 78.5-79.5 ºC); δH (300 
MHz; CDCl3) 1.28 (3 H, s, CH3), 1.45 (3 H, s, CH3), 2.46 (3 H, s, Ar-CH3), 3.23 (3 H, s,         
-OCH3), 4.01 (2 H, dd, J 7.3 and 1.5, H-5), 4.31 (1 H, dt, J 7.3 and 0.8, H-4), 4.53 (1 H, d, J 
6.0, H-2), 4.60 (1 H, dd, J 6.0 and 0.8, H-3), 4.93 (1 H, s, H-1), 7.36 (2 H, d, J 8.2, Ar-H) and 
7.81 (2 H, d, J 8.2, Ar-H); δC (75 MHz; CDCl3,) 22.1 (Ar-CH3), 25.2 (CH3), 26.7 (CH3), 55.4 
(OCH3), 69.6 (CH2), 81.7 (CH), 83.9 (CH), 85.3 (CH), 109.8 (CH), 113.1 (C), 128.4 (ArC), 
130.3 (ArC), 133.1 (C) and 145.5 (C). m/z (ES+): 380.46 [M+Na]+ (100%). HRMS (ES): 
Found 381.0978. Calcd. for C16H22O7NaS, 381.0984. 
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5.1.3.3 Methyl-2,3-O-isopropylidene-5-deoxy-5-fluoro-β-D-
 ribofuranoside 84 7 
 
 
A solution of TBAF.3H2O (2.2 g, 6.97 mmol) in anhydrous acetonitrile (5.5 cm3) was added 
to a stirred solution of methyl-2,3-O-isopropylidene-5-O-tosyl-β-D-ribofuranoside 102 (2.0 g, 
5.58 mmol) in anhydrous MeCN (20 cm3) at RT and the reaction was then heated under reflux 
for 24 h. The reaction mixture was cooled and concentrated under vacuum to give a brown 
oil. The oil was dissolved in ethyl acetate (15 cm3), washed with water (2 x 15 cm3) and dried 
over MgSO4. The solvent was removed under vacuum to give the crude product as a yellow 
oil which was purified over silica gel eluting with diethyl ether:pet. ether 5:2 to afford 84 
(0.86 g, 59%) as a clear oil. δH (300 MHz; CDCl3) 1.33 (3 H, s, CH3), 1.49 (3 H, s, CH3), 
3.33 (3 H, s, OCH3), 4.28-4.48 (3 H, m, 2 x H-5 and H-4), 4.59 (1 H, dd, J 6.0 and 2.4, H-2), 
4.69 (1 H, d, J 6.0, H-3), 4.99 (1 H, d, J 2.4, H-1); δC (75 MHz CDCl3); 25.3 (CH3), 26.8 
(CH3), 55.3 (OCH3), 81.4 (d, 3JC-F 4.2 , C-3), 82.2-84.5 (d, 1JC-F 172.5, C-5), 84.7-85.0 (d,    
2JC-F 22.3, C-4), 85.4 (C-2), 109.6 (C-1), 113.0 (C); δF (282 MHz, CDCl3) -225.29 (dt,         
2JF-H 48.3 and 3JF-H 21.4). 
 
 
. 
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5.1.3.4 5-Deoxy-5-fluoro-D-ribose 71 11 
 
 
Dilute sulphuric acid (0.02 M, 6 cm3) was added to methyl-2,3-O-isopropylidene-5-deoxy-5-
fluoro-β-D-ribofuranoside 84 (0.72 g, 3.5 mmol) with stirring. The reaction was then  heated 
under reflux and found to be complete by 19F NMR spectroscopy within 4 h. Calcium 
carbonate was added to neutralise the excess of acid and calcium sulfate was removed from 
the product by centrifugation. The supernatant was filtered through celite and lyophilised to 
yield 5-deoxy-5-fluoro-D-ribose 71 (0.47 g, 88%) as a pale yellow syrup. The 1H-NMR (300 
MHz, D2O) spectrum recorded for 71 was too complex to interpret conclusively. δC  (75 
MHz;  D2O): 69.2 (d, 4JC-F 7.0, α / β, C-3), 69.3 (d, 3JC-F 7.2, α / β, C-3), 70. 9, 75.4 (α / β, C-
2), 80.7 (d, 3JC-F  22.5, α / β, C-4), 81.4 (d, 3JC-F 17.8,  α / β, C-4), 82.5 (d, 1JC-F 168.6,  α / β, 
C-5), 84.8 (d, 1JC-F 168.4,  α / β, C-5), 96.8 (α , C-1), 101.4 (β, C-1); δF (282 MHz, D2O): -
228.53 (β, dt, and 2JF-H 46.5 and 3JF-H 26.0), -230.83 (α, dt, 2JF-H 46.5 and 3JF-H 27.9). m/z 
(GC-MS after derivatisation with MSTFA): 217 (100%), 191 (23), 143 (32), 73 (74). 
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5.1.4 Synthesis of 5-deoxy-5-fluoro-D-xylose 74 
5.1.4.1 1,2-Di-O-isopropylidene-5-O-tosyl-D-xylofuranose 105 12 
 
 
Purified p-toluenesulfonyl chloride (1.31 g, 6.31 mmol) was added portion wise to a solution 
of 1,2-di-O-isopropylidene-D-xylofuranose 104 (1.20 g, 6.25 mmol) in anhydrous pyridine 
(15 cm3) at 0 ºC and after 4 h at RT the reaction was found to be complete by TLC analysis. 
The reaction mixture was quenched into ice water (25 cm3) and the resulting white precipitate 
was filtered and washed with ice water (3 x 15 cm3) to remove the excess of pyridine. The 
white precipitate collected was dissolved in diethyl ether (15 cm3), dried over MgSO4 and the 
solvent removed under reduced pressure. Recrystallisation from THF/Et2O furnished 105 
(1.53 g, 74%) as a white solid; M.p. 85 ºC. δH (300 MHz; CDCl3): 1.30 (3 H,s, -CH3), 1.46 
(3H, s, CH3), 2.45 (3 H, s, OCH3), 3.48 (1 H, s, OH), 4.09-4.18 (1 H, m, H-4), 4.30-4.37 (3 H, 
m, H-5), 4.51 (1 H, d, J 3.6, H-2), 5.88 (1 H, d, J  3.6, H-1), 7.36 (2 H, d, J 8.2, Ar-H), 7.80 (2 
H, d, J 8.2, Ar-H). m/z (CI+): 345.10 [M+H]+ (100%). HRMS (CI): Found 345.1011. Calcd. 
for C15H21O7S, 345.1008. 
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5.1.4.2 1,2-O-Isopropylidene-5-deoxy-5-fluoro--D-xylofuranose 
 106 13 
 
 
A solution of TBAF trihydrate (2.2 g, 6.97 mmol) in anhydrous acetonitrile (5 cm3) was 
added to 1,2-di-O-isopropylidene-5-O-tosyl-D-xylofuranose 105 (0.98 g, 5.10 mmol) in 
anhydrous acetonitrile (20 cm3) at 25 ºC and the reaction was heated under reflux for 24 h. 
The reaction mixture was cooled and concentrated under reduced pressure to give an oil. The 
oil was dissolved in ethyl acetate (15 cm3), washed with water (2 x 15 cm3) and dried over 
MgSO4. The solvent was removed under reduced pressure to give the crude product as a 
yellow oil which was purified over silica gel eluting with diethyl ether:pet. ether 5:2 to afford 
106 (0.44 g, 57%) as a white solid. δH (300 MHz; CDCl3): 1.33 (3 H, s, CH3), 1.50 (3H, s, 
CH3), 3.48 (1 H, brs, OH), 4.33-4.45 (2 H, dm, H-3 and H-4), 4.53 (1 H, dd, J 6.0 and 1.3, 
H-2),  4.65 (1 H, ddd, J  47.1 and 10.2 and 5.1, H-5), 4.81 (1 H, ddd, J  47.1 and 10.2 and 5.1, 
H-5) and 5.98 (1 H, d, J  3.7, H-1). δF (282 MHz, CDCl3, F-H decoupled): 232.4. m/z (CI+): 
193.09 [M+H]+ 
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5.1.4.3 5-Deoxy-5-fluoro-D-xylofuranose 74 13 
 
 
 
Dilute sulfuric acid (0.02 M, 6 cm3) was added to 1,2-O-isopropylidene-5-deoxy-5-fluoro--
D-xylofuranose 106 (0.72 g, 3.5 mmol) with stirring at RT. The reaction was heated under 
reflux and found to be complete by 19F NMR spectroscopy within 4 h. Calcium carbonate was 
added to neutralise the excess of acid and the calcium sulfate was removed from the product 
by centrifugation. The supernatant was filtered through celite and lyophilised to yield 5-
deoxy-5-fluoro-D-xylose 74 (0.47 g, 83%) as a pale yellow syrup.  
The 1H-NMR (300 MHz, D2O) spectrum recorded for 74 was too complex to interpret 
conclusively. δF (282 MHz, D2O): 228.49 (β, dt, and 2JF-H 47.5 and 3JF-H 24.2), 230.60 (α, 
dt, 2JF-H 47.5 and 3JF-H 24.2). 
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5.1.5 Fluoroacetaldehyde 26 14 
 
 
Fluoroethanol 68 (5 cm3, 85.0 mmol) was added to a suspension of pyridinium dichromate 
(PDC) (10.0 g, 26.5 mmol) in dichloromethane (60 cm3) and the reaction was heated under 
reflux for 16 h. The reaction was allowed to cool and the solution distilled into a separating 
funnel containing water (25 cm3). After mixing, the organic layer was separated and extracted 
with a further volume of water (15 cm3). The aqueous layers were combined and analysed by 
19F NMR spectroscopy. The sample was shown to approximately 40% fluoroacetaldehyde 26. 
δF (376 MHz, D2O): 224.44 (60%) (tt, 2JF-H 47.3 and 3JF-H 31.8; fluoroethanol 68), 231.02 
(40%) ( dt, 2JF-H 47.3 and 3JF,H 10.3; fluoroacetaldehyde 26). 
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5.2 Biochemical protocols 
5.2.1 General experimental procedures 
5.2.1.1 Reagents and enzymes  
Streptomyces cattleya NRRL 8057 was obtained form The   Queen’s   University   of   Belfast,  
Microbial Biochemistry Section, Food Science Department, Belfast (originally from United 
States Department of Agriculture, Agricultural Research Service, Midwest Area Northen 
Regional Research Laboratories, Peoria, Illinois, USA). 
Commercially available reagents and enzymes were used when available and purchased from 
either Acros, Fermentas, Fluka, Novagen, Promega or Sigma Biochemicals. The details for 
the enzymes are as follows: immobilised purine nucleoside phosphorylase (PNPase, 
EC 2.4.2.1, E. coli, donated by GlaxoSmithKline), purine nucleoside phosphorylase (PNPase, 
EC 2.4.2.1, unknown bacterial source, N-8264, 15.5 units/mg), 5-adenylic acid deaminase 
(EC 3.5.4.6, from Aspergillus species, A 1907, 0.11 units/mg), phytase (EC 3.1.3.8, from 
Aspergillus ficuum, P 9792, 3.5 units/mg), and glucose isomerase (Sweetzyme T, from 
Streptomyces murinus, G-4166, 350 units/mg). The competent cells BL21(DE3), BL21 (DE3) 
Gold and C43(DE3) were purchased from Invitrogen in 50 µl aliquots.  
For [18F]fluoride production, a CTI RDS-111 cyclotron (CTI/Siemens) and for determination 
of radioactivity a Capintec well reader (CRC-15R) were used. 
 
5.2.1.2 Cell culture and microbiological work 
All microbiological work was carried out under sterile conditions in a Gallenkamp flowhood. 
All work described involving cells, cell-free extract or protein solutions was performed at 
4 ºC if not otherwise stated. Glassware, media and consumables were sterilised by 
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autoclaving. Cell cultures were incubated in a temperature controlled Gallenkamp orbital 
incubator and resting cells on a temperature controlled Innova 2000 platform shaker. 
Centrifugation was carried out on a Beckman Avanti instrument at 14,000 rpm, at 20,000 
(JA 25.50) or at 9,000 rpm (JLA 9.100). For   microcentrifugation   (50−1500 l), an 
Eppendorf 5415C centrifuge was used. Sonication was performed with a Sonics & Materials 
Inc., Vibra Cell apparatus. Lyophilisation was carried out on an FTS, flexi-dry freeze dryer. 
Protein concentration was determined using a Nanodrop ND1000 spectrophotometer. Samples 
were concentrated using a SPD1010 Speed Vac system. Ultra-pure water was collected from a 
USF Elga Maxima water supply system. 
 
5.2.1.3 Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectra were recorded on either Bruker Avance 400    
(1H, 400 MHz; 19F, 376 MHz), or Bruker Avance 500 (1H, 500 MHz; 19F, 470 MHz) using 
GPE Ltd  NMR tubes (GPE-S-5-300 NMR tubes). NMR spectra were acquired using D2O or 
10% D2O in buffer or water. 
Chemical shifts for 1H and 19F NMR spectra were recorded using deuterated solvent as the 
lock and residual solvent as the internal standard. When D2O was used, the water signal was 
designated the internal reference at 4.79 ppm (1H).2 19F NMR spectra were referenced to 
CFCl3 as the external standard. 
NMR spectra are described in parts per million (ppm) and are reported consecutively as 
chemical  shift   (δH or δF), relative integral, multiplicity (s, singlet; d, doublet; dd, doublet of 
doublets; dt, doublet of triplets), coupling constant (J) in Herzt (Hz) and assignment.  
All NMR spectra were recorded at 25 ºC, unless otherwise stated and were analysed using 
Bruker TopSpin (Version 2.0 Bruker BioSpin 2006) software. 
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5.2.1.4 Gas Chromatography Mass Spectrometry (GC-MS) 
GC-MS analysis was performed on a Hewlett Packard 5890 gas chromatograph linked to an 
HP 5970B mass selective detector controlled by an HP300 series computer. The gas 
chromatograph was fitted with an autosampler and equipped with an Ultra 1 fused-silica wall-
coated open tubular capillary column (12 x 0.2 mm x 0.33 m) with 5% biphenyl,             
95% dimethyl polysiloxane as the bonded phase. 
 
GC-MS Determination of persilylated derivatives 
Using the method described by Hamilton et al.,15 lyophilised supernatant (1 ml) of samples 
was derivatised by the addition of N-trimethylsilyl-N-methyl trifluoroacetamide (MSTFA)    
(1 ml) and then heating to 100 ºC for 1 h. After cooling to room temperature, the samples 
were passed through a Pasteur pipette containing a cotton wool plug and analysed by GC-MS 
under the following conditions. The oven was programmed to start at 100 C for 1 min and 
then ramped at 10 °C/min to 300 C. The injector port temperature was set at 250 C and the 
sample (1 l) injected splitless. The mass spectrometer was operated in the full scan electron 
impact mode. 
 
5.2.1.5 High Performance Liquid Chromatography (HPLC) 
HPLC analyses were carried out on a Varian Prostar HPLC system, consisting of a solvent 
delivery system (230, Prostar solvent delivery module), a dual wavelength UV-Vis detector 
(Varian 325, Prostar) and a Prostar 400 autosampler. An analytical Macherery-Nagel C-18 
column (Hypersil-ODS, 120-5, 250 x 4.6 mm) was used at a flow rate of 1 ml/min. Sample 
volumes of 100 µl were used, of which 20 µl was automatically injected. Solvents that were 
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used were HPLC grade and filtered before use. The mobile phases consisted of 2 solvents;    
A, 50 mM KH2PO4: acetonitrile (95:5) and solvent B, 50 mM KH2PO4: acetonitrile (80:20). 
Runs were monitored at 254 nm by gradient elution over 30 min from 0% B to 100% B. 
 
 HPLC analysis of radioactive compounds 
High performance liquid chromatography (HPLC) was carried out under the conditions 
described as follows. Aliquots of the reaction mixture were analysed under the conditions 
stated below at a constant flow rate of 1 ml/min for 15 min. 
 
Stationary phase Mobile phase 
ZORBAX Carbohydrate analysis column 85:15 MeCN/H2O 
Hypersil ODS  90:10 NaH2PO4/MeCN 
 
Analysis of the radiolabelled samples was conducted on a Gynkotek HPLC system composed 
of a two head gradient pump (P580), a column oven (STHS8S) and a UV detector 
(UVD340S) coupled in series with a BIOSCAN NaI detector (B-FC-3200), equipped with a 
Phenomenex Luna C-18  column  (250  x  4.5  mm,  5  μm)  or a Macherery-Nagel C-18 column 
(Hypersil-ODS, 120-5, 250 x 4.6 mm). 
 
5.2.1.6 Fast Performance Liquid Chromatography (FPLC) 
Protein purification was carried out on an ÄKTA™ HPLC system. Buffers were filtered and 
kept at 4 ºC. Protein elution was monitored at 280 nm collecting samples of 4 ml. Protein 
purification was carried out on an ÄKTA™ HPLC basic system at room temperature. The 
following techniques were employed: hydrophobic interaction chromatography (HIC) using 
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Phenyl Sepharose HP, 40 ml bed volume (Amersham Biosciences); size exclusion 
chromatography using a HiLoad™ 16/60 Superdex™ 200 gel filtration column (Pharmacia 
Biotech Inc.) and anion exchange chromatography using a Q, 5 ml bed volume anion 
exchange column (Amersham Biosciences). Typical flow rates were between 1 ml/min and 2 
ml/min. 
 
5.2.1.7 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed on an Invitrogen XCell SureLock™ mini-cell apparatus connected 
to an Amersham Pharmacia biotech EPS 301 power supply operating at a constant current of 
125 mA for 35 min. NuPAGETM Bis-Tris 10 well gels containing either 10% or 412% of 
acrylamide were used. 
A. Sample preparation for SDS-PAGE 
Protein samples for SDS-PAGE analysis were prepared as follows. To 20 µl of protein sample 
was added 5 µl of NuPAGE™  LDS sample buffer, and the protein was denatured at 100 ºC for 
3 min. A sample (10-20 µl) was then added to the sample wells of the pre-cast NuPAGE™ 
Bis-Tris gel. Prestained pageruler protein ladder (SM0661, Fermentas) was used as a guide 
for MW determination. 
B. Staining and destaining of SDS gels 
The gel was stained by soaking in a solution of Coomassie blue G250 dye for 3060 min at 
4 ºC. Destaining was achieved by soaking in distilled water and microwaving for 10 min at 
full power. The composition of the stain solution is as follows: coomassie blue G250 (2.0g), 
methanol (400 ml), glacial acetic acid (70 ml) and ultra pure water (530 ml).  
CHAPTER 5 
 
 207 
5.2.2 Culturing conditions of S. cattleya16 
5.2.2.1 Growth and maintenance of S. cattleya on agar  
Streptomyces cattleya NRRL 8057 was originally supplied by Prof. D. B. Harper at the 
Queen’s University of Belfast, Microbial Biochemistry Section, Food Science Department, 
Belfast. Cultures were maintained on agar plates containing soybean flour (2% w/v), mannitol 
(2% w/v), agar (1.5% w/v) and tap water. The plates were incubated at 30 oC for 28 days or 
until sporulation could be detected. The resultant static cultures were stored at 4 oC. 
 
 
5.2.2.2 Culture medium and growth conditions of S. cattleya  
Streptomyces cattleya seed and batch cultures were grown in conical flasks (500 ml) 
containing chemically defined medium (90 ml). The medium was prepared as follows: sterile 
ultra-pure water (450 ml) was added to ion solution (150 ml), filtered carbon solution (75 ml), 
(see Section 5.2.2.3), sterile phosphate buffer (75 ml, 150 mM, pH 7.0) and sterile potassium 
fluoride (3 ml, 0.5 M). The seed cultures were prepared by transferring spores from a static 
culture as described above, and added to a conical flask (500 ml) containing chemically 
defined medium (90 ml).  After incubation for 6 days at 28 oC on an orbital shaker (180 rpm), 
an aliquot (0.3 ml) of spores was used to inoculate the batch cultures. The batch cultures were 
incubated at 28 oC, on an orbital shaker at 180 rpm for 68 days. 
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5.2.2.3 Media procedure for growing S. cattleya  
A.  Ion solution 
The following reagents were added to ultra-pure water (900 ml).  
NH4Cl   6.75 g 
NaCl   2.25 g  
MgSO4.7H2O  2.25 g  
CaCO3   1.13 g 
FeSO4.7H2O  0.113 g  
CoCl2.6H2O  0.045 g 
ZnSO4.7H2O  0.045 g.   
The solution was sterilised by autoclaving prior to use. 
 
B.  Carbon source solution 
The following reagents were added to ultra-pure water (900 ml).   
glycerol    45 g  
monosodium glutamate  22.5 g 
myo-inositol    1.8 g  
para-aminobenzoic acid  450 μl of freshly prepared solution 1 mg/ml 
The solution was sterilised by filtration into pre-sterilised Schott bottles. 
 
CHAPTER 5 
 
 209 
5.2.3 Preparation of resting cell cultures of S. cattleya 
After 6 days of growth, S. cattleya cells were harvested by centrifugation (9,100 rpm, 25 min) 
and the resulting pellet was washed three times with phosphate buffer (50 mM, pH 6.8). After 
the final wash, the bacterial pellet was stored at –80 oC until required. 
 
5.2.4 Preparation of cell-free extract (CFE) of S. cattleya 
CFE was prepared by re-suspending frozen cells of S. cattleya (0.10.4 mg/mL) in an 
appropiate buffer (50 mM KH2PO4, pH 6.8 or 50 mM Tris-HCl, pH 7.8) and left to stir for 
20 min at 4 oC. Ultra-sonication (10 x 60 sec, at 60% duty cycle) was used to disrupt the cells 
and the cell debris was removed by centrifugation (14,000 rpm, 20 min). The resulting clear 
supernatant was used as a CFE. 
 
5.2.5 Assay to determine biosynthetic activity                  
in a CFE of S. cattleya 
Assay 1:  CFE  (500  μl),  SAM  49 (50  μl,  20  mM)  and  KF  (10  μl,  0.5  M)  was   incubated  for  
16 h at 37 oC. The sample was then heated (100 oC, 3 min) and the denatured protein removed 
by centrifugation (14,000 rpm, 15 min). D2O  (100  μl)  was  added  to  the  supernatant  which was 
then analysed by 19F NMR spectroscopy. The production of fluoroacetate (FAc) 17 and / or 
4-fluorothreonine (4-FT) 39 confirmed that the CFE was active. The presence of 17 or 39 was 
determined by comparison against reference samples.  
 
Assay 2: CFE (500  μl)  and  5´-FDA 47 (100  μl,  18.6 mM) was incubated for 16 h at 37 oC. 
The sample was then heated (100 oC, 3 min) and the denatured protein removed by 
centrifugation (14,000 rpm, 15 min). D2O  (100  μl)  was  added  to  the  supernatant  which  was  
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then analysed by 19F NMR spectroscopy. The production of FAc 17 and / or 4-FT 39 
confirmed that the CFE was active. The presence of FAc 17 or 4-FT 39 was determined by 
comparison against reference samples.  
 
5.2.6 Protein purification by ammonium sulfate 
 precipitation 
A CFE was prepared following the procedure described in Section 5.2.4. According to the 
volume of the supernatant, ammonium sulfate was slowly added to the desired % saturation 
level (Table 5.1). After all the ammonium sulfate was dissolved by stirring for 20 min at 4 oC, 
the precipitated solution was centrifuged (20 min, 14,000 rpm) and the supernatant either 
discarded or kept for further precipitation. The protein pellet could then be used directly or 
kept at –80 oC.  
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
 
 211 
Table 5.1 Ammonium sulfate table showing grams of ammonium sulfate added to 100 ml of 
solution.17 
 Final concentration of ammonium sulfate, % saturation at 0oC      
                                    
 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 
  g solid ammonium sulfate to add to 100 ml of solution      
0 10.7 13.6 16.6 19.7 22.2 26.2 29.5 33.1 36.6 40.4 44.2 48.3 52.3 56.7 61.1 65.9 70.7 
5 8.0 10.9 13.9 16.8 20.0 23.2 26.6 30.0 33.6 37.3 41.1 45.0 49.1 53.3 57.8 62.4 67.1 
10 5.4 8.2 11.1 14.4 17.1 20.3 23.6 27.0 30.5 34.2 37.9 41.8 45.8 50.0 54.4 58.9 63.6 
15 2.6 5.5 8.3 11.3 14.3 17.4 20.7 24.0 27.5 31.0 34.8 38.6 42.6 46.6 51.0 55.5 60.0 
20 0 2.7 5.6 8.4 11.5 14.5 17.7 21.0 24.4 28.0 31.6 35.4 39.2 43.3 47.6 51.9 56.5 
25  0 2.7 5.7 8.5 11.7 14.8 18.2 21.4 24.8 28.4 32.1 36.0 40.1 44.2 48.5 52.9 
30   0 2.8 5.7 8.7 11.9 15.0 18.4 21.7 25.3 28.9 32.8 36.7 40.8 45.1 49.5 
35    0 2.8 5.8 8.8 12.0 15.3 18.7 22.1 25.8 29.5 33.4 37.4 41.6 45.9 
40     0 2.9 5.9 9.0 12.2 15.5 19.0 22.5 26.2 30.0 34.0 38.1 42.4 
45      0 2.9 6.0 9.1 12.5 15.8 19.3 22.9 26.7 30.6 34.7 38.8 
50       0 3.0 6.1 9.3 12.7 16.1 19.7 23.3 27.2 31.2 35.3 
55        0 3 6.2 9.4 12.9 16.3 20.0 23.8 27.7 31.7 
60         0 3.1 6.3 9.6 13.1 16.6 20.4 24.2 28.3 
65          0 3.1 6.4 9.8 13.4 17.0 20.8 24.7 
70           0 3.2 6.6 10.0 13.6 17.3 21.2 
75            0 3.2 6.7 10.2 13.9 17.6 
80             0 3.3 6.8 10.4 14.1 
85              0 3.4 6.9 10.6 
90               0 3.4 7.1 
95                0 3.5 
100                                 0 
 
5.2.7 Partial purification of an isomerase from S. cattleya 
S. cattleya CFE (150 ml) was subjected to ammonium sulfate precipitation following the 
protocol previously detailed. The protein pellet corresponding to the 35-50 % ammonium 
sulfate cut was dissolved in phosphate buffer (50 mM, pH 6.8) supplemented with 
1 M (NH4)2SO4 in a total volume of 6 ml with a protein concentration of ~20 mg / ml. This 
protein solution was filtered through a 0.45 µm HT Tuffryn® membrane filter.  Partially 
purified fractions (200 µl) were incubated with 5-FDRP 61 (100 µl) for 16 h at 37 oC to assay 
for isomerase activity.  After this time the protein was denatured at 100 oC for 3 min and 
removed by centrifugation (14,000 rpm / 5 min).  The supernatant was retained and assayed 
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by 19F NMR spectroscopy for isomerase activity. Selected spectroscopic data: δF (470 MHz, 
10% D2O) 5-FDRulP 69 231.34 (dt, 2JF-H 47.0 and 3JF-H 20.9). 
 
5.2.7.1 Hydrophobic interaction chromatography (HIC)  
The dissolved protein pellet (5 ml) was injected onto a 40 ml Phenyl sepharose HP column 
equilibrated with 2 column volumes of phosphate buffer (50 mM, pH 6.8) containing 
1 M (NH4)2SO4.  The column was washed with a further two column volumes and 
subsequently eluted by applying a step wise gradient at 2 ml/min from 1 M to 
0 M (NH4)2SO4. The protein fractions (12 ml in total, 1.3 mg protein/ml) eluted at the end of 
the gradient were found to be active when assayed for isomerase activity.  
 
5.2.7.2 Size exclusion chromatography  
The eluent (~ 12 ml) from the HIC purification step was concentrated to 2 ml using a 10 kDa 
Amicon® Ultra-15 centrifugal concentrator.  The concentrated protein was loaded onto a 
HiLoad™ 16/60 Superdex™ 200 gel filtration column (Pharmacia Biotech Inc.) equilibrated 
with Tris buffer (50 mM, pH 7.2) supplemented with 0.3 M KCl at a constant flow rate of 
1 ml/min.  Protein was eluted isocratically over 180 ml. Isomerase activity was found in the 
protein fractions eluted between 7280 ml with a protein concentration of 0.5 mg/ml. 
 
5.2.7.3 Ion exchange chromatography (IEC) 
The eluent (8 ml) from the size exclusion column was concentrated to 2 ml using a 10 kDa 
Amicon® Ultra-15 centrifugal concentrator. The concentrated protein was then desalted using 
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a HiTrapTM desalting column (5 ml) to remove KCl.  The sample was then re-concentrated to 
~2 ml by the same method. 
The concentrated protein sample (2 ml) was applied to an anion exchange column (Q, 5 ml 
sepharose) which was pre-equilibrated with five column volumes of tris buffer (50 mM, 
pH 7.2).  The loaded protein sample was washed with two column volumes and subsequently 
eluted using a step wise gradient of tris buffer (50 mM, pH 7.2) containing 1 M KCl at a flow 
rate of 2 ml / min.  The peak containing isomerase activity eluted after a gradient of 250 mM 
KCl with a total protein concentration of 1.5 mg / ml. 
 
5.2.8 Chemo-enzymatic preparation of 5-FDI 50 4 
5´-FDA 47 (100   μl,   18.6 mM) and 5´-adenylic acid deaminase (2 mg) were suspended in 
phosphate buffer (50 mM, pH 6.8) in a total volume of 1 ml and incubated for 16 h at 37 oC. 
The sample was then heated (100 oC, 3 min) and the denatured protein removed by 
centrifugation (14,000 rpm, 15 min). The supernatant was supplemented with D2O and 
analysed by 19F NMR spectroscopy showing 100% conversion to 5´-deoxy-5´-fluoroinosine, 
5´-FDI 50. δF (470 MHz; D2O): 231.52 (dt, 2JF-H 47.2 and 3JF-H 29.5); m/z (ES+): 271.03 
[M+H]+ (100%). 
 
5.2.9 Chemo-enzymatic preparation of 5-FDRP 61  
5´-Deoxy-5´-fluoroinosine, 5´-FDI 50 (5 mg/ml, 1 ml) was incubated with an immobilised 
PNPase (30 mg) and incubated at 37 oC until the best conversion was observed (approx. 40% 
conversion to 5-FDRP 61). The sample was then denatured at 100 oC for 3 min and the 
precipated protein removed by centrifugation (14,000 rpm, 15 min). The sample was analysed 
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by 19F NMR spectroscopy. δF (470 MHz; D2O): (5´-FDI 50, ~60%) 231.52 (dt, 2JF-H 47.2 
and 3JF-H 29.5) and (5-FDRP 61, ~40%) 230.75 (dt, 2JF-H 47.3 and 3JF-H 28.2).  
 
5.2.10 Chemo-enzymatic preparation of 5-FDRul 73 
Immobilised glucose isomerase (30 mg) was added to an aqueous solution of 5-FDR 71 (1ml, 
5 mg/ml KH2PO4 buffer, 200 mM, pH 6.8). Samples were incubated at 37 ºC for 6 h, 
following the reaction by 19F NMR spectroscopy every hour. Samples (100 l) of the reaction 
mixture were taken every hour and the protein was denatured by heating (100 ºC, 3 min) and 
removed by centrifugation (14,000 rpm, 15 min). The supernatant was then analysed by 
19F NMR spectroscopy to reveal the production of 5-FDRul 73. δF (470 MHz, D2O): 231.22 
(dt, 2JF-H 46.9 and 3JF-H 20.5). 
 
5.2.11 Chemo-enzymatic preparation of 5-FDXul 75 
Immobilised glucose isomerase (30 mg) was added to an aqueous solution of 5-FDX 74 (1ml, 
5 mg/ml KH2PO4 buffer, 200 mM, pH 6.8). Samples were incubated at 37 ºC for 3 h, 
following the reaction by 19F NMR spectroscopy every hour. Samples (100 l) of the reaction 
mixture were taken every hour and the protein was denatured by heating (100 ºC, 3 min) and 
removed by centrifugation (14,000 rpm, 15 min). The supernatant was then analysed by       
19F NMR spectroscopy to reveal the production of 5-FDXul 75. δF (470 MHz, D2O): 228.55 
(dt, 2JF-H  46.1  and 3JF-H 15.4). 
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5.2.12 Incubations in CFEs of S. cattleya 
5.2.12.1 Preparation of 5-FDRulP 69 
A stock solution of 5-FDRP 61 was prepared as previously described in Section 5.2.9. 
Samples of 5-FDRulP 69  were prepared using the following protocol: S. cattleya CFE 
(400 l, 0.1 g cells/ml) was incubated with the 5-FDRP 61 stock solution (100 l) and EDTA 
(30 mM). Samples were incubated at 37 ºC for 6 h. The protein was denatured by heating 
(100º C, 3 min) and removed by centrifugation (14,000 rpm, 15 min). The supernatant was 
then analysed by 19F NMR spectroscopy. δF (470 MHz, D2O): 231.34 (dt, 2JF-H 47.0 and 3JF-
H 20.9). m/z (GC-MS, after MSTFA derivatisation): 521 (M-, 100%), 506 (M--CH3, 52). 
 
 
5.2.12.2 Preparation of 5-FDRul 73 
Phytase (100 l, 10 mg/ml) was added to a sample of 5-deoxy-5-fluoro-D-ribulose-1-
phosphate (5-FDRulP) 69 (500 l) prepared using the protocol described above. The sample 
was incubated at 37 ºC for 16 h. The protein was then denatured by heating (100 ºC, 3 min) 
and removed by centrifugation (14,000 rpm, 15 min). The supernatant was then analysed by 
19F NMR spectroscopy. Selected spectroscopic data for 73. δF (470 MHz, D2O): 231.22 (dt, 
2JF-H 46.9 and 3JF-H 20.2).  
 
5.2.12.3 Incubation 5-FDRul 73 in a CFE of S. cattleya 
A sample of 5-FDRul 73 (100 µl) containing an excess of 5-FDR 71 was incubated with a 
CFE (500 µl) for 16 hrs at 37 oC.  After this time the sample was denatured at 100 oC for 
3 min and the precipitated protein removed by centrifugation (14,000 rpm, 5 min). The 
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supernatant was supplemented with D2O and analysed by 19F NMR spectroscopy. 
δF (470 MHz, 10% D2O)  5-FDR 71, 230.83 (α-anomer, dt, 2JF-H 46.5 and 3JF-H 27.9), 
228.53 (β-anomer, dt, 2JF-H 46.5 and 3JF-H 26.0) and 5-FDRul 73, 231.22 (dt, 2JF-H 46.9 and 
3JF-H 20.2).   
 
 
5.2.13 GC-MS Determination of the persilylated derivative of 
 5-FDRulP 69 
GC-MS analysis of the persilylated 5-deoxy-5-fluoro-D-ribulose-1-phosphate (5-FDRulP) 69 
was   carried   out   by   Dr   J.   Hamilton   (Queen’s   University,   Belfast). Lyophilised samples of 
5-FDRulP 69 were derivatised by the addition of N-trimethylsilyl-N-methyl 
trifluoroacetamide (MSTFA) (1 mL) and then heating to 100 ºC for 1 h. After cooling to room 
temperature, the samples were passed through a Pasteur pipette containing a cotton wool plug 
and analysed by GC–MS under the following conditions. The oven was programmed to start 
at 100 C for 1 min and then ramped at 10 °C/min to 300 C. The injector port temperature 
was set at 250 C and the sample (1 l) injected splitless. The mass spectrometer was 
operated in the full scan electron impact mode measuring ion currents between 30 and 
550 amu to obtain the mass spectra of fluororibulose phosphate. The molecular weight of 
5-FDRulP 69 was confirmed using chemical ionization mass spectrometry with methane as 
the reagent gas. 
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5.2.14 Expression of recombinant flA and purification 
E. coli BL21(DE3) transformed with pET28-flA was grown in Luria Bertrani broth 
containing 100 µg/ml kanamycin at 37 ºC until an absorbance of 0.4–0.6 at 600 nm was 
reached. Over-expression of flA was induced by adding isopropylthiogalactoside (IPTG) to 
0.2 mM and the incubation was continued at 16 ºC overnight. Cells were collected, 
resuspended in buffer A consisting of 50 mM phosphate buffer (pH 7.8) supplemented with 
imidazole (10 mM). The cells were lysed by sonication, ten times at 60% duty cycle for 1 min 
with intervals of cooling for 30 sec depending on the volume. The disrupted cell suspension 
was centrifuged for 30 min at 10,000 rpm and the clear supernatant was retained. Prior to 
further purification, this supernatant was first filtered through a 0.45 m EZEE Syringe filter 
(Elkay Laboratory Products Ltd.) and then through a 0.22 m Millex®GP Filter Unit 
(Millipore Corporation). A HisTrap™ HP column packed with precharged Ni Sepharose™ 
High Performance was equilibrated with buffer B. The intracellular fraction was applied to 
this column and after extensive washing of the column with buffer B, recombinant protein 
bound on the resin was eluted with buffer C. The fluorinase-containing fractions were pooled 
together and concentrated using an Amicon® Ultra-15 centrifugal filter (Millipore 
Corporation). 
 
Buffer A Buffer B Buffer C
10 mM phosphate
pH 7.8
10 mM phosphate
pH 7.8
10 mM phosphate
pH 7.8
10 mM imidazole 30 mM imidazole 500 mM imidazole
 
 
The protein was further purified by gel filtration fast protein liquid chromatography (FPLC) 
on a HiLoad™ 16/60 Superdex™ 200 gel filtration column (Pharmacia Biotech Inc.) 
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equilibrated with 50 mM Tris-HCl buffer (pH 7.8) and eluted at a constant flow rate of 
1 ml/min using the same buffer. 
The protein was used directly in this buffer or dialysed using dialysis tubing (MW 10 kDa   
cut off) against 2 l of the required buffer for the corresponding experiment overnight at 4 ºC. 
For long term storage, the purified recombinant fluorinase was kept at 80 ºC. 
 
5.2.14.1 Assay for the over-expressed flA 
A. 19F NMR assay 
The fluorinase enzyme (280 l, 1.5 mg/ml) was incubated with SAM 49 (10 l, 20 mM) and 
KF (10 l, 500 mM) at 37 ºC for 3 h. The sample was heated (100 ºC, 3 min) and the 
denatured protein removed by centrifugation (14,000 rpm, 15 min). D2O (100 l) was added 
to the supernatant which was then analysed by 19F NMR spectroscopy. A synthetic standard 
was used to confirm the production of 5´-deoxy-5´-fluoroadenosine, 5´-FDA 47. 
B. HPLC assay 
In a total reaction volume of 100 µl, the fluorinase enzyme (80 l, 1.5 mg/ml) was incubated 
with SAM 49 (10 l, 20 mM) and KF (10 l, 500 mM) at 37 ºC for 3 h. The product was 
heated (100 ºC, 3 min) and the denatured protein removed by centrifugation (14,000 rpm,    
15 min). HPLC analysis (UV detection) against a synthetic reference compound was used to 
confirm the production of 5´-FDA 47. 
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5.2.15 T. vivax IAG-NH over-expression and purification 
5.2.15.1 Expression vector 
The T. vivax IAG-NH recombinant plasmid subcloned into a pQE-30 (Qiagen) expression 
plasmid vector was supplied by Dr J. Steyaert (Vrije Universiteit Brussel). After its start 
codon, the pQE-30 expression vector possesses six consecutive histidine codons (coding for a 
6 x His-tag). It also encodes a gene for ampicillin resistance and target gene expression is 
induced by IPTG via a T5 promoter. 
 
Figure 5.1 pQE-30, pQE-31 and pQE-32 plasmid map (taken from Qiagen, The QIAexpressionist™  
2003)  pQE vectors for N-terminal 6xHis tag constructs. PT5: T5 promoter, lac O: lac operator, 
RBS: ribosome-binding site, ATG: start codon, 6xHis: 6xHis tag sequence, MCS: multiple 
cloning site with restriction sites indicated, Stop Codons: stop codons in all three reading 
frames, Col E1: Col E1 origin of replication, Ampicillin: ampicillin resistance gene. 
 
5.2.15.2 Transformation of competent cells     
 with the iagnh ORF in pQE-30 
Chemically competent E. coli cells were purchased from Invitrogen. The competent cells 
were present in vials containing 50 l  aliquots. To transform these cells, each 50 l aliquot 
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was placed on ice and allowed to thaw for 25 min, while gently mixing to evenly resuspend 
the cells. After thawing, addition of 2 l of plasmid DNA was added directly to each aliquot, 
stirring gently and returning the vial on ice for 20 min. Heat shock was performed by heating 
the vials for 30 seconds in a 42 ºC water bath. The vials were then placed on ice for 5 min. LB 
medium (250 l) was added to each vial on ice. The vials were then incubated at 37 ºC while 
shaking at 250 rpm for 1.5 h. An aliquot (100 l) of the transformed cells was added onto an 
agar plate containing the antibiotic ampicillin, and evenly distributed using a plate spreader. 
The plates were then incubated at 37 ºC overnight. 
 
5.2.15.3 Expression of iagnh and purification of IAG-NH 
A.  Expression trials 
Single colonies were picked and grown up in LB (2 ml) containing 2 l of ampicillin 
(100 mg/ml) at 37 ºC for ~16 h on an orbital shaker at 250 rpm. After this time, aliquots were 
used to inoculate fresh growth medium (4 ml) for the over-expression trials. The fresh 
inoculated LB containing ampicillin was incubated at 37 ºC until a OD600 = 0.40.6 was 
reached. Expression was then induced with IPTG. The following variables were altered to 
optimise expression of soluble IAG-NH. 
 
E. coli
Host strain
Growth 
Media
IPTG conc. 
(mM)
Induction T  (ºC) Incubation T (ºC)
BL21(DE3)Gold LB 0.2 4 16
C43(DE3) TB 0.5 25 25
-------- -------- 1 42 --------
-------- -------- 2 -------- --------
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For each expression trial, samples (1 ml) were taken at various intervals for analysis. Cells 
were harvested by centrifugation (14,000 rpm, 5 min) and the resulting pellet was 
resuspended in phosphate buffer (1 ml, 50 mM, pH 7.0). The cells were then lysed by 
sonication at 60 cycles for 20 sec. After sonication, the cells were centrifugated (14,000 rpm, 
15 min) and the resultant cell pellet and the supernatant were retained as the insoluble and 
soluble fractions respectively for SDS-PAGE analysis. 
B.  Large scale expression of IAG-NH 
Gene expression was achieved by addition of cell stock (2 l) of E. coli BL21(DE3)Gold or 
C43(DE3) cells containing the iagnh ORF in pQE-30 in 50% glycerol to LB (20 ml) 
containing 100 µg/l ampicillin (20 l, 100 mg/ml). The starting cultures were incubated at 
37 ºC for 16 h. These overnight cultures were used to inoculate 2 l baffled flasks containing 
LB medium (1 l) and the antibiotic ampicillin (final concentration 100 µg/l). These were 
incubated at 37 ºC with shaking (180 rpm) until the cells reached an OD600 between 0.4 and 
0.6. The medium was then cooled to 25 ºC and IPTG was added to a final concentration of 
0.5 mM to initiate the expression of the recombinant protein. The inoculated flasks were then 
incubated at 16 ºC for 16 h on an orbital shaker (160 rpm). After this time, the cells were 
harvested by centrifugation (9,000 rpm; 20 min) and the resulting pellet was either stored at 
80 ºC or used directly for protein purification. 
C.  Purification of IAG-NH 
Cells were resuspended in buffer A consisting of 50 mM phosphate buffer (pH 7.0) 
supplemented with 1 M NaCl, 1 mM CaCl2 and protease inhibitor cocktail (1 g/ml). The 
cells were lysed by sonication, ten times at 60% duty cycle for 1 min with intervals of cooling 
for 30 seconds, depending on the volume. The disrupted cell suspension was centrifuged for 
30 min at 10,000 rpm and the clear supernatant was retained as cell-free extract (CFE). Prior 
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to further purification, this CFE was first filtered through a 0.45 m EZEE Syringe filter 
(Elkay Laboratory Products Ltd.) and then through a 0.22 m Millex®GP Filter Unit 
(Millipore Corporation). A HisTrap™ HP column packed with precharged Ni Sepharose™ 
High Performance was equilibrated with buffer B. The intracellular fraction was applied to 
this column and after extensive washing of the column with buffer B, the His-tagged 
nucleoside hydrolase was eluted with buffer C. The nucleoside hydrolase-containing fractions 
were neutralised with NaOH, combined and concentrated using an Amicon® Ultra-15 
centrifugal filter (Millipore Corporation). 
 
Buffer A Buffer B Buffer C
50 mM phosphate
pH 7.0
50 mM phosphate
pH 7.0
50 mM sodium acetate 
pH 5.0
1 M NaCl 1 M NaCl 1 M NaCl
1 mM NaCl2 -------- --------  
 
This fraction was then loaded onto a HiLoad™ 16/60 Superdex™ 200 gel filtration column 
(Pharmacia Biotech Inc.) equilibrated with 20 mM Tris-HCl (pH 8.0), 150 mM NaCl and 
eluted at a constant flow rate of 1 ml/min using the same buffer. 
The purified nucleoside hydrolase was then dialysed using dialysis tubing (MW 10 kDa 
cut off) against 2 l of the required buffer for the experiment overnight at 4 ºC. The protein 
preparation was used directly for the experiments or glycerol was added to a final 
concentration of 5%, and the protein was snap-frozen in liquid N2 and stored at 80 ºC for 
later enzymatic assays. 
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5.2.15.4 Assay for the over-expressed iagnh 
A. 19F NMR assay 
In a total reaction volume of 700 µl, a preparation of T. vivax IAG-NH enzyme (300 l) was 
incubated with synthetic 5´-FDA 47 (30 l, 18.6 mM) in HEPES buffer (370 l, 50 mM, 
1 mM CaCl2, pH 8.0) at 37 ºC for 2 h. The protein was then denatured by heating (100 ºC, 
3 min) and removed by centrifugation (14,000 rpm, 15 min). The supernatant was supplement 
with D2O (100 l) and subsequently analysed by 19F NMR spectroscopy. A synthetic standard 
was used to confirm the production of 5-deoxy-5-fluoro-D-ribose, 5-FDR 71. 
B. HPLC assay 
In a total reaction volume of 100 µl, the T. vivax IAG-NH enzyme (30 l, 1.5 mg/ml) was 
incubated either with 5´-FDA 47 (30 l, 18.6 mM) or adenosine 112 (30 l, 18.6 mM) at 
37 ºC for 2 h. The product was heated (100 ºC, 3 min) and the denatured protein removed by 
centrifugation (14,000 rpm, 15 min). HPLC analysis (UV detection) against a reference 
sample of adenine 62 was used to confirm the hydrolysis of 5´-FDA 47 or adenosine 112. 
 
 
5.2.16 5’-FDA as a substrate for the T. vivax IAG-NH  
5.2.16.1 Incubation  of  5’-FDA 47 in a CFE of T. vivax IAG-NH 
A cell-free extract (CFE, 300 l) containing NH activity was incubated with synthetic 
5´-FDA 47 (30 l, 18.6 mM) in phosphate buffer (400 l, 50 mM, 1 mM CaCl2) at 37 ºC for 
16 h. After this time, the protein was then denatured by heating (100 ºC, 3 min) and removed 
by centrifugation (14,000 rpm, 15 min). The supernatant was supplement with D2O (100 l) 
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and subsequently analysed by 19F NMR spectroscopy. Selected spectroscopic data for 
5-FDR 71: F (470 MHz; 10% D2O): 228.46 (β, dt, 2JF-H 46.5, 3JF-H 26.0), 230.77 (α, dt, 
2JF-H 46.5, 3JF-H 27.9). 
 
5.2.16.2 pH  profile  incubations  of  5’-FDA 47 with T. vivax IAG-NH  
Partially purified IAG-NH was taken directly after nickel column purification and divided in 
three fractions which were dialysed in tree different buffers (50 mM MES, pH 5.5; 50 mM 
PBS, pH 7.0 and 50 mM TRIS, pH 8.5) respectively. Experiments were carried out by 
incubating the TvNH (500 l, 0.5 mg/ml) with synthetic 5´-FDA 47 (30 l, 18.6 mM) in the 
corresponding buffer (170 l) supplemented with CaCl2 (1mM) and  D2O (100 l) at 37 ºC 
and 55 ºC. The hydrolysis of 5´-FDA 47 was followed by recording a 19F{1H} NMR spectrum 
every two hours. A synthetic standard was used to confirm the production of 5-deoxy-5-
fluoro-D-ribose,  5-FDR 71. 
 
 
5.2.17 Enzymatic preparation of 5’-FDA 47 
The fluorinase enzyme (280 l, 1.5 mg/ml) was incubated with SAM 49 (10 l, 20 mM) and 
KF (10 l, 500 mM) for a period of 4 h at 37 ºC. After this time, the sample was heated 
(100 ºC, 3 min) and the denatured protein removed by centrifugation (14,000 rpm, 15 min). 
The supernatant was supplemented with D2O (100 l) and analysed by 19F NMR spectroscopy 
to reveal the production of 5´-FDA 47. F (470 MHz; 10% D2O): 231.06 (dt, 2JF-H 47.6, 
3JF-H 23.8). HPLC analysis (UV detection) against a synthetic reference compound was also 
used to confirm the production of 47. 
CHAPTER 5 
 
 225 
5.2.18 Enzymatic preparation of 5-FDR 71 from SAM 49 
5.2.18.1 Sequential one-pot synthesis  
5´-FDA 47 was prepared enzymatically as previously described in Section 5.2.17. This 
sample containing 5´-FDA 47 was supplemented with a freshly prepared CFE (400 l) of 
TvNH in MES buffer (50 mM, pH 5.5; 1 mM CaCl2) and incubated for further 30 min. The 
sample was heated (100 ºC, 3 min) and the denatured protein removed by centrifugation 
(14,000 rpm, 15 min). The supernatant was then analysed by 19F NMR spectroscopy, showing 
formation of 5-FDR 71. F (470 MHz; 10% D2O): 228.45 (β, dt, 2JF-H 47.5, 3JF-H 24.2), 
230.77 (α, dt, 2JF-H 47.5, 3JF-H 24.2). HPLC analysis (UV detection) against a synthetic 
reference of adenine 62 was also used to confirm the hydrolysis of 5´-FDA 47. 
 
5.2.18.2 One-pot synthesis  
The fluorinase (280 l, 1.5 mg/ml) was incubated with SAM 49 (10 l, 20 mM), KF (10 l, 
500 mM) and a preparation (400 l) of the overexpressed T. vivax nucleoside hydrolase in 
phosphate buffer (50 mM, pH 7.8; 1 mM CaCl2) for a period of 2 h at 37 ºC. After this time, 
the reaction mixture was heated at 100 ºC for 3 min and the denatured protein was removed 
by centrifugation (14,000 rpm, 15 min). The supernatant was supplement with D2O (100 l) 
and analysed by 19F NMR spectroscopy. Only production of 5-deoxy-5-fluoro-D-ribose, 
5-FDR 71, was detected. F (470 MHz; 10% D2O): 228.45 (β, dt, 2JF-H 47.5, 3JF-H 24.2), 
230.77 (α, dt, 2JF-H 47.5, 3JF-H 24.2). HPLC analysis (UV detection) against a synthetic 
reference of adenine 62 was also used to confirm the hydrolysis of 5´-FDA 47. 
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5.2.18.3 Enzymatic preparation of [18F]FDR [18F]71 from SAM 49  
A. Sequential one-pot synthesis 
The fluorinase enzyme (70 l, 35.3 mg/ml) was incubated with SAM 49 (30 l, 20 mM) and 
aqueous [18F]F- (50 l, solution in [18O]H2O, 72 MBq) at 37 ºC for 4 h. An aliquot of the 
mixture was analysed by analytical HPLC against a standard 5´-FDA 47, confirming 
production of 5´-deoxy-5´-[18F]fluoroadenosine ([18F]FDA) [18F]47. A preparation of purified 
nucleoside hydrolase in HEPES buffer (100 L, 16 mg/mL; 50 mM, pH 8.0) was added to the 
remaining fluorinase reaction mixture along with small volume of the buffer (50 L, 50 mM 
HEPES, 1 mM CaCl2, pH 8.0) containing the enzyme co-factor necessary for the hydrolase 
reaction. Following the addition of T. vivax IAG-NH, the enzyme cocktail was incubated for a 
further 45 minutes at 37 ºC, and an aliquot was taken for HPLC analysis. Formation of 5-
deoxy-5-[18F]fluoro-D-ribose ([18F]FDR) [18F]71 was observed in a 9:1 ratio of [18F]FDA 
[18F]47 to [18F]FDR [18F]71. 
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B. One-pot synthesis 
A typical reaction mixture combined the reagents indicated below. Experiments were 
performed at 37 ºC and aliquots of the reaction mixtures analysed by HPLC as previously 
described. 
Experiment 1 Experiment 2
Fluorinase
(35 mg/ml)
70 µl 70 µl
SAM  
(20 mM) 
30 µl 30 µl
T. vivax IAG-NH
100 µl
(16 mg/ml)
100 µl
(35 mg/ml)
[18F]fluoride in [18O]H2O 100 µl 100 µl
Buffer
(50 mM HEPES, 1mM CaCl2, pH 8.0)
50 µl 50 µl
 
 
Experiment 1: HPLC analysis confirmed the production of [18F]FDA [18F]47 and [18F]FDR 
[18F]71 in a 9:1 ratio (see Chapter 4, Figure 4.14) after 4 h incubation.  
 
Experiment 2: HPLC analysis confirmed the production of [18F]FDA [18F]47 and [18F]FDR 
[18F]71 (see Chapter 4, Figure 4.18) after 4.5 h incubation. After 8 h [18F]FDR [18F]71 
represents 31% of the total radioactivity detected ([18F]fluoride does not elute from the 
column under the conditions of the analysis). 
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